'L-dopa'
(id=1837643 ; fe=L-dopa ; type=1 ; niveau=200 ; luminosité=25 ; somme entrante=10167 creation date=2015-07-30 touchdate=2025-12-11 04:17:39.000)

≈ 2919 relations sortantes L-dopa -- r_associated #0: 258 / 1 -> médecine n1=L-dopa | n2=médecine | rel=r_associated | relid=0 | w=258 L-dopa -- r_associated #0: 151 / 0.585 -> chimie n1=L-dopa | n2=chimie | rel=r_associated | relid=0 | w=151 L-dopa -- r_associated #0: 131 / 0.508 -> dopa n1=L-dopa | n2=dopa | rel=r_associated | relid=0 | w=131 L-dopa -- r_associated #0: 129 / 0.5 -> en:levodopa n1=L-dopa | n2=en:levodopa | rel=r_associated | relid=0 | w=129 L-dopa -- r_associated #0: 127 / 0.492 -> dopamine n1=L-dopa | n2=dopamine | rel=r_associated | relid=0 | w=127 L-dopa -- r_associated #0: 122 / 0.473 -> dihydroxyphénylalanines n1=L-dopa | n2=dihydroxyphénylalanines | rel=r_associated | relid=0 | w=122 L-dopa -- r_associated #0: 119 / 0.461 -> dihydroxyphénylalanine n1=L-dopa | n2=dihydroxyphénylalanine | rel=r_associated | relid=0 | w=119 L-dopa -- r_associated #0: 119 / 0.461 -> en:2-fluorodopa n1=L-dopa | n2=en:2-fluorodopa | rel=r_associated | relid=0 | w=119 L-dopa -- r_associated #0: 119 / 0.461 -> en:alpha-methyldopamine n1=L-dopa | n2=en:alpha-methyldopamine | rel=r_associated | relid=0 | w=119 L-dopa -- r_associated #0: 119 / 0.461 -> en:betalains n1=L-dopa | n2=en:betalains | rel=r_associated | relid=0 | w=119 L-dopa -- r_associated #0: 119 / 0.461 -> en:iron(iii)-dopa complex n1=L-dopa | n2=en:iron(iii)-dopa complex | rel=r_associated | relid=0 | w=119 L-dopa -- r_associated #0: 118 / 0.457 -> en:adrogolide n1=L-dopa | n2=en:adrogolide | rel=r_associated | relid=0 | w=118 L-dopa -- r_associated #0: 118 / 0.457 -> en:dopamine agonist n1=L-dopa | n2=en:dopamine agonist | rel=r_associated | relid=0 | w=118 L-dopa -- r_associated #0: 118 / 0.457 -> en:melphalan n1=L-dopa | n2=en:melphalan | rel=r_associated | relid=0 | w=118 L-dopa -- r_associated #0: 117 / 0.453 -> DOPA n1=L-dopa | n2=DOPA | rel=r_associated | relid=0 | w=117 L-dopa -- r_associated #0: 117 / 0.453 -> en:3-prenyl-beta-hydroxytyrosine n1=L-dopa | n2=en:3-prenyl-beta-hydroxytyrosine | rel=r_associated | relid=0 | w=117 L-dopa -- r_associated #0: 117 / 0.453 -> en:cyclo-dopa n1=L-dopa | n2=en:cyclo-dopa | rel=r_associated | relid=0 | w=117 L-dopa -- r_associated #0: 117 / 0.453 -> en:diiodotyrosine n1=L-dopa | n2=en:diiodotyrosine | rel=r_associated | relid=0 | w=117 L-dopa -- r_associated #0: 116 / 0.45 -> en:catecholamine n1=L-dopa | n2=en:catecholamine | rel=r_associated | relid=0 | w=116 L-dopa -- r_associated #0: 116 / 0.45 -> en:dopa 4-phosphate n1=L-dopa | n2=en:dopa 4-phosphate | rel=r_associated | relid=0 | w=116 L-dopa -- r_associated #0: 116 / 0.45 -> en:dopamine n1=L-dopa | n2=en:dopamine | rel=r_associated | relid=0 | w=116 L-dopa -- r_associated #0: 113 / 0.438 -> en:therapeutic epinephrine n1=L-dopa | n2=en:therapeutic epinephrine | rel=r_associated | relid=0 | w=113 L-dopa -- r_associated #0: 112 / 0.434 -> en:dopaminergic agents n1=L-dopa | n2=en:dopaminergic agents | rel=r_associated | relid=0 | w=112 L-dopa -- r_associated #0: 111 / 0.43 -> doper n1=L-dopa | n2=doper | rel=r_associated | relid=0 | w=111 L-dopa -- r_associated #0: 111 / 0.43 -> en:5-hydroxydopa n1=L-dopa | n2=en:5-hydroxydopa | rel=r_associated | relid=0 | w=111 L-dopa -- r_associated #0: 111 / 0.43 -> en:methyldopa n1=L-dopa | n2=en:methyldopa | rel=r_associated | relid=0 | w=111 L-dopa -- r_associated #0: 111 / 0.43 -> en:n-beta-alanyl-5-s-glutathionyl-3,4-dihydroxyphenylalanine n1=L-dopa | n2=en:n-beta-alanyl-5-s-glutathionyl-3,4-dihydroxyphenylalanine | rel=r_associated | relid=0 | w=111 L-dopa -- r_associated #0: 109 / 0.422 -> en:methyltyrosines n1=L-dopa | n2=en:methyltyrosines | rel=r_associated | relid=0 | w=109 L-dopa -- r_associated #0: 108 / 0.419 -> en:cocaine n1=L-dopa | n2=en:cocaine | rel=r_associated | relid=0 | w=108 L-dopa -- r_associated #0: 107 / 0.415 -> en:3-(2-fluoro-4,5-dihydroxyphenyl)-2-methylalanine n1=L-dopa | n2=en:3-(2-fluoro-4,5-dihydroxyphenyl)-2-methylalanine | rel=r_associated | relid=0 | w=107 L-dopa -- r_associated #0: 107 / 0.415 -> en:l-tyrosine n1=L-dopa | n2=en:l-tyrosine | rel=r_associated | relid=0 | w=107 L-dopa -- r_associated #0: 107 / 0.415 -> lévodopa n1=L-dopa | n2=lévodopa | rel=r_associated | relid=0 | w=107 L-dopa -- r_associated #0: 106 / 0.411 -> en:phosphotyrosine n1=L-dopa | n2=en:phosphotyrosine | rel=r_associated | relid=0 | w=106 L-dopa -- r_associated #0: 105 / 0.407 -> en:2,4-dihydroxyphenylalanine n1=L-dopa | n2=en:2,4-dihydroxyphenylalanine | rel=r_associated | relid=0 | w=105 L-dopa -- r_associated #0: 105 / 0.407 -> en:3-iodotyrosine n1=L-dopa | n2=en:3-iodotyrosine | rel=r_associated | relid=0 | w=105 L-dopa -- r_associated #0: 105 / 0.407 -> en:3-o-methyl-6-fluoro-dopa n1=L-dopa | n2=en:3-o-methyl-6-fluoro-dopa | rel=r_associated | relid=0 | w=105 L-dopa -- r_associated #0: 105 / 0.407 -> en:5-s-cysteinyl-3,4-dihydroxyphenylalanine n1=L-dopa | n2=en:5-s-cysteinyl-3,4-dihydroxyphenylalanine | rel=r_associated | relid=0 | w=105 L-dopa -- r_associated #0: 105 / 0.407 -> en:6-hydroxydopa quinone n1=L-dopa | n2=en:6-hydroxydopa quinone | rel=r_associated | relid=0 | w=105 L-dopa -- r_associated #0: 105 / 0.407 -> en:dopaquinone n1=L-dopa | n2=en:dopaquinone | rel=r_associated | relid=0 | w=105 L-dopa -- r_associated #0: 105 / 0.407 -> en:fluorine f 18 fluorodopa n1=L-dopa | n2=en:fluorine f 18 fluorodopa | rel=r_associated | relid=0 | w=105 L-dopa -- r_associated #0: 105 / 0.407 -> en:pergolide n1=L-dopa | n2=en:pergolide | rel=r_associated | relid=0 | w=105 L-dopa -- r_associated #0: 105 / 0.407 -> en:phenylalanine n1=L-dopa | n2=en:phenylalanine | rel=r_associated | relid=0 | w=105 L-dopa -- r_associated #0: 103 / 0.399 -> en:isoproterenol n1=L-dopa | n2=en:isoproterenol | rel=r_associated | relid=0 | w=103 L-dopa -- r_associated #0: 103 / 0.399 -> en:poly(3,4-dihydroxyphenylalanine) n1=L-dopa | n2=en:poly(3,4-dihydroxyphenylalanine) | rel=r_associated | relid=0 | w=103 L-dopa -- r_associated #0: 100 / 0.388 -> l-dopa n1=L-dopa | n2=l-dopa | rel=r_associated | relid=0 | w=100 L-dopa -- r_associated #0: 99 / 0.384 -> 3,4 n1=L-dopa | n2=3,4 | rel=r_associated | relid=0 | w=99 L-dopa -- r_associated #0: 99 / 0.384 -> en:benztropine n1=L-dopa | n2=en:benztropine | rel=r_associated | relid=0 | w=99 L-dopa -- r_associated #0: 98 / 0.38 -> catécholamines n1=L-dopa | n2=catécholamines | rel=r_associated | relid=0 | w=98 L-dopa -- r_associated #0: 98 / 0.38 -> en:norepinephrine, dl- n1=L-dopa | n2=en:norepinephrine, dl- | rel=r_associated | relid=0 | w=98 L-dopa -- r_associated #0: 96 / 0.372 -> catécholamine n1=L-dopa | n2=catécholamine | rel=r_associated | relid=0 | w=96 L-dopa -- r_associated #0: 95 / 0.368 -> inhibiteurs de la COMT n1=L-dopa | n2=inhibiteurs de la COMT | rel=r_associated | relid=0 | w=95 L-dopa -- r_associated #0: 95 / 0.368 -> l-3-hydroxytyrosine n1=L-dopa | n2=l-3-hydroxytyrosine | rel=r_associated | relid=0 | w=95 L-dopa -- r_associated #0: 95 / 0.368 -> préparation de L-dopa n1=L-dopa | n2=préparation de L-dopa | rel=r_associated | relid=0 | w=95 L-dopa -- r_associated #0: 94 / 0.364 -> en:L-dopa n1=L-dopa | n2=en:L-dopa | rel=r_associated | relid=0 | w=94 L-dopa -- r_associated #0: 93 / 0.36 -> en:dopa n1=L-dopa | n2=en:dopa | rel=r_associated | relid=0 | w=93 L-dopa -- r_associated #0: 93 / 0.36 -> préparation de l-dopa n1=L-dopa | n2=préparation de l-dopa | rel=r_associated | relid=0 | w=93 L-dopa -- r_associated #0: 92 / 0.357 -> toxicologie n1=L-dopa | n2=toxicologie | rel=r_associated | relid=0 | w=92 L-dopa -- r_associated #0: 90 / 0.349 -> L-DOPA n1=L-dopa | n2=L-DOPA | rel=r_associated | relid=0 | w=90 L-dopa -- r_associated #0: 87 / 0.337 -> maladie de Parkinson n1=L-dopa | n2=maladie de Parkinson | rel=r_associated | relid=0 | w=87 L-dopa -- r_associated #0: 85 / 0.329 -> en:2,6-difluoro-3,4-dihydroxyphenylalanine n1=L-dopa | n2=en:2,6-difluoro-3,4-dihydroxyphenylalanine | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:24 hr ropinirole 4 mg extended release oral tablet n1=L-dopa | n2=en:24 hr ropinirole 4 mg extended release oral tablet | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:5-lipoyl-dopa n1=L-dopa | n2=en:5-lipoyl-dopa | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:8 hr carbidopa 23.75 mg / levodopa 95 mg extended release oral capsule n1=L-dopa | n2=en:8 hr carbidopa 23.75 mg / levodopa 95 mg extended release oral capsule | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:8 hr carbidopa 61.25 mg / levodopa 245 mg extended release oral capsule n1=L-dopa | n2=en:8 hr carbidopa 61.25 mg / levodopa 245 mg extended release oral capsule | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:agonists n1=L-dopa | n2=en:agonists | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:alentemol n1=L-dopa | n2=en:alentemol | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:analysis aspect n1=L-dopa | n2=en:analysis aspect | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:anticholinergic agent n1=L-dopa | n2=en:anticholinergic agent | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:apomorphine n1=L-dopa | n2=en:apomorphine | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:apomorphine hydrochloride 10mg/ml injection solution 2ml ampule n1=L-dopa | n2=en:apomorphine hydrochloride 10mg/ml injection solution 2ml ampule | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:arbutamine n1=L-dopa | n2=en:arbutamine | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:besonprodil n1=L-dopa | n2=en:besonprodil | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:biperiden n1=L-dopa | n2=en:biperiden | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:botiacrine n1=L-dopa | n2=en:botiacrine | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:brasofensine maleate n1=L-dopa | n2=en:brasofensine maleate | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:carbidopa 10 mg / levodopa 100 mg disintegrating oral tablet n1=L-dopa | n2=en:carbidopa 10 mg / levodopa 100 mg disintegrating oral tablet | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:carbidopa 10 mg / levodopa 100 mg oral tablet n1=L-dopa | n2=en:carbidopa 10 mg / levodopa 100 mg oral tablet | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:carbidopa 25 mg / levodopa 250 mg oral tablet n1=L-dopa | n2=en:carbidopa 25 mg / levodopa 250 mg oral tablet | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:carbidopa 50 mg / levodopa 200 mg extended release oral tablet n1=L-dopa | n2=en:carbidopa 50 mg / levodopa 200 mg extended release oral tablet | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:chemical synthesis n1=L-dopa | n2=en:chemical synthesis | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:ciladopa n1=L-dopa | n2=en:ciladopa | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:cliropamine n1=L-dopa | n2=en:cliropamine | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:cycrimine hydrochloride n1=L-dopa | n2=en:cycrimine hydrochloride | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:dihydroergocornine mesylate n1=L-dopa | n2=en:dihydroergocornine mesylate | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:dihydroergocristine mesylate n1=L-dopa | n2=en:dihydroergocristine mesylate | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:dihydroergotamine mesylate n1=L-dopa | n2=en:dihydroergotamine mesylate | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:dobutamine n1=L-dopa | n2=en:dobutamine | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:dopa 3-phosphate n1=L-dopa | n2=en:dopa 3-phosphate | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:dopa decarboxylase n1=L-dopa | n2=en:dopa decarboxylase | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:dopamine precursors/ l-amino acid decarboxylase inhibitors n1=L-dopa | n2=en:dopamine precursors/ l-amino acid decarboxylase inhibitors | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:droxidopa n1=L-dopa | n2=en:droxidopa | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:ethopropazine n1=L-dopa | n2=en:ethopropazine | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:exposure as collected domain n1=L-dopa | n2=en:exposure as collected domain | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:fencamfamin n1=L-dopa | n2=en:fencamfamin | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:fencamfamin hydrochloride n1=L-dopa | n2=en:fencamfamin hydrochloride | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:fenoldopam n1=L-dopa | n2=en:fenoldopam | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:flunamine n1=L-dopa | n2=en:flunamine | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:free fractionated catecholamine n1=L-dopa | n2=en:free fractionated catecholamine | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:glycyltyrosine n1=L-dopa | n2=en:glycyltyrosine | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:ibopamine n1=L-dopa | n2=en:ibopamine | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:in blood n1=L-dopa | n2=en:in blood | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:in urine n1=L-dopa | n2=en:in urine | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:levodopa 500 mg oral capsule n1=L-dopa | n2=en:levodopa 500 mg oral capsule | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:lisuride n1=L-dopa | n2=en:lisuride | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:melanin n1=L-dopa | n2=en:melanin | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:memantine n1=L-dopa | n2=en:memantine | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:mesocarb n1=L-dopa | n2=en:mesocarb | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:n-acetyl-alpha, beta-dehydro-3,4-dihydroxyphenylalanine ethyl ester n1=L-dopa | n2=en:n-acetyl-alpha, beta-dehydro-3,4-dihydroxyphenylalanine ethyl ester | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:n-formylmethionine leucyl-phenylalanine n1=L-dopa | n2=en:n-formylmethionine leucyl-phenylalanine | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:normetanephrine n1=L-dopa | n2=en:normetanephrine | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:orphenadrine n1=L-dopa | n2=en:orphenadrine | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:pramipexole dihydrochloride 3mg extended release tablet n1=L-dopa | n2=en:pramipexole dihydrochloride 3mg extended release tablet | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:pramipexole dihydrochloride 750microgram extended release tablet n1=L-dopa | n2=en:pramipexole dihydrochloride 750microgram extended release tablet | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:prodipine n1=L-dopa | n2=en:prodipine | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:rasagiline 0.5mg tablet n1=L-dopa | n2=en:rasagiline 0.5mg tablet | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:rasagiline mesylate n1=L-dopa | n2=en:rasagiline mesylate | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:ropinirole 2mg tablet n1=L-dopa | n2=en:ropinirole 2mg tablet | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:ropinirole 5mg tablet n1=L-dopa | n2=en:ropinirole 5mg tablet | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:rotigotine 2mg/24hours transdermal patch n1=L-dopa | n2=en:rotigotine 2mg/24hours transdermal patch | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:rotigotine 4mg/24hours transdermal patch n1=L-dopa | n2=en:rotigotine 4mg/24hours transdermal patch | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:roxindole n1=L-dopa | n2=en:roxindole | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:selegiline n1=L-dopa | n2=en:selegiline | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:selegiline 1.25mg orally disintegrating tablet n1=L-dopa | n2=en:selegiline 1.25mg orally disintegrating tablet | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 85 / 0.329 -> en:taxonomic n1=L-dopa | n2=en:taxonomic | rel=r_associated | relid=0 | w=85 L-dopa -- r_associated #0: 80 / 0.31 -> en:2,4,5-trihydroxyphenylalanine quinone n1=L-dopa | n2=en:2,4,5-trihydroxyphenylalanine quinone | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:24 hr pramipexole dihydrochloride 2.25 mg extended release oral tablet n1=L-dopa | n2=en:24 hr pramipexole dihydrochloride 2.25 mg extended release oral tablet | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:3-methoxytyramine n1=L-dopa | n2=en:3-methoxytyramine | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:3-methoxytyrosine n1=L-dopa | n2=en:3-methoxytyrosine | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:3-o-sulfato-6-fluoro-dopa n1=L-dopa | n2=en:3-o-sulfato-6-fluoro-dopa | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:3,4,6-trihydroxyphenylalanine quinone n1=L-dopa | n2=en:3,4,6-trihydroxyphenylalanine quinone | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:6-hydroxydopa n1=L-dopa | n2=en:6-hydroxydopa | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:8 hr carbidopa 36.25 mg / levodopa 145 mg extended release oral capsule n1=L-dopa | n2=en:8 hr carbidopa 36.25 mg / levodopa 145 mg extended release oral capsule | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:alentemol hydrobromide n1=L-dopa | n2=en:alentemol hydrobromide | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:amantadine n1=L-dopa | n2=en:amantadine | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:antimuscarinic agent used in parkinsonism n1=L-dopa | n2=en:antimuscarinic agent used in parkinsonism | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:antiparkinson agents, other n1=L-dopa | n2=en:antiparkinson agents, other | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:apomorphine diacetate n1=L-dopa | n2=en:apomorphine diacetate | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:apomorphine hydrochloride 30mg/3ml prefilled pen n1=L-dopa | n2=en:apomorphine hydrochloride 30mg/3ml prefilled pen | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:aspects of adverse effects n1=L-dopa | n2=en:aspects of adverse effects | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:aspects of radiation effects n1=L-dopa | n2=en:aspects of radiation effects | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:benserazide hydrochloride n1=L-dopa | n2=en:benserazide hydrochloride | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:biperiden hydrochloride n1=L-dopa | n2=en:biperiden hydrochloride | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:brasofensine n1=L-dopa | n2=en:brasofensine | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:brexpiprazole n1=L-dopa | n2=en:brexpiprazole | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:bromocriptine n1=L-dopa | n2=en:bromocriptine | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:cabergoline n1=L-dopa | n2=en:cabergoline | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:carbidopa 12.5mg/levodopa 50mg/entacapone 200mg tablet n1=L-dopa | n2=en:carbidopa 12.5mg/levodopa 50mg/entacapone 200mg tablet | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:carbidopa 25 mg / levodopa 100 mg disintegrating oral tablet n1=L-dopa | n2=en:carbidopa 25 mg / levodopa 100 mg disintegrating oral tablet | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:carbidopa 25 mg / levodopa 100 mg oral tablet n1=L-dopa | n2=en:carbidopa 25 mg / levodopa 100 mg oral tablet | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:carbidopa 25mg/levodopa 100mg/entacapone 200mg tablet n1=L-dopa | n2=en:carbidopa 25mg/levodopa 100mg/entacapone 200mg tablet | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:carbidopa anhydrous n1=L-dopa | n2=en:carbidopa anhydrous | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:carmantadine n1=L-dopa | n2=en:carmantadine | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:cellular secretion n1=L-dopa | n2=en:cellular secretion | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:chemical aspects n1=L-dopa | n2=en:chemical aspects | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:cianergoline n1=L-dopa | n2=en:cianergoline | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:deficiency aspects n1=L-dopa | n2=en:deficiency aspects | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:dihydroergocristine n1=L-dopa | n2=en:dihydroergocristine | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:dihydroergocryptine n1=L-dopa | n2=en:dihydroergocryptine | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:dihydroergotamine n1=L-dopa | n2=en:dihydroergotamine | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:dihydroxyphenylalanine hydrochloride, (2:1) n1=L-dopa | n2=en:dihydroxyphenylalanine hydrochloride, (2:1) | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:diprobutine n1=L-dopa | n2=en:diprobutine | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:dopa, dl- n1=L-dopa | n2=en:dopa, dl- | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:dopamantine n1=L-dopa | n2=en:dopamantine | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:dopexamine n1=L-dopa | n2=en:dopexamine | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:dopexamine hydrochloride n1=L-dopa | n2=en:dopexamine hydrochloride | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:drug effect n1=L-dopa | n2=en:drug effect | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:entacapone n1=L-dopa | n2=en:entacapone | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:entacapone 200mg tablet n1=L-dopa | n2=en:entacapone 200mg tablet | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:epinephrine n1=L-dopa | n2=en:epinephrine | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:epinephrine + norepinephrine n1=L-dopa | n2=en:epinephrine + norepinephrine | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:ergonovine n1=L-dopa | n2=en:ergonovine | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:ergonovine maleate n1=L-dopa | n2=en:ergonovine maleate | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:fosopamine n1=L-dopa | n2=en:fosopamine | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:gamma-glutamyl dopa n1=L-dopa | n2=en:gamma-glutamyl dopa | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:genetic aspects n1=L-dopa | n2=en:genetic aspects | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:halonamine n1=L-dopa | n2=en:halonamine | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:hyoscyamine n1=L-dopa | n2=en:hyoscyamine | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:l-tyrosine powder n1=L-dopa | n2=en:l-tyrosine powder | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:lergotrile n1=L-dopa | n2=en:lergotrile | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:lergotrile mesylate n1=L-dopa | n2=en:lergotrile mesylate | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:levodopa 100 mg oral capsule n1=L-dopa | n2=en:levodopa 100 mg oral capsule | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:levodopa 100 mg oral tablet n1=L-dopa | n2=en:levodopa 100 mg oral tablet | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:lometraline hydrochloride n1=L-dopa | n2=en:lometraline hydrochloride | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:manifaxine n1=L-dopa | n2=en:manifaxine | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:melevodopa n1=L-dopa | n2=en:melevodopa | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:memantine hydrochloride n1=L-dopa | n2=en:memantine hydrochloride | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:mesulergine n1=L-dopa | n2=en:mesulergine | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:metabolic aspects n1=L-dopa | n2=en:metabolic aspects | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:metaproterenol n1=L-dopa | n2=en:metaproterenol | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:metergoline n1=L-dopa | n2=en:metergoline | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:methyldopate hydrochloride n1=L-dopa | n2=en:methyldopate hydrochloride | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:nebicapone n1=L-dopa | n2=en:nebicapone | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:nolomirole n1=L-dopa | n2=en:nolomirole | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:omidoline n1=L-dopa | n2=en:omidoline | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:p-fluorophenylalanine n1=L-dopa | n2=en:p-fluorophenylalanine | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:pardoprunox n1=L-dopa | n2=en:pardoprunox | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:pardoprunox hydrochloride n1=L-dopa | n2=en:pardoprunox hydrochloride | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:pergolide mesylate n1=L-dopa | n2=en:pergolide mesylate | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:pharmacokinetic aspects n1=L-dopa | n2=en:pharmacokinetic aspects | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:phenylalanine supplementation n1=L-dopa | n2=en:phenylalanine supplementation | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:phenylthiohydantoin-3,4-dihydroxyphenylalanine n1=L-dopa | n2=en:phenylthiohydantoin-3,4-dihydroxyphenylalanine | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:physiological aspects n1=L-dopa | n2=en:physiological aspects | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:piribedil n1=L-dopa | n2=en:piribedil | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:piroheptine n1=L-dopa | n2=en:piroheptine | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:pramipexole n1=L-dopa | n2=en:pramipexole | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:pramipexole dihydrochloride n1=L-dopa | n2=en:pramipexole dihydrochloride | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:pramipexole dihydrochloride 4.5mg extended release tablet n1=L-dopa | n2=en:pramipexole dihydrochloride 4.5mg extended release tablet | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:pramipexole dihydrochloride 500micrograms tablet n1=L-dopa | n2=en:pramipexole dihydrochloride 500micrograms tablet | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:pramipexole dihydrochloride 750microgram tablet n1=L-dopa | n2=en:pramipexole dihydrochloride 750microgram tablet | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:procyclidine n1=L-dopa | n2=en:procyclidine | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:procyclidine hydrochloride n1=L-dopa | n2=en:procyclidine hydrochloride | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:proterguride n1=L-dopa | n2=en:proterguride | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:quinagolide n1=L-dopa | n2=en:quinagolide | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:radafaxine n1=L-dopa | n2=en:radafaxine | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:rasagiline n1=L-dopa | n2=en:rasagiline | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:romergoline n1=L-dopa | n2=en:romergoline | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:ropinirole n1=L-dopa | n2=en:ropinirole | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:ropinirole 250micrograms tablet n1=L-dopa | n2=en:ropinirole 250micrograms tablet | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:ropinirole hydrochloride n1=L-dopa | n2=en:ropinirole hydrochloride | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:rotigotine n1=L-dopa | n2=en:rotigotine | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:sinemet n1=L-dopa | n2=en:sinemet | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:standards characteristics n1=L-dopa | n2=en:standards characteristics | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:sumanirole n1=L-dopa | n2=en:sumanirole | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:tolcapone n1=L-dopa | n2=en:tolcapone | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:tolcapone 100mg tablet n1=L-dopa | n2=en:tolcapone 100mg tablet | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:tolcapone 200mg tablet n1=L-dopa | n2=en:tolcapone 200mg tablet | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:toxicity aspects n1=L-dopa | n2=en:toxicity aspects | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:trihexyphenidyl n1=L-dopa | n2=en:trihexyphenidyl | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:trihexyphenidyl hydrochloride n1=L-dopa | n2=en:trihexyphenidyl hydrochloride | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:triiodotyrosine n1=L-dopa | n2=en:triiodotyrosine | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:vanoxerine n1=L-dopa | n2=en:vanoxerine | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 80 / 0.31 -> en:zelandopam n1=L-dopa | n2=en:zelandopam | rel=r_associated | relid=0 | w=80 L-dopa -- r_associated #0: 79 / 0.306 -> barrière hémato-encéphalique n1=L-dopa | n2=barrière hémato-encéphalique | rel=r_associated | relid=0 | w=79 L-dopa -- r_associated #0: 76 / 0.295 -> 3,4-dihydroxyphénylalanine n1=L-dopa | n2=3,4-dihydroxyphénylalanine | rel=r_associated | relid=0 | w=76 L-dopa -- r_associated #0: 75 / 0.291 -> biologie n1=L-dopa | n2=biologie | rel=r_associated | relid=0 | w=75 L-dopa -- r_associated #0: 75 / 0.291 -> précurseur n1=L-dopa | n2=précurseur | rel=r_associated | relid=0 | w=75 L-dopa -- r_associated #0: 65 / 0.252 -> en:adrogolide hydrochloride n1=L-dopa | n2=en:adrogolide hydrochloride | rel=r_associated | relid=0 | w=65 L-dopa -- r_associated #0: 65 / 0.252 -> en:aplindore n1=L-dopa | n2=en:aplindore | rel=r_associated | relid=0 | w=65 L-dopa -- r_associated #0: 65 / 0.252 -> en:aplindore fumarate n1=L-dopa | n2=en:aplindore fumarate | rel=r_associated | relid=0 | w=65 L-dopa -- r_associated #0: 65 / 0.252 -> en:aromatic amino acid decarboxylase inhibitors n1=L-dopa | n2=en:aromatic amino acid decarboxylase inhibitors | rel=r_associated | relid=0 | w=65 L-dopa -- r_associated #0: 65 / 0.252 -> en:benserazide n1=L-dopa | n2=en:benserazide | rel=r_associated | relid=0 | w=65 L-dopa -- r_associated #0: 65 / 0.252 -> en:bioformation n1=L-dopa | n2=en:bioformation | rel=r_associated | relid=0 | w=65 L-dopa -- r_associated #0: 65 / 0.252 -> en:budipine n1=L-dopa | n2=en:budipine | rel=r_associated | relid=0 | w=65 L-dopa -- r_associated #0: 65 / 0.252 -> en:carbidopa n1=L-dopa | n2=en:carbidopa | rel=r_associated | relid=0 | w=65 L-dopa -- r_associated #0: 65 / 0.252 -> en:carmoxirole n1=L-dopa | n2=en:carmoxirole | rel=r_associated | relid=0 | w=65 L-dopa -- r_associated #0: 65 / 0.252 -> en:dopa decarboxylase inhibitors n1=L-dopa | n2=en:dopa decarboxylase inhibitors | rel=r_associated | relid=0 | w=65 L-dopa -- r_associated #0: 65 / 0.252 -> en:doreptide n1=L-dopa | n2=en:doreptide | rel=r_associated | relid=0 | w=65 L-dopa -- r_associated #0: 65 / 0.252 -> en:etisulergine n1=L-dopa | n2=en:etisulergine | rel=r_associated | relid=0 | w=65 L-dopa -- r_associated #0: 65 / 0.252 -> en:immunology aspects n1=L-dopa | n2=en:immunology aspects | rel=r_associated | relid=0 | w=65 L-dopa -- r_associated #0: 65 / 0.252 -> en:in cerebrospinal fluid n1=L-dopa | n2=en:in cerebrospinal fluid | rel=r_associated | relid=0 | w=65 L-dopa -- r_associated #0: 65 / 0.252 -> en:l-norepinephrine n1=L-dopa | n2=en:l-norepinephrine | rel=r_associated | relid=0 | w=65 L-dopa -- r_associated #0: 65 / 0.252 -> en:mechanism of action qualifier n1=L-dopa | n2=en:mechanism of action qualifier | rel=r_associated | relid=0 | w=65 L-dopa -- r_associated #0: 65 / 0.252 -> en:medifoxamine n1=L-dopa | n2=en:medifoxamine | rel=r_associated | relid=0 | w=65 L-dopa -- r_associated #0: 65 / 0.252 -> en:metanephrine n1=L-dopa | n2=en:metanephrine | rel=r_associated | relid=0 | w=65 L-dopa -- r_associated #0: 65 / 0.252 -> en:oxiperomide n1=L-dopa | n2=en:oxiperomide | rel=r_associated | relid=0 | w=65 L-dopa -- r_associated #0: 65 / 0.252 -> en:selegiline hydrochloride 5mg tablet n1=L-dopa | n2=en:selegiline hydrochloride 5mg tablet | rel=r_associated | relid=0 | w=65 L-dopa -- r_associated #0: 65 / 0.252 -> en:sibenadet hydrochloride n1=L-dopa | n2=en:sibenadet hydrochloride | rel=r_associated | relid=0 | w=65 L-dopa -- r_associated #0: 60 / 0.233 -> en:alpha-difluoromethyl-dopa n1=L-dopa | n2=en:alpha-difluoromethyl-dopa | rel=r_associated | relid=0 | w=60 L-dopa -- r_associated #0: 60 / 0.233 -> en:amino acid n1=L-dopa | n2=en:amino acid | rel=r_associated | relid=0 | w=60 L-dopa -- r_associated #0: 60 / 0.233 -> en:antiparkinsonian agent n1=L-dopa | n2=en:antiparkinsonian agent | rel=r_associated | relid=0 | w=60 L-dopa -- r_associated #0: 60 / 0.233 -> en:apomorphine hydrochloride n1=L-dopa | n2=en:apomorphine hydrochloride | rel=r_associated | relid=0 | w=60 L-dopa -- r_associated #0: 60 / 0.233 -> en:apomorphine hydrochloride anhydrous n1=L-dopa | n2=en:apomorphine hydrochloride anhydrous | rel=r_associated | relid=0 | w=60 L-dopa -- r_associated #0: 60 / 0.233 -> en:butaperazine n1=L-dopa | n2=en:butaperazine | rel=r_associated | relid=0 | w=60 L-dopa -- r_associated #0: 60 / 0.233 -> en:butaperazine maleate n1=L-dopa | n2=en:butaperazine maleate | rel=r_associated | relid=0 | w=60 L-dopa -- r_associated #0: 60 / 0.233 -> en:carbidopa + levodopa 25mg/100mg m/r tablet n1=L-dopa | n2=en:carbidopa + levodopa 25mg/100mg m/r tablet | rel=r_associated | relid=0 | w=60 L-dopa -- r_associated #0: 60 / 0.233 -> en:catechol-o-methyltransferase inhibitor n1=L-dopa | n2=en:catechol-o-methyltransferase inhibitor | rel=r_associated | relid=0 | w=60 L-dopa -- r_associated #0: 60 / 0.233 -> en:contraindications aspect n1=L-dopa | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60 L-dopa -- r_associated #0: 60 / 0.233 -> en:cycrimine n1=L-dopa | n2=en:cycrimine | rel=r_associated | relid=0 | w=60 L-dopa -- r_associated #0: 60 / 0.233 -> en:diphenhydramine n1=L-dopa | n2=en:diphenhydramine | rel=r_associated | relid=0 | w=60 L-dopa -- r_associated #0: 60 / 0.233 -> en:fenclonine n1=L-dopa | n2=en:fenclonine | rel=r_associated | relid=0 | w=60 L-dopa -- r_associated #0: 60 / 0.233 -> en:fenoldopam mesylate n1=L-dopa | n2=en:fenoldopam mesylate | rel=r_associated | relid=0 | w=60 L-dopa -- r_associated #0: 60 / 0.233 -> en:historical aspects qualifier n1=L-dopa | n2=en:historical aspects qualifier | rel=r_associated | relid=0 | w=60 L-dopa -- r_associated #0: 60 / 0.233 -> en:methixene n1=L-dopa | n2=en:methixene | rel=r_associated | relid=0 | w=60 L-dopa -- r_associated #0: 60 / 0.233 -> en:monoamine oxidase b (mao-b) inhibitors n1=L-dopa | n2=en:monoamine oxidase b (mao-b) inhibitors | rel=r_associated | relid=0 | w=60 L-dopa -- r_associated #0: 60 / 0.233 -> en:oxidopamine n1=L-dopa | n2=en:oxidopamine | rel=r_associated | relid=0 | w=60 L-dopa -- r_associated #0: 60 / 0.233 -> en:pareptide n1=L-dopa | n2=en:pareptide | rel=r_associated | relid=0 | w=60 L-dopa -- r_associated #0: 60 / 0.233 -> en:poisoning aspects n1=L-dopa | n2=en:poisoning aspects | rel=r_associated | relid=0 | w=60 L-dopa -- r_associated #0: 60 / 0.233 -> en:poly(o,o'-dicarbobenzoyx-l-beta-3,4-dihydroxyphenyl-alpha- alanine) n1=L-dopa | n2=en:poly(o,o'-dicarbobenzoyx-l-beta-3,4-dihydroxyphenyl-alpha- alanine) | rel=r_associated | relid=0 | w=60 L-dopa -- r_associated #0: 60 / 0.233 -> en:preladenant n1=L-dopa | n2=en:preladenant | rel=r_associated | relid=0 | w=60 L-dopa -- r_associated #0: 60 / 0.233 -> en:ropinirole 500micrograms tablet n1=L-dopa | n2=en:ropinirole 500micrograms tablet | rel=r_associated | relid=0 | w=60 L-dopa -- r_associated #0: 60 / 0.233 -> en:ropinirole 8mg extended release tablet n1=L-dopa | n2=en:ropinirole 8mg extended release tablet | rel=r_associated | relid=0 | w=60 L-dopa -- r_associated #0: 60 / 0.233 -> en:therapeutic use - qualifier n1=L-dopa | n2=en:therapeutic use - qualifier | rel=r_associated | relid=0 | w=60 L-dopa -- r_associated #0: 45 / 0.174 -> en:cysteinyldopa n1=L-dopa | n2=en:cysteinyldopa | rel=r_associated | relid=0 | w=45 L-dopa -- r_associated #0: 40 / 0.155 -> en:toxicology n1=L-dopa | n2=en:toxicology | rel=r_associated | relid=0 | w=40 L-dopa -- r_associated #0: 35 / 0.136 -> en:5-fluorodopa n1=L-dopa | n2=en:5-fluorodopa | rel=r_associated | relid=0 | w=35 L-dopa -- r_associated #0: 35 / 0.136 -> en:biperiden lactate n1=L-dopa | n2=en:biperiden lactate | rel=r_associated | relid=0 | w=35 L-dopa -- r_associated #0: 35 / 0.136 -> en:dihydroergocornine n1=L-dopa | n2=en:dihydroergocornine | rel=r_associated | relid=0 | w=35 L-dopa -- r_associated #0: 35 / 0.136 -> en:docarpamine n1=L-dopa | n2=en:docarpamine | rel=r_associated | relid=0 | w=35 L-dopa -- r_associated #0: 35 / 0.136 -> en:dopa melanin n1=L-dopa | n2=en:dopa melanin | rel=r_associated | relid=0 | w=35 L-dopa -- r_associated #0: 35 / 0.136 -> en:etilevodopa n1=L-dopa | n2=en:etilevodopa | rel=r_associated | relid=0 | w=35 L-dopa -- r_associated #0: 35 / 0.136 -> en:free catecholamines n1=L-dopa | n2=en:free catecholamines | rel=r_associated | relid=0 | w=35 L-dopa -- r_associated #0: 35 / 0.136 -> en:istradefylline n1=L-dopa | n2=en:istradefylline | rel=r_associated | relid=0 | w=35 L-dopa -- r_associated #0: 35 / 0.136 -> en:pramipexole 700micrograms tablet n1=L-dopa | n2=en:pramipexole 700micrograms tablet | rel=r_associated | relid=0 | w=35 L-dopa -- r_associated #0: 35 / 0.136 -> en:tirofiban n1=L-dopa | n2=en:tirofiban | rel=r_associated | relid=0 | w=35 L-dopa -- r_associated #0: 35 / 0.136 -> médicaments n1=L-dopa | n2=médicaments | rel=r_associated | relid=0 | w=35 L-dopa -- r_associated #0: 30 / 0.116 -> en:24 hr pramipexole dihydrochloride 3.75 mg extended release oral tablet n1=L-dopa | n2=en:24 hr pramipexole dihydrochloride 3.75 mg extended release oral tablet | rel=r_associated | relid=0 | w=30 L-dopa -- r_associated #0: 30 / 0.116 -> en:delergotrile n1=L-dopa | n2=en:delergotrile | rel=r_associated | relid=0 | w=30 L-dopa -- r_associated #0: 25 / 0.097 -> en:dihydroxyphenylalanine n1=L-dopa | n2=en:dihydroxyphenylalanine | rel=r_associated | relid=0 | w=25 L-dopa -- r_associated #0: 17 / 0.066 -> Maladie de Parkinson n1=L-dopa | n2=Maladie de Parkinson | rel=r_associated | relid=0 | w=17 L-dopa -- r_associated #0: 16 / 0.062 -> médicament n1=L-dopa | n2=médicament | rel=r_associated | relid=0 | w=16 L-dopa -- r_associated #0: 15 / 0.058 -> dopa-décarboxylase n1=L-dopa | n2=dopa-décarboxylase | rel=r_associated | relid=0 | w=15 L-dopa -- r_associated #0: 14 / 0.054 -> glaucome n1=L-dopa | n2=glaucome | rel=r_associated | relid=0 | w=14 L-dopa -- r_associated #0: 13 / 0.05 -> Enterococcus faecalis n1=L-dopa | n2=Enterococcus faecalis | rel=r_associated | relid=0 | w=13 L-dopa -- r_associated #0: 12 / 0.047 -> contre-indication n1=L-dopa | n2=contre-indication | rel=r_associated | relid=0 | w=12 L-dopa -- r_associated #0: 11 / 0.043 -> amoxicilline n1=L-dopa | n2=amoxicilline | rel=r_associated | relid=0 | w=11 L-dopa -- r_associated #0: 11 / 0.043 -> antibiotiques n1=L-dopa | n2=antibiotiques | rel=r_associated | relid=0 | w=11 L-dopa -- r_associated #0: 11 / 0.043 -> tyrosine n1=L-dopa | n2=tyrosine | rel=r_associated | relid=0 | w=11 L-dopa -- r_associated #0: 10 / 0.039 -> en:medical supplies n1=L-dopa | n2=en:medical supplies | rel=r_associated | relid=0 | w=10 L-dopa -- r_associated #0: 10 / 0.039 -> en:medicines n1=L-dopa | n2=en:medicines | rel=r_associated | relid=0 | w=10 L-dopa -- r_associated #0: 8 / 0.031 -> carbidopa n1=L-dopa | n2=carbidopa | rel=r_associated | relid=0 | w=8 L-dopa -- r_associated #0: 7 / 0.027 -> clarithromycine n1=L-dopa | n2=clarithromycine | rel=r_associated | relid=0 | w=7 L-dopa -- r_associated #0: 6 / 0.023 -> substance n1=L-dopa | n2=substance | rel=r_associated | relid=0 | w=6 L-dopa -- r_associated #0: 5 / 0.019 -> 3TC n1=L-dopa | n2=3TC | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> abatacept n1=L-dopa | n2=abatacept | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> acarbose n1=L-dopa | n2=acarbose | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> acénocoumarol n1=L-dopa | n2=acénocoumarol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> acétaminophène n1=L-dopa | n2=acétaminophène | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> acétylcystéine n1=L-dopa | n2=acétylcystéine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> acide docosahexaènoïque n1=L-dopa | n2=acide docosahexaènoïque | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> acide lactique n1=L-dopa | n2=acide lactique | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> Acide lactique n1=L-dopa | n2=Acide lactique | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> acide tranexamique n1=L-dopa | n2=acide tranexamique | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> acitrétine n1=L-dopa | n2=acitrétine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> agent antibactérien n1=L-dopa | n2=agent antibactérien | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> agent antinéoplasique n1=L-dopa | n2=agent antinéoplasique | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> agent biologique n1=L-dopa | n2=agent biologique | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> agent tensioactif n1=L-dopa | n2=agent tensioactif | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> agent tératogène n1=L-dopa | n2=agent tératogène | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> agoniste dopaminergique n1=L-dopa | n2=agoniste dopaminergique | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> aller ensemble n1=L-dopa | n2=aller ensemble | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> allergie à un médicament n1=L-dopa | n2=allergie à un médicament | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> allergie aux médicaments n1=L-dopa | n2=allergie aux médicaments | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> allergie médicamenteuse n1=L-dopa | n2=allergie médicamenteuse | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> amifampridine n1=L-dopa | n2=amifampridine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> amifostine n1=L-dopa | n2=amifostine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> anæsthésique n1=L-dopa | n2=anæsthésique | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> anesthésique n1=L-dopa | n2=anesthésique | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> angiostatine n1=L-dopa | n2=angiostatine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> anhydride arsénieux n1=L-dopa | n2=anhydride arsénieux | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> antibiotique n1=L-dopa | n2=antibiotique | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> antienzyme n1=L-dopa | n2=antienzyme | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> antimétabolite n1=L-dopa | n2=antimétabolite | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> apixaban n1=L-dopa | n2=apixaban | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> arsenic blanc n1=L-dopa | n2=arsenic blanc | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> artésunate n1=L-dopa | n2=artésunate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> asparaginase n1=L-dopa | n2=asparaginase | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> astringente n1=L-dopa | n2=astringente | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> aténolol n1=L-dopa | n2=aténolol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> auranofine n1=L-dopa | n2=auranofine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> axitinib n1=L-dopa | n2=axitinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> Azadirachta indica n1=L-dopa | n2=Azadirachta indica | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> baclofen n1=L-dopa | n2=baclofen | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> baclofène n1=L-dopa | n2=baclofène | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> baricitinib n1=L-dopa | n2=baricitinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> belimumab n1=L-dopa | n2=belimumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> bevacizumab n1=L-dopa | n2=bevacizumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> bléomycine sulfate n1=L-dopa | n2=bléomycine sulfate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> busulfan n1=L-dopa | n2=busulfan | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> cabergoline n1=L-dopa | n2=cabergoline | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> cannabidiol n1=L-dopa | n2=cannabidiol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> cannabinol n1=L-dopa | n2=cannabinol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> capécitabine n1=L-dopa | n2=capécitabine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> capsaïcine n1=L-dopa | n2=capsaïcine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> capsaïsine n1=L-dopa | n2=capsaïsine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> carbendazime n1=L-dopa | n2=carbendazime | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> carbonate de lithium n1=L-dopa | n2=carbonate de lithium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> carbonate lithium n1=L-dopa | n2=carbonate lithium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> carcinogène n1=L-dopa | n2=carcinogène | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> carmustine n1=L-dopa | n2=carmustine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> cefpodoxime proxétil n1=L-dopa | n2=cefpodoxime proxétil | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> ceritinib n1=L-dopa | n2=ceritinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> certolizumab n1=L-dopa | n2=certolizumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> cétirizine n1=L-dopa | n2=cétirizine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> cetuximab n1=L-dopa | n2=cetuximab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> chélateur n1=L-dopa | n2=chélateur | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> chlorhydrate d'hydralazine n1=L-dopa | n2=chlorhydrate d'hydralazine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> chlorhydrate de doxorubicine n1=L-dopa | n2=chlorhydrate de doxorubicine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> chlorhydrate de métronidazole n1=L-dopa | n2=chlorhydrate de métronidazole | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> cimétidine n1=L-dopa | n2=cimétidine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> cis-diaminedichloroplatine n1=L-dopa | n2=cis-diaminedichloroplatine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> cisplatine n1=L-dopa | n2=cisplatine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> citrate de clomifène n1=L-dopa | n2=citrate de clomifène | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> citrate de clomiphène n1=L-dopa | n2=citrate de clomiphène | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> citrate de magnésium n1=L-dopa | n2=citrate de magnésium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> citrulline n1=L-dopa | n2=citrulline | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> clé à fourche n1=L-dopa | n2=clé à fourche | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> clé à fourches n1=L-dopa | n2=clé à fourches | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> clé ouverte n1=L-dopa | n2=clé ouverte | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> clef n1=L-dopa | n2=clef | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> clef à fourche n1=L-dopa | n2=clef à fourche | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> clef à fourches n1=L-dopa | n2=clef à fourches | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> clef ouverte n1=L-dopa | n2=clef ouverte | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> cobalamine n1=L-dopa | n2=cobalamine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> cortisol n1=L-dopa | n2=cortisol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> coumaphène n1=L-dopa | n2=coumaphène | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> créatine phosphate n1=L-dopa | n2=créatine phosphate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> curcumine n1=L-dopa | n2=curcumine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> cycloleucine n1=L-dopa | n2=cycloleucine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> cyclophosphamide n1=L-dopa | n2=cyclophosphamide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> cystéinyldopa n1=L-dopa | n2=cystéinyldopa | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> dabrafenib n1=L-dopa | n2=dabrafenib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> daclatasvir n1=L-dopa | n2=daclatasvir | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> dactinomycine n1=L-dopa | n2=dactinomycine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> dapsone n1=L-dopa | n2=dapsone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> dasatinib n1=L-dopa | n2=dasatinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> dextran n1=L-dopa | n2=dextran | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> dextrane n1=L-dopa | n2=dextrane | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> dichlorhydrate d'histamine n1=L-dopa | n2=dichlorhydrate d'histamine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> dicumarol n1=L-dopa | n2=dicumarol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> diéthylstilbestrol n1=L-dopa | n2=diéthylstilbestrol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> diéthylstilboestrol n1=L-dopa | n2=diéthylstilboestrol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> digitoxine n1=L-dopa | n2=digitoxine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> dihydroergocornine n1=L-dopa | n2=dihydroergocornine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> diphenhydramine n1=L-dopa | n2=diphenhydramine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> diphénhydramine n1=L-dopa | n2=diphénhydramine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> dobutamine n1=L-dopa | n2=dobutamine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> docusate n1=L-dopa | n2=docusate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> dopaquinone n1=L-dopa | n2=dopaquinone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> E100 n1=L-dopa | n2=E100 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> E100(i) n1=L-dopa | n2=E100(i) | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> E1200 n1=L-dopa | n2=E1200 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> E1521 n1=L-dopa | n2=E1521 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> E270 n1=L-dopa | n2=E270 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> E553(iii) n1=L-dopa | n2=E553(iii) | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> eau distillée n1=L-dopa | n2=eau distillée | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> échinomycine n1=L-dopa | n2=échinomycine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> emtricitabine n1=L-dopa | n2=emtricitabine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:((o,o-diacetyl)-l-dopa-methylester)succinyldiamide n1=L-dopa | n2=en:((o,o-diacetyl)-l-dopa-methylester)succinyldiamide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:(o,o-diacetyl)-l-dopa-methylester fumaric diamide n1=L-dopa | n2=en:(o,o-diacetyl)-l-dopa-methylester fumaric diamide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:(o,o-diacetyl)-l-dopa-methylester maleic diamide n1=L-dopa | n2=en:(o,o-diacetyl)-l-dopa-methylester maleic diamide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:[18f]-labeled substance p antagonist receptor quantifier n1=L-dopa | n2=en:[18f]-labeled substance p antagonist receptor quantifier | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:[18f]l-fac n1=L-dopa | n2=en:[18f]l-fac | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:1,2-carbon c 13-labeled glucose n1=L-dopa | n2=en:1,2-carbon c 13-labeled glucose | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:11 epicortisol n1=L-dopa | n2=en:11 epicortisol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:13-deoxydoxorubicin n1=L-dopa | n2=en:13-deoxydoxorubicin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:14c bms-275183 n1=L-dopa | n2=en:14c bms-275183 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:16,16-dimethyl prostaglandin e2 n1=L-dopa | n2=en:16,16-dimethyl prostaglandin e2 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:17-hydroxycorticosterone n1=L-dopa | n2=en:17-hydroxycorticosterone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:18-f-fluoroacetate n1=L-dopa | n2=en:18-f-fluoroacetate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:18f-fhbg n1=L-dopa | n2=en:18f-fhbg | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:18f-fluoroazomycin arabinoside n1=L-dopa | n2=en:18f-fluoroazomycin arabinoside | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:18f-labeled mini-peg spacered rgd dimer n1=L-dopa | n2=en:18f-labeled mini-peg spacered rgd dimer | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:2-fluoropropionyl-labeled pegylated dimeric rgd peptide n1=L-dopa | n2=en:2-fluoropropionyl-labeled pegylated dimeric rgd peptide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:2-hydroxyoleic acid n1=L-dopa | n2=en:2-hydroxyoleic acid | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:2-methoxyestradiol n1=L-dopa | n2=en:2-methoxyestradiol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:2-methoxyestradiol nanocrystal colloidal dispersion n1=L-dopa | n2=en:2-methoxyestradiol nanocrystal colloidal dispersion | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:2'-f-ara-deoxyuridine n1=L-dopa | n2=en:2'-f-ara-deoxyuridine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:2g-1 tcr retroviral vector-transduced lymphocytes n1=L-dopa | n2=en:2g-1 tcr retroviral vector-transduced lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:3-deazauridine n1=L-dopa | n2=en:3-deazauridine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:3'-aminomethyl nicotine-p. aeruginosa r-exoprotein a conjugate vaccine n1=L-dopa | n2=en:3'-aminomethyl nicotine-p. aeruginosa r-exoprotein a conjugate vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:3'-c-ethynylcytidine n1=L-dopa | n2=en:3'-c-ethynylcytidine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:4-1bb agonist monoclonal antibody pf-05082566 n1=L-dopa | n2=en:4-1bb agonist monoclonal antibody pf-05082566 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:4-peptide melanoma vaccine n1=L-dopa | n2=en:4-peptide melanoma vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:5-fitc-labeled gi-heptapeptide n1=L-dopa | n2=en:5-fitc-labeled gi-heptapeptide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:5-fluorouracil/salicylic acid topical solution n1=L-dopa | n2=en:5-fluorouracil/salicylic acid topical solution | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:5-ht3 receptor antagonist n1=L-dopa | n2=en:5-ht3 receptor antagonist | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:5-s-glutathionyl-beta-alanyl-l-dopa n1=L-dopa | n2=en:5-s-glutathionyl-beta-alanyl-l-dopa | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases isoform 3 inhibitor act-pfk-158 n1=L-dopa | n2=en:6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases isoform 3 inhibitor act-pfk-158 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:6,8-bis(benzylthio)octanoic acid n1=L-dopa | n2=en:6,8-bis(benzylthio)octanoic acid | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:7-cyanoquinocarcinol n1=L-dopa | n2=en:7-cyanoquinocarcinol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:7-hydroxystaurosporine n1=L-dopa | n2=en:7-hydroxystaurosporine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:8-hydroxyquinoline sulfate ointment n1=L-dopa | n2=en:8-hydroxyquinoline sulfate ointment | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:abagovomab n1=L-dopa | n2=en:abagovomab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:abarelix n1=L-dopa | n2=en:abarelix | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:abatacept n1=L-dopa | n2=en:abatacept | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:abbv-221 n1=L-dopa | n2=en:abbv-221 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:abexinostat n1=L-dopa | n2=en:abexinostat | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:abiraterone acetate n1=L-dopa | n2=en:abiraterone acetate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:abortifacient agents n1=L-dopa | n2=en:abortifacient agents | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:abr-217620 n1=L-dopa | n2=en:abr-217620 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:absorbable adhesion barrier gel n1=L-dopa | n2=en:absorbable adhesion barrier gel | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:absorbable fibrin sealant patch n1=L-dopa | n2=en:absorbable fibrin sealant patch | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:absorbable gelatin sponge n1=L-dopa | n2=en:absorbable gelatin sponge | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:absorbable modified polymer hemostatic powder n1=L-dopa | n2=en:absorbable modified polymer hemostatic powder | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:abt-751 n1=L-dopa | n2=en:abt-751 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:abvd regimen n1=L-dopa | n2=en:abvd regimen | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:abve regimen n1=L-dopa | n2=en:abve regimen | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ac regimen n1=L-dopa | n2=en:ac regimen | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:acai berry juice n1=L-dopa | n2=en:acai berry juice | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:acalabrutinib n1=L-dopa | n2=en:acalabrutinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:acarbose n1=L-dopa | n2=en:acarbose | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:acenocoumarol n1=L-dopa | n2=en:acenocoumarol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:acetaminophen n1=L-dopa | n2=en:acetaminophen | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:acetylcysteine n1=L-dopa | n2=en:acetylcysteine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:acid of milk n1=L-dopa | n2=en:acid of milk | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:acitretin n1=L-dopa | n2=en:acitretin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:acivicin n1=L-dopa | n2=en:acivicin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:acodazole n1=L-dopa | n2=en:acodazole | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:acolbifene hydrochloride n1=L-dopa | n2=en:acolbifene hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:acs 84 n1=L-dopa | n2=en:acs 84 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:activin type 2b receptor fc fusion protein stm 434 n1=L-dopa | n2=en:activin type 2b receptor fc fusion protein stm 434 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:acyclovir sodium n1=L-dopa | n2=en:acyclovir sodium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ad-hcmv-flt3l n1=L-dopa | n2=en:ad-hcmv-flt3l | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ad-isf35 n1=L-dopa | n2=en:ad-isf35 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ad-sig-hmuc-1/ecdcd40l vaccine n1=L-dopa | n2=en:ad-sig-hmuc-1/ecdcd40l vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ad5-ycd/muttk(sr39)rep-adp n1=L-dopa | n2=en:ad5-ycd/muttk(sr39)rep-adp | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ad5.sstr/tk.rgd n1=L-dopa | n2=en:ad5.sstr/tk.rgd | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ad5cmv-p53 gene n1=L-dopa | n2=en:ad5cmv-p53 gene | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:adecatumumab n1=L-dopa | n2=en:adecatumumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:adefovir dipivoxil n1=L-dopa | n2=en:adefovir dipivoxil | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:adenosine a2a receptor antagonist pbf-509 n1=L-dopa | n2=en:adenosine a2a receptor antagonist pbf-509 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:adenosine cyclic phosphate 6 [hp_x] in 1 ml / apiole (parsley) 6 [hp_x] in 1 ml / levodopa 6 [hp_x] in 1 ml / melatonin 6 [hp_x] in 1 ml / sus scrofa pineal gland 8 [hp_x] in 1 ml / sus scrofa thalamus lateral geniculate nucleus 8 [hp_x] in 1 ml / visc n1=L-dopa | n2=en:adenosine cyclic phosphate 6 [hp_x] in 1 ml / apiole (parsley) 6 [hp_x] in 1 ml / levodopa 6 [hp_x] in 1 ml / melatonin 6 [hp_x] in 1 ml / sus scrofa pineal gland 8 [hp_x] in 1 ml / sus scrofa thalamus lateral geniculate nucleus 8 [hp_x] in 1 ml / visc | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:adenovector encoding mda7 n1=L-dopa | n2=en:adenovector encoding mda7 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:adenovector-transduced ap1903-inducible myd88/cd40-expressing autologous psma-specific prostate cancer vaccine bpx-201 n1=L-dopa | n2=en:adenovector-transduced ap1903-inducible myd88/cd40-expressing autologous psma-specific prostate cancer vaccine bpx-201 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:adenovirus 5-cd40 ligand n1=L-dopa | n2=en:adenovirus 5-cd40 ligand | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:adenovirus 5-human guanylyl cyclase c-padre vaccine n1=L-dopa | n2=en:adenovirus 5-human guanylyl cyclase c-padre vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:adenovirus b7-1 n1=L-dopa | n2=en:adenovirus b7-1 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:adenovirus encoding rat her-2/neu n1=L-dopa | n2=en:adenovirus encoding rat her-2/neu | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:adenovirus encoding recombinant human endostatin n1=L-dopa | n2=en:adenovirus encoding recombinant human endostatin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:adenovirus-mediated human interleukin-12 n1=L-dopa | n2=en:adenovirus-mediated human interleukin-12 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:adenovirus-mediated human interleukin-12 inxn-2001 plus activator ligand inxn-1001 n1=L-dopa | n2=en:adenovirus-mediated human interleukin-12 inxn-2001 plus activator ligand inxn-1001 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:adenovirus-p53 transduced dendritic cell vaccine n1=L-dopa | n2=en:adenovirus-p53 transduced dendritic cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:adenovirus/cytomegalovirus/epstein-barr virus-specific allogeneic cytotoxic t lymphocytes n1=L-dopa | n2=en:adenovirus/cytomegalovirus/epstein-barr virus-specific allogeneic cytotoxic t lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:adgmcaix-transduced autologous dendritic cells n1=L-dopa | n2=en:adgmcaix-transduced autologous dendritic cells | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:adh-1 n1=L-dopa | n2=en:adh-1 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:adipose-derived regenerative cells n1=L-dopa | n2=en:adipose-derived regenerative cells | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:adrtvp-1-transduced prostate cancer cell-based vaccine n1=L-dopa | n2=en:adrtvp-1-transduced prostate cancer cell-based vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ae37 peptide/gm-csf vaccine n1=L-dopa | n2=en:ae37 peptide/gm-csf vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:aee788 n1=L-dopa | n2=en:aee788 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:aeg35156 n1=L-dopa | n2=en:aeg35156 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:afatinib dimaleate n1=L-dopa | n2=en:afatinib dimaleate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:afimoxifene n1=L-dopa | n2=en:afimoxifene | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:afp gene hepatocellular carcinoma vaccine n1=L-dopa | n2=en:afp gene hepatocellular carcinoma vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:afp464 n1=L-dopa | n2=en:afp464 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:afuresertib n1=L-dopa | n2=en:afuresertib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ag-024322 n1=L-dopa | n2=en:ag-024322 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:agatolimod sodium n1=L-dopa | n2=en:agatolimod sodium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:agerafenib n1=L-dopa | n2=en:agerafenib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ak 3012 n1=L-dopa | n2=en:ak 3012 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:akt 1/2 inhibitor bay1125976 n1=L-dopa | n2=en:akt 1/2 inhibitor bay1125976 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:akt inhibitor azd5363 n1=L-dopa | n2=en:akt inhibitor azd5363 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:akt inhibitor gsk2141795 n1=L-dopa | n2=en:akt inhibitor gsk2141795 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:akt inhibitor ly2780301 n1=L-dopa | n2=en:akt inhibitor ly2780301 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:akt inhibitor mk2206 n1=L-dopa | n2=en:akt inhibitor mk2206 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:akt inhibitor sr13668 n1=L-dopa | n2=en:akt inhibitor sr13668 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:akt/erk inhibitor onc201 n1=L-dopa | n2=en:akt/erk inhibitor onc201 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:al-721 n1=L-dopa | n2=en:al-721 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:al721 n1=L-dopa | n2=en:al721 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:albuterol sulfate n1=L-dopa | n2=en:albuterol sulfate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:aldesleukin n1=L-dopa | n2=en:aldesleukin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:aldoxorubicin n1=L-dopa | n2=en:aldoxorubicin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:alectinib n1=L-dopa | n2=en:alectinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:alefacept n1=L-dopa | n2=en:alefacept | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:alfuzosin hydrochloride n1=L-dopa | n2=en:alfuzosin hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:algenpantucel-l n1=L-dopa | n2=en:algenpantucel-l | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:alisertib n1=L-dopa | n2=en:alisertib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:alk inhibitor x-396 n1=L-dopa | n2=en:alk inhibitor x-396 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:alk/ros1 inhibitor pf-06463922 n1=L-dopa | n2=en:alk/ros1 inhibitor pf-06463922 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:alk/trk inhibitor tsr-011 n1=L-dopa | n2=en:alk/trk inhibitor tsr-011 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:alk5 inhibitor tew-7197 n1=L-dopa | n2=en:alk5 inhibitor tew-7197 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:allodepleted haploidentical t cells-expressing inducible caspase 9 n1=L-dopa | n2=en:allodepleted haploidentical t cells-expressing inducible caspase 9 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:allodepleted t cell immunotherapeutic atir101 n1=L-dopa | n2=en:allodepleted t cell immunotherapeutic atir101 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:allogeneic aml antigen-expressing dendritic cell vaccine n1=L-dopa | n2=en:allogeneic aml antigen-expressing dendritic cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:allogeneic b7.1/hla-a1 transfected tumor cell vaccine n1=L-dopa | n2=en:allogeneic b7.1/hla-a1 transfected tumor cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:allogeneic cd19-specific car-modified cd8 plus central memory-derived virus-specific t cells n1=L-dopa | n2=en:allogeneic cd19-specific car-modified cd8 plus central memory-derived virus-specific t cells | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:allogeneic cd56-positive cd3-negative natural killer cells n1=L-dopa | n2=en:allogeneic cd56-positive cd3-negative natural killer cells | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:allogeneic cmv/adv-specific cytotoxic t lymphocytes n1=L-dopa | n2=en:allogeneic cmv/adv-specific cytotoxic t lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:allogeneic cytomegalovirus-specific cytotoxic t lymphocytes n1=L-dopa | n2=en:allogeneic cytomegalovirus-specific cytotoxic t lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:allogeneic dendritic cell vaccine combig-dc n1=L-dopa | n2=en:allogeneic dendritic cell vaccine combig-dc | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:allogeneic dendritic cell-myeloma idiotype vaccine n1=L-dopa | n2=en:allogeneic dendritic cell-myeloma idiotype vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:allogeneic epstein-barr virus-specific cytotoxic t-lymphocytes n1=L-dopa | n2=en:allogeneic epstein-barr virus-specific cytotoxic t-lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:allogeneic gm-csf-based myeloma cell vaccine n1=L-dopa | n2=en:allogeneic gm-csf-based myeloma cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:allogeneic gm-csf-secreting lethally irradiated whole melanoma cell vaccine n1=L-dopa | n2=en:allogeneic gm-csf-secreting lethally irradiated whole melanoma cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:allogeneic gm-csf-secreting tumor vaccine panc 6.03 pcdna-1/gm-neo n1=L-dopa | n2=en:allogeneic gm-csf-secreting tumor vaccine panc 6.03 pcdna-1/gm-neo | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:allogeneic large multivalent immunogen breast cancer vaccine n1=L-dopa | n2=en:allogeneic large multivalent immunogen breast cancer vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:allogeneic lmp1/lmp2-specific cytotoxic t-lymphocytes n1=L-dopa | n2=en:allogeneic lmp1/lmp2-specific cytotoxic t-lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:allogeneic mesothelioma tumor lysate-pulsed autologous dendritic cell vaccine n1=L-dopa | n2=en:allogeneic mesothelioma tumor lysate-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:allogeneic natural killer cell line mg4101 n1=L-dopa | n2=en:allogeneic natural killer cell line mg4101 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:allogeneic natural killer cell line nk-92 n1=L-dopa | n2=en:allogeneic natural killer cell line nk-92 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:allogeneic tumor cell vaccine n1=L-dopa | n2=en:allogeneic tumor cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:allosteric bcr-abl tyrosine kinase inhibitor abl001 n1=L-dopa | n2=en:allosteric bcr-abl tyrosine kinase inhibitor abl001 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:aloe vera gel n1=L-dopa | n2=en:aloe vera gel | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:alpha fetoprotein adenoviral vector vaccine n1=L-dopa | n2=en:alpha fetoprotein adenoviral vector vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:alpha fetoprotein plasmid dna vaccine n1=L-dopa | n2=en:alpha fetoprotein plasmid dna vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:alpha galactosylceramide n1=L-dopa | n2=en:alpha galactosylceramide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:alpha-1-proteinase inhibitor human n1=L-dopa | n2=en:alpha-1-proteinase inhibitor human | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:alpha-1,3-galactosyltransferase-expressing allogeneic renal cell carcinoma vaccine n1=L-dopa | n2=en:alpha-1,3-galactosyltransferase-expressing allogeneic renal cell carcinoma vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:alpha-folate receptor-targeting thymidylate synthase inhibitor onx-0801 n1=L-dopa | n2=en:alpha-folate receptor-targeting thymidylate synthase inhibitor onx-0801 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:alpha-gal glycosphingolipids n1=L-dopa | n2=en:alpha-gal glycosphingolipids | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:alpha-galactosylceramide-pulsed autologous dendritic cells n1=L-dopa | n2=en:alpha-galactosylceramide-pulsed autologous dendritic cells | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:alpha-lipoic acid-palladium/vitamin/mineral supplement n1=L-dopa | n2=en:alpha-lipoic acid-palladium/vitamin/mineral supplement | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:alpha-tocopheryloxyacetic acid n1=L-dopa | n2=en:alpha-tocopheryloxyacetic acid | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:alpha-type-1 polarized dendritic cells n1=L-dopa | n2=en:alpha-type-1 polarized dendritic cells | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:altiratinib n1=L-dopa | n2=en:altiratinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:alvac-cea b7.1 vaccine n1=L-dopa | n2=en:alvac-cea b7.1 vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:alvac-eso-1 vaccine n1=L-dopa | n2=en:alvac-eso-1 vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:alvac-hb7.1 n1=L-dopa | n2=en:alvac-hb7.1 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:alvac-mart-1 vaccine n1=L-dopa | n2=en:alvac-mart-1 vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:alvelestat n1=L-dopa | n2=en:alvelestat | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:alvespimycin hydrochloride n1=L-dopa | n2=en:alvespimycin hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:alvocidib hydrochloride n1=L-dopa | n2=en:alvocidib hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:amantadine hydrochloride n1=L-dopa | n2=en:amantadine hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:amatuximab n1=L-dopa | n2=en:amatuximab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:american ginseng n1=L-dopa | n2=en:american ginseng | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:American ginseng n1=L-dopa | n2=en:American ginseng | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ametantrone n1=L-dopa | n2=en:ametantrone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:amifampridine n1=L-dopa | n2=en:amifampridine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:amifostine n1=L-dopa | n2=en:amifostine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:amikacin sulfate n1=L-dopa | n2=en:amikacin sulfate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:aminobenzoate potassium n1=L-dopa | n2=en:aminobenzoate potassium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:aminocamptothecin n1=L-dopa | n2=en:aminocamptothecin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:aminocamptothecin colloidal dispersion n1=L-dopa | n2=en:aminocamptothecin colloidal dispersion | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:aminocaproic acid n1=L-dopa | n2=en:aminocaproic acid | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:aminosyn n1=L-dopa | n2=en:aminosyn | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:amitriptyline hydrochloride n1=L-dopa | n2=en:amitriptyline hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ammonia n-13 n1=L-dopa | n2=en:ammonia n-13 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ammonium glycyrrhizate n1=L-dopa | n2=en:ammonium glycyrrhizate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:amnion-derived cellular cytokine solution n1=L-dopa | n2=en:amnion-derived cellular cytokine solution | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:amolimogene bepiplasmid n1=L-dopa | n2=en:amolimogene bepiplasmid | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:amonafide dihydrochloride n1=L-dopa | n2=en:amonafide dihydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:amonafide l-malate n1=L-dopa | n2=en:amonafide l-malate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:amphotericin b deoxycholate n1=L-dopa | n2=en:amphotericin b deoxycholate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:amrubicin hydrochloride n1=L-dopa | n2=en:amrubicin hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:amsilarotene n1=L-dopa | n2=en:amsilarotene | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:amuvatinib n1=L-dopa | n2=en:amuvatinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anagrelide hydrochloride n1=L-dopa | n2=en:anagrelide hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anagrelide prolonged-release formulation n1=L-dopa | n2=en:anagrelide prolonged-release formulation | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:analgesic agent n1=L-dopa | n2=en:analgesic agent | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anamorelin hydrochloride n1=L-dopa | n2=en:anamorelin hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anaxirone n1=L-dopa | n2=en:anaxirone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ancestim n1=L-dopa | n2=en:ancestim | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:androgen antagonist apc-100 n1=L-dopa | n2=en:androgen antagonist apc-100 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:androgen receptor antagonist arn-509 n1=L-dopa | n2=en:androgen receptor antagonist arn-509 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:androgen receptor antagonist shr3680 n1=L-dopa | n2=en:androgen receptor antagonist shr3680 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:androgen receptor antisense oligonucleotide azd5312 n1=L-dopa | n2=en:androgen receptor antisense oligonucleotide azd5312 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:androgen receptor antisense oligonucleotide ezn-4176 n1=L-dopa | n2=en:androgen receptor antisense oligonucleotide ezn-4176 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:androgen receptor inhibitor epi-506 n1=L-dopa | n2=en:androgen receptor inhibitor epi-506 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:androstane steroid he3235 n1=L-dopa | n2=en:androstane steroid he3235 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anesthetic agent n1=L-dopa | n2=en:anesthetic agent | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:angiogenesis inhibitor gt-111 n1=L-dopa | n2=en:angiogenesis inhibitor gt-111 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:angiogenesis inhibitor ji-101 n1=L-dopa | n2=en:angiogenesis inhibitor ji-101 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:angiostatin n1=L-dopa | n2=en:angiostatin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:angle closure glaucoma n1=L-dopa | n2=en:angle closure glaucoma | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anhydrovinblastine n1=L-dopa | n2=en:anhydrovinblastine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:aniline mustard n1=L-dopa | n2=en:aniline mustard | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:annamycin liposomal n1=L-dopa | n2=en:annamycin liposomal | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:annonaceous acetogenins n1=L-dopa | n2=en:annonaceous acetogenins | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:answer n1=L-dopa | n2=en:answer | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:answer [sb] back n1=L-dopa | n2=en:answer [sb] back | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:answer sb back n1=L-dopa | n2=en:answer sb back | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:answer somebody back n1=L-dopa | n2=en:answer somebody back | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anthocyanin-rich corn extract n1=L-dopa | n2=en:anthocyanin-rich corn extract | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti c-kit antibody-drug conjugate lop628 n1=L-dopa | n2=en:anti c-kit antibody-drug conjugate lop628 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-a33 monoclonal antibody krn330 n1=L-dopa | n2=en:anti-a33 monoclonal antibody krn330 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-a5b1 integrin monoclonal antibody pf-04605412 n1=L-dopa | n2=en:anti-a5b1 integrin monoclonal antibody pf-04605412 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-ags-5 antibody-drug conjugate asg-5me n1=L-dopa | n2=en:anti-ags-5 antibody-drug conjugate asg-5me | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-ags-8 monoclonal antibody ags-8m4 n1=L-dopa | n2=en:anti-ags-8 monoclonal antibody ags-8m4 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-alk-1 monoclonal antibody pf-03446962 n1=L-dopa | n2=en:anti-alk-1 monoclonal antibody pf-03446962 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-allergic agents n1=L-dopa | n2=en:anti-allergic agents | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-alpha5beta1 integrin antibody mint1526a n1=L-dopa | n2=en:anti-alpha5beta1 integrin antibody mint1526a | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-alphavbeta3 monoclonal antibody emd 525797 n1=L-dopa | n2=en:anti-alphavbeta3 monoclonal antibody emd 525797 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-ang2 monoclonal antibody medi-3617 n1=L-dopa | n2=en:anti-ang2 monoclonal antibody medi-3617 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-b4 blocked ricin immunotoxin n1=L-dopa | n2=en:anti-b4 blocked ricin immunotoxin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-c-fms monoclonal antibody amg 820 n1=L-dopa | n2=en:anti-c-fms monoclonal antibody amg 820 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-c-kit monoclonal antibody ktn0158 n1=L-dopa | n2=en:anti-c-kit monoclonal antibody ktn0158 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-c-met monoclonal antibody abt-700 n1=L-dopa | n2=en:anti-c-met monoclonal antibody abt-700 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-c-met monoclonal antibody argx-111 n1=L-dopa | n2=en:anti-c-met monoclonal antibody argx-111 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-c-met monoclonal antibody ly2875358 n1=L-dopa | n2=en:anti-c-met monoclonal antibody ly2875358 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-c-met monoclonal antibody sait301 n1=L-dopa | n2=en:anti-c-met monoclonal antibody sait301 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-ca19-9 monoclonal antibody 5b1 n1=L-dopa | n2=en:anti-ca19-9 monoclonal antibody 5b1 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-ca6-dm4 immunoconjugate sar566658 n1=L-dopa | n2=en:anti-ca6-dm4 immunoconjugate sar566658 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd123 monoclonal antibody csl360 n1=L-dopa | n2=en:anti-cd123 monoclonal antibody csl360 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd123 monoclonal antibody csl362 n1=L-dopa | n2=en:anti-cd123 monoclonal antibody csl362 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd123 x anti-cd3 bispecific antibody xmab1404 n1=L-dopa | n2=en:anti-cd123 x anti-cd3 bispecific antibody xmab1404 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd123/cd3 monoclonal antibody mgd006 n1=L-dopa | n2=en:anti-cd123/cd3 monoclonal antibody mgd006 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd157 monoclonal antibody men1112 n1=L-dopa | n2=en:anti-cd157 monoclonal antibody men1112 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd19 monoclonal antibody mdx-1342 n1=L-dopa | n2=en:anti-cd19 monoclonal antibody mdx-1342 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd19 monoclonal antibody xmab5574 n1=L-dopa | n2=en:anti-cd19 monoclonal antibody xmab5574 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd19-car fmc63-28z retroviral vector-transduced allogeneic t-lymphocytes n1=L-dopa | n2=en:anti-cd19-car fmc63-28z retroviral vector-transduced allogeneic t-lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd19-car retroviral vector-transduced autologous t cells n1=L-dopa | n2=en:anti-cd19-car retroviral vector-transduced autologous t cells | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd19-car-cd3zeta-4-1bb-expressing allogenic natural killer cells n1=L-dopa | n2=en:anti-cd19-car-cd3zeta-4-1bb-expressing allogenic natural killer cells | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd19-dm4 immunoconjugate sar3419 n1=L-dopa | n2=en:anti-cd19-dm4 immunoconjugate sar3419 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd19/anti-cd22 bispecific immunotoxin dt2219arl n1=L-dopa | n2=en:anti-cd19/anti-cd22 bispecific immunotoxin dt2219arl | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd19/cd3 tetravalent antibody afm11 n1=L-dopa | n2=en:anti-cd19/cd3 tetravalent antibody afm11 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd20 b9e9 scfv-streptavidin fusion protein n1=L-dopa | n2=en:anti-cd20 b9e9 scfv-streptavidin fusion protein | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd20 monoclonal antibody pro131921 n1=L-dopa | n2=en:anti-cd20 monoclonal antibody pro131921 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd20 monoclonal antibody sct400 n1=L-dopa | n2=en:anti-cd20 monoclonal antibody sct400 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd20 monoclonal antibody tl011 n1=L-dopa | n2=en:anti-cd20 monoclonal antibody tl011 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd20 monoclonal antibody-interferon-alpha fusion protein ign002 n1=L-dopa | n2=en:anti-cd20 monoclonal antibody-interferon-alpha fusion protein ign002 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd20-car-cd3zeta-4-1bb-expressing autologous t-lymphocyte cells n1=L-dopa | n2=en:anti-cd20-car-cd3zeta-4-1bb-expressing autologous t-lymphocyte cells | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd20-engineered toxin body mt-3724 n1=L-dopa | n2=en:anti-cd20-engineered toxin body mt-3724 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd20/cd3 monoclonal antibody regn1979 n1=L-dopa | n2=en:anti-cd20/cd3 monoclonal antibody regn1979 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd200 monoclonal antibody alxn6000 n1=L-dopa | n2=en:anti-cd200 monoclonal antibody alxn6000 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd22 car-expressing t lymphocytes n1=L-dopa | n2=en:anti-cd22 car-expressing t lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd22 monoclonal antibody-mmae conjugate dcdt2980s n1=L-dopa | n2=en:anti-cd22 monoclonal antibody-mmae conjugate dcdt2980s | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd22-car m971-bbz lentiviral vector-transduced autologous t lymphocytes n1=L-dopa | n2=en:anti-cd22-car m971-bbz lentiviral vector-transduced autologous t lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd25-pbd antibody-drug conjugate adct-301 n1=L-dopa | n2=en:anti-cd25-pbd antibody-drug conjugate adct-301 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd27l antibody-drug conjugate amg 172 n1=L-dopa | n2=en:anti-cd27l antibody-drug conjugate amg 172 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd3 immunotoxin a-dmdt390-bisfv(ucht1) n1=L-dopa | n2=en:anti-cd3 immunotoxin a-dmdt390-bisfv(ucht1) | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd3 okt3/humanized anti-gd2 3f8 bispecific antibody-activated t lymphocytes n1=L-dopa | n2=en:anti-cd3 okt3/humanized anti-gd2 3f8 bispecific antibody-activated t lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd3/anti-cd20 trifunctional bispecific monoclonal antibody fbta05 n1=L-dopa | n2=en:anti-cd3/anti-cd20 trifunctional bispecific monoclonal antibody fbta05 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd3/anti-egfr-bispecific monoclonal antibody-armed activated autologous t-lymphocytes n1=L-dopa | n2=en:anti-cd3/anti-egfr-bispecific monoclonal antibody-armed activated autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd30 monoclonal antibody mdx-1401 n1=L-dopa | n2=en:anti-cd30 monoclonal antibody mdx-1401 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd33 antibody-drug conjugate imgn779 n1=L-dopa | n2=en:anti-cd33 antibody-drug conjugate imgn779 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd33 monoclonal antibody-dm4 conjugate ave9633 n1=L-dopa | n2=en:anti-cd33 monoclonal antibody-dm4 conjugate ave9633 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd33/cd3 bite antibody amg 330 n1=L-dopa | n2=en:anti-cd33/cd3 bite antibody amg 330 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd37 monoclonal antibody bi 836826 n1=L-dopa | n2=en:anti-cd37 monoclonal antibody bi 836826 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd38 monoclonal antibody mor03087 n1=L-dopa | n2=en:anti-cd38 monoclonal antibody mor03087 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd38 monoclonal antibody sar650984 n1=L-dopa | n2=en:anti-cd38 monoclonal antibody sar650984 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd40 monoclonal antibody chi lob 7/4 n1=L-dopa | n2=en:anti-cd40 monoclonal antibody chi lob 7/4 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd40 monoclonal antibody sea-cd40 n1=L-dopa | n2=en:anti-cd40 monoclonal antibody sea-cd40 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd44 monoclonal antibody ro5429083 n1=L-dopa | n2=en:anti-cd44 monoclonal antibody ro5429083 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd45 bc8 monoclonal antibody-streptavidin conjugate n1=L-dopa | n2=en:anti-cd45 bc8 monoclonal antibody-streptavidin conjugate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd45 monoclonal antibody bc8 n1=L-dopa | n2=en:anti-cd45 monoclonal antibody bc8 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd47 monoclonal antibody cc-90002 n1=L-dopa | n2=en:anti-cd47 monoclonal antibody cc-90002 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd47 monoclonal antibody hu5f9-g4 n1=L-dopa | n2=en:anti-cd47 monoclonal antibody hu5f9-g4 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd7 immunotoxin n1=L-dopa | n2=en:anti-cd7 immunotoxin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd70 antibody-drug conjugate mdx-1203 n1=L-dopa | n2=en:anti-cd70 antibody-drug conjugate mdx-1203 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd70 antibody-drug conjugate sgn-cd70a n1=L-dopa | n2=en:anti-cd70 antibody-drug conjugate sgn-cd70a | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd70 monoclonal antibody argx-110 n1=L-dopa | n2=en:anti-cd70 monoclonal antibody argx-110 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd73 monoclonal antibody medi9447 n1=L-dopa | n2=en:anti-cd73 monoclonal antibody medi9447 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cd98 monoclonal antibody ign523 n1=L-dopa | n2=en:anti-cd98 monoclonal antibody ign523 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cea bite monoclonal antibody amg211 n1=L-dopa | n2=en:anti-cea bite monoclonal antibody amg211 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cea igcd28tcr-transduced autologous t cells n1=L-dopa | n2=en:anti-cea igcd28tcr-transduced autologous t cells | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cea tcr retroviral vector-transduced autologous peripheral blood lymphocytes n1=L-dopa | n2=en:anti-cea tcr retroviral vector-transduced autologous peripheral blood lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cea-car autologous t lymphocytes n1=L-dopa | n2=en:anti-cea-car autologous t lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cea/anti-hsg bispecific monoclonal antibody tf2 n1=L-dopa | n2=en:anti-cea/anti-hsg bispecific monoclonal antibody tf2 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cea/cd3 bispecific antibody ro6958688 n1=L-dopa | n2=en:anti-cea/cd3 bispecific antibody ro6958688 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-ceacam1 monoclonal antibody cm-24 n1=L-dopa | n2=en:anti-ceacam1 monoclonal antibody cm-24 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-ceacam5 antibody-drug conjugate sar408701 n1=L-dopa | n2=en:anti-ceacam5 antibody-drug conjugate sar408701 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-cldn6 monoclonal antibody imab027 n1=L-dopa | n2=en:anti-cldn6 monoclonal antibody imab027 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-csf1r monoclonal antibody fpa008 n1=L-dopa | n2=en:anti-csf1r monoclonal antibody fpa008 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-csf1r monoclonal antibody imc-cs4 n1=L-dopa | n2=en:anti-csf1r monoclonal antibody imc-cs4 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-ctgf monoclonal antibody fg-3019 n1=L-dopa | n2=en:anti-ctgf monoclonal antibody fg-3019 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-ctla-4 mab rna-transfected autologous dendritic cell vaccine n1=L-dopa | n2=en:anti-ctla-4 mab rna-transfected autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-ctla-4 monoclonal antibody agen1884 n1=L-dopa | n2=en:anti-ctla-4 monoclonal antibody agen1884 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-ctla4 moab rna/gitrl rna-transfected autologous dendritic cell vaccine n1=L-dopa | n2=en:anti-ctla4 moab rna/gitrl rna-transfected autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-denatured collagen monoclonal antibody trc093 n1=L-dopa | n2=en:anti-denatured collagen monoclonal antibody trc093 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-dkk-1 monoclonal antibody ly2812176 n1=L-dopa | n2=en:anti-dkk-1 monoclonal antibody ly2812176 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-dkk1 monoclonal antibody bhq880 n1=L-dopa | n2=en:anti-dkk1 monoclonal antibody bhq880 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-dll4 monoclonal antibody medi0639 n1=L-dopa | n2=en:anti-dll4 monoclonal antibody medi0639 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-dll4/vegf bispecific monoclonal antibody omp-305b83 n1=L-dopa | n2=en:anti-dll4/vegf bispecific monoclonal antibody omp-305b83 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-egfr monoclonal antibody gc1118 n1=L-dopa | n2=en:anti-egfr monoclonal antibody gc1118 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-egfr monoclonal antibody mixture mm-151 n1=L-dopa | n2=en:anti-egfr monoclonal antibody mixture mm-151 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-egfr monoclonal antibody mixture sym004 n1=L-dopa | n2=en:anti-egfr monoclonal antibody mixture sym004 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-egfr monoclonal antibody ro5083945 n1=L-dopa | n2=en:anti-egfr monoclonal antibody ro5083945 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-egfr monoclonal antibody sct200 n1=L-dopa | n2=en:anti-egfr monoclonal antibody sct200 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-egfr monoclonal antibody syn004 n1=L-dopa | n2=en:anti-egfr monoclonal antibody syn004 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-egfr tap antibody-drug conjugate imgn289 n1=L-dopa | n2=en:anti-egfr tap antibody-drug conjugate imgn289 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-egfr/c-met bispecific antibody jnj-61186372 n1=L-dopa | n2=en:anti-egfr/c-met bispecific antibody jnj-61186372 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-egfrviii antibody drug conjugate amg 595 n1=L-dopa | n2=en:anti-egfrviii antibody drug conjugate amg 595 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-egfrviii car-transduced allogeneic t-lymphocytes n1=L-dopa | n2=en:anti-egfrviii car-transduced allogeneic t-lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-egfrviii immunotoxin mr1-1 n1=L-dopa | n2=en:anti-egfrviii immunotoxin mr1-1 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-endosialin monoclonal antibody morab-004 n1=L-dopa | n2=en:anti-endosialin monoclonal antibody morab-004 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-enpp3 antibody-drug conjugate ags-16c3f n1=L-dopa | n2=en:anti-enpp3 antibody-drug conjugate ags-16c3f | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-enpp3/mmaf antibody-drug conjugate ags-16m8f n1=L-dopa | n2=en:anti-enpp3/mmaf antibody-drug conjugate ags-16m8f | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-epcam antibody fragment-pseudomonas-exotoxin fusion protein n1=L-dopa | n2=en:anti-epcam antibody fragment-pseudomonas-exotoxin fusion protein | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-epha2 monoclonal antibody ds-8895a n1=L-dopa | n2=en:anti-epha2 monoclonal antibody ds-8895a | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-epha2 monoclonal antibody-mmaf immunoconjugate medi-547 n1=L-dopa | n2=en:anti-epha2 monoclonal antibody-mmaf immunoconjugate medi-547 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-epidermal growth factor receptor 2 antibody expressing pluripotent killer t-lymphocytes n1=L-dopa | n2=en:anti-epidermal growth factor receptor 2 antibody expressing pluripotent killer t-lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-erbb2/anti-erbb3 bispecific monoclonal antibody mm-111 n1=L-dopa | n2=en:anti-erbb2/anti-erbb3 bispecific monoclonal antibody mm-111 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-erbb3 monoclonal antibody av-203 n1=L-dopa | n2=en:anti-erbb3 monoclonal antibody av-203 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-erbb3 monoclonal antibody ktn3379 n1=L-dopa | n2=en:anti-erbb3 monoclonal antibody ktn3379 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-etbr/mmae antibody-drug conjugate dedn6526a n1=L-dopa | n2=en:anti-etbr/mmae antibody-drug conjugate dedn6526a | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-fgf23 igg1 monoclonal antibody krn23 n1=L-dopa | n2=en:anti-fgf23 igg1 monoclonal antibody krn23 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-fgfr2 antibody bay1179470 n1=L-dopa | n2=en:anti-fgfr2 antibody bay1179470 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-fgfr2 antibody-drug conjugate bay1187982 n1=L-dopa | n2=en:anti-fgfr2 antibody-drug conjugate bay1187982 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-fgfr2 monoclonal antibody fpa144 n1=L-dopa | n2=en:anti-fgfr2 monoclonal antibody fpa144 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-fgfr3 antibody-drug conjugate ly3076226 n1=L-dopa | n2=en:anti-fgfr3 antibody-drug conjugate ly3076226 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-fgfr3 monoclonal antibody b-701 n1=L-dopa | n2=en:anti-fgfr3 monoclonal antibody b-701 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-flt3 monoclonal antibody imc-eb10 n1=L-dopa | n2=en:anti-flt3 monoclonal antibody imc-eb10 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-fucosyl-gm1 monoclonal antibody bms-986012 n1=L-dopa | n2=en:anti-fucosyl-gm1 monoclonal antibody bms-986012 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-ganglioside gm2 monoclonal antibody biw-8962 n1=L-dopa | n2=en:anti-ganglioside gm2 monoclonal antibody biw-8962 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-gcc antibody-drug conjugate mln0264 n1=L-dopa | n2=en:anti-gcc antibody-drug conjugate mln0264 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-gd2 monoclonal antibody morab-028 n1=L-dopa | n2=en:anti-gd2 monoclonal antibody morab-028 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-gitr agonistic monoclonal antibody incagn01876 n1=L-dopa | n2=en:anti-gitr agonistic monoclonal antibody incagn01876 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-gitr monoclonal antibody gwn 323 n1=L-dopa | n2=en:anti-gitr monoclonal antibody gwn 323 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-gitr monoclonal antibody mk-4166 n1=L-dopa | n2=en:anti-gitr monoclonal antibody mk-4166 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-gnrh vaccine pep223 n1=L-dopa | n2=en:anti-gnrh vaccine pep223 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-gpa33/cd3 monoclonal antibody mgd007 n1=L-dopa | n2=en:anti-gpa33/cd3 monoclonal antibody mgd007 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-gpc3 monoclonal antibody gc33 n1=L-dopa | n2=en:anti-gpc3 monoclonal antibody gc33 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-gpc3-car autologous t lymphocytes n1=L-dopa | n2=en:anti-gpc3-car autologous t lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-hb-egf monoclonal antibody khk2866 n1=L-dopa | n2=en:anti-hb-egf monoclonal antibody khk2866 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-hbegf monoclonal antibody u3-1565 n1=L-dopa | n2=en:anti-hbegf monoclonal antibody u3-1565 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-her-2-car retroviral vector-transduced autologous peripheral blood lymphocytes n1=L-dopa | n2=en:anti-her-2-car retroviral vector-transduced autologous peripheral blood lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-her2 antibody-drug conjugate arx788 n1=L-dopa | n2=en:anti-her2 antibody-drug conjugate arx788 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-her2 monoclonal antibody ct-p6 n1=L-dopa | n2=en:anti-her2 monoclonal antibody ct-p6 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-her2-car autologous cmv-specific cytotoxic t-lymphocytes n1=L-dopa | n2=en:anti-her2-car autologous cmv-specific cytotoxic t-lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-her3 monoclonal antibody gsk2849330 n1=L-dopa | n2=en:anti-her3 monoclonal antibody gsk2849330 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-her3 monoclonal antibody ljm716 n1=L-dopa | n2=en:anti-her3 monoclonal antibody ljm716 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-hgf monoclonal antibody tak-701 n1=L-dopa | n2=en:anti-hgf monoclonal antibody tak-701 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-hif-1alpha lna antisense oligonucleotide ezn-2968 n1=L-dopa | n2=en:anti-hif-1alpha lna antisense oligonucleotide ezn-2968 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-hla-a2/ny-eso-1 tcr-transduced autologous t lymphocytes n1=L-dopa | n2=en:anti-hla-a2/ny-eso-1 tcr-transduced autologous t lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-hla-dr monoclonal antibody immu-114 n1=L-dopa | n2=en:anti-hla-dr monoclonal antibody immu-114 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-human chorionic gonadotropin vaccine n1=L-dopa | n2=en:anti-human chorionic gonadotropin vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-human gitr monoclonal antibody trx518 n1=L-dopa | n2=en:anti-human gitr monoclonal antibody trx518 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-icam-1 monoclonal antibody bi-505 n1=L-dopa | n2=en:anti-icam-1 monoclonal antibody bi-505 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-icos agonist antibody gsk3359609 n1=L-dopa | n2=en:anti-icos agonist antibody gsk3359609 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-icos monoclonal antibody medi-570 n1=L-dopa | n2=en:anti-icos monoclonal antibody medi-570 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-igf-1r monoclonal antibody ave1642 n1=L-dopa | n2=en:anti-igf-1r monoclonal antibody ave1642 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-igf-1r recombinant monoclonal antibody biib022 n1=L-dopa | n2=en:anti-igf-1r recombinant monoclonal antibody biib022 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-igf1/2 monoclonal antibody medi-573 n1=L-dopa | n2=en:anti-igf1/2 monoclonal antibody medi-573 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-il-1 alpha monoclonal antibody mabp1 n1=L-dopa | n2=en:anti-il-1 alpha monoclonal antibody mabp1 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-il-13 humanized monoclonal antibody tnx-650 n1=L-dopa | n2=en:anti-il-13 humanized monoclonal antibody tnx-650 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-il-4/il-13 combination agent qbx258 n1=L-dopa | n2=en:anti-il-4/il-13 combination agent qbx258 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-il-8 monoclonal antibody humax-il8 n1=L-dopa | n2=en:anti-il-8 monoclonal antibody humax-il8 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-inflammatory agents n1=L-dopa | n2=en:anti-inflammatory agents | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-integrin monoclonal antibody-dm4 immunoconjugate imgn388 n1=L-dopa | n2=en:anti-integrin monoclonal antibody-dm4 immunoconjugate imgn388 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-kir monoclonal antibody iph 2101 n1=L-dopa | n2=en:anti-kir monoclonal antibody iph 2101 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-lag-3 monoclonal antibody bms-986016 n1=L-dopa | n2=en:anti-lag-3 monoclonal antibody bms-986016 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-lag-3 monoclonal antibody lag525 n1=L-dopa | n2=en:anti-lag-3 monoclonal antibody lag525 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-lamp1 antibody-drug conjugate sar428926 n1=L-dopa | n2=en:anti-lamp1 antibody-drug conjugate sar428926 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-ly6e antibody-drug conjugate dlye5953a n1=L-dopa | n2=en:anti-ly6e antibody-drug conjugate dlye5953a | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-masp-2 monoclonal antibody oms721 n1=L-dopa | n2=en:anti-masp-2 monoclonal antibody oms721 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-melanin monoclonal antibody pti-6d2 n1=L-dopa | n2=en:anti-melanin monoclonal antibody pti-6d2 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-mesothelin icasp9m28z car-transduced autologous t lymphocytes n1=L-dopa | n2=en:anti-mesothelin icasp9m28z car-transduced autologous t lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-mesothelin-pseudomonas exotoxin 24 cytolytic fusion protein lmb-100 n1=L-dopa | n2=en:anti-mesothelin-pseudomonas exotoxin 24 cytolytic fusion protein lmb-100 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-met monoclonal antibody mixture sym015 n1=L-dopa | n2=en:anti-met monoclonal antibody mixture sym015 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-met/egfr monoclonal antibody ly3164530 n1=L-dopa | n2=en:anti-met/egfr monoclonal antibody ly3164530 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-mmp-9 monoclonal antibody gs-5745 n1=L-dopa | n2=en:anti-mmp-9 monoclonal antibody gs-5745 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-muc1 car-transduced autologous t-lymphocytes n1=L-dopa | n2=en:anti-muc1 car-transduced autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-muc1 monoclonal antibody bth1704 n1=L-dopa | n2=en:anti-muc1 monoclonal antibody bth1704 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-myeloma monoclonal antibody-dm4 immunoconjugate bt-062 n1=L-dopa | n2=en:anti-myeloma monoclonal antibody-dm4 immunoconjugate bt-062 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-myostatin monoclonal antibody ly2495655 n1=L-dopa | n2=en:anti-myostatin monoclonal antibody ly2495655 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-napi2b/mmae antibody-drug conjugate dnib0600a n1=L-dopa | n2=en:anti-napi2b/mmae antibody-drug conjugate dnib0600a | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-nectin 4 antibody-drug conjugate asg-22ce n1=L-dopa | n2=en:anti-nectin 4 antibody-drug conjugate asg-22ce | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-nectin-4 monoclonal antibody-drug conjugate ags-22m6e n1=L-dopa | n2=en:anti-nectin-4 monoclonal antibody-drug conjugate ags-22m6e | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-neuropilin-1 monoclonal antibody mnrp1685a n1=L-dopa | n2=en:anti-neuropilin-1 monoclonal antibody mnrp1685a | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-nf-p2x7 antibody ointment bil-010t n1=L-dopa | n2=en:anti-nf-p2x7 antibody ointment bil-010t | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-nucleolin aptamer as1411 n1=L-dopa | n2=en:anti-nucleolin aptamer as1411 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-ofa immunotherapeutic bb-mpi-03 n1=L-dopa | n2=en:anti-ofa immunotherapeutic bb-mpi-03 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-ox40 monoclonal antibody n1=L-dopa | n2=en:anti-ox40 monoclonal antibody | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-ox40 monoclonal antibody gsk3174998 n1=L-dopa | n2=en:anti-ox40 monoclonal antibody gsk3174998 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-ox40 monoclonal antibody medi0562 n1=L-dopa | n2=en:anti-ox40 monoclonal antibody medi0562 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-p53 t-cell receptor-transduced peripheral blood lymphocytes n1=L-dopa | n2=en:anti-p53 t-cell receptor-transduced peripheral blood lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-pd-1 fusion protein amp-224 n1=L-dopa | n2=en:anti-pd-1 fusion protein amp-224 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-pd-1 monoclonal antibody bgb-a317 n1=L-dopa | n2=en:anti-pd-1 monoclonal antibody bgb-a317 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-pd-1 monoclonal antibody medi0680 n1=L-dopa | n2=en:anti-pd-1 monoclonal antibody medi0680 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-pd-1 monoclonal antibody regn2810 n1=L-dopa | n2=en:anti-pd-1 monoclonal antibody regn2810 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-pd-1 monoclonal antibody shr-1210 n1=L-dopa | n2=en:anti-pd-1 monoclonal antibody shr-1210 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-pd-l1 monoclonal antibody ly3300054 n1=L-dopa | n2=en:anti-pd-l1 monoclonal antibody ly3300054 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-pd-l1/tgfbetarii fusion protein msb0011359c n1=L-dopa | n2=en:anti-pd-l1/tgfbetarii fusion protein msb0011359c | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-pdgfr alpha monoclonal antibody medi-575 n1=L-dopa | n2=en:anti-pdgfr alpha monoclonal antibody medi-575 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-pgf monoclonal antibody ro5323441 n1=L-dopa | n2=en:anti-pgf monoclonal antibody ro5323441 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-pkn3 sirna atu027 n1=L-dopa | n2=en:anti-pkn3 sirna atu027 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-plgf monoclonal antibody tb-403 n1=L-dopa | n2=en:anti-plgf monoclonal antibody tb-403 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-programmed cell death protein 1 antibody expressing pluripotent killer t-lymphocytes n1=L-dopa | n2=en:anti-programmed cell death protein 1 antibody expressing pluripotent killer t-lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-prolactin receptor antibody lfa102 n1=L-dopa | n2=en:anti-prolactin receptor antibody lfa102 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-psma monoclonal antibody mdx1201-a488 n1=L-dopa | n2=en:anti-psma monoclonal antibody mdx1201-a488 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-psma monoclonal antibody-mmae conjugate n1=L-dopa | n2=en:anti-psma monoclonal antibody-mmae conjugate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-psma/cd3 bite monoclonal antibody mt112 n1=L-dopa | n2=en:anti-psma/cd3 bite monoclonal antibody mt112 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-psma/cd3 monoclonal antibody mor209/es414 n1=L-dopa | n2=en:anti-psma/cd3 monoclonal antibody mor209/es414 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-rspo3 monoclonal antibody omp-131r10 n1=L-dopa | n2=en:anti-rspo3 monoclonal antibody omp-131r10 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-sclu monoclonal antibody ab-16b5 n1=L-dopa | n2=en:anti-sclu monoclonal antibody ab-16b5 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-sema4d monoclonal antibody vx15/2503 n1=L-dopa | n2=en:anti-sema4d monoclonal antibody vx15/2503 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-slitrk6 monoclonal antibody-mmae conjugate ags15e n1=L-dopa | n2=en:anti-slitrk6 monoclonal antibody-mmae conjugate ags15e | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-ta-muc1 monoclonal antibody pankomab n1=L-dopa | n2=en:anti-ta-muc1 monoclonal antibody pankomab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-tf monoclonal antibody alt-836 n1=L-dopa | n2=en:anti-tf monoclonal antibody alt-836 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-tgf-beta rii monoclonal antibody imc-tr1 n1=L-dopa | n2=en:anti-tgf-beta rii monoclonal antibody imc-tr1 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-thyroglobulin mtcr-transduced autologous peripheral blood lymphocytes n1=L-dopa | n2=en:anti-thyroglobulin mtcr-transduced autologous peripheral blood lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-tim-3 monoclonal antibody mbg453 n1=L-dopa | n2=en:anti-tim-3 monoclonal antibody mbg453 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-tumor necrosis factor alpha drug n1=L-dopa | n2=en:anti-tumor necrosis factor alpha drug | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-tweak monoclonal antibody ro5458640 n1=L-dopa | n2=en:anti-tweak monoclonal antibody ro5458640 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-vegf anticalin prs-050-peg40 n1=L-dopa | n2=en:anti-vegf anticalin prs-050-peg40 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-vegf/ang2 nanobody bi 836880 n1=L-dopa | n2=en:anti-vegf/ang2 nanobody bi 836880 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-vegfc monoclonal antibody vgx-100 n1=L-dopa | n2=en:anti-vegfc monoclonal antibody vgx-100 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-vegfr3 monoclonal antibody imc-3c5 n1=L-dopa | n2=en:anti-vegfr3 monoclonal antibody imc-3c5 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-vista monoclonal antibody jnj 61610588 n1=L-dopa | n2=en:anti-vista monoclonal antibody jnj 61610588 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:anti-von willebrand factor nanobody n1=L-dopa | n2=en:anti-von willebrand factor nanobody | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:antiangiogenic drug combination tl-118 n1=L-dopa | n2=en:antiangiogenic drug combination tl-118 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:antibacterial agent n1=L-dopa | n2=en:antibacterial agent | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:antibiotic n1=L-dopa | n2=en:antibiotic | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:antibiotic sq109 n1=L-dopa | n2=en:antibiotic sq109 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:antibody-drug conjugate abbv-085 n1=L-dopa | n2=en:antibody-drug conjugate abbv-085 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:antibody-drug conjugate abbv-399 n1=L-dopa | n2=en:antibody-drug conjugate abbv-399 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:antibody-drug conjugate adct-402 n1=L-dopa | n2=en:antibody-drug conjugate adct-402 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:antibody-drug conjugate bay79-4620 n1=L-dopa | n2=en:antibody-drug conjugate bay79-4620 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:antibody-drug conjugate dfrf4539a n1=L-dopa | n2=en:antibody-drug conjugate dfrf4539a | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:antibody-drug conjugate sc-002 n1=L-dopa | n2=en:antibody-drug conjugate sc-002 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:antibody-drug conjugate sc-003 n1=L-dopa | n2=en:antibody-drug conjugate sc-003 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:antibody-drug conjugate sc16ld6.5 n1=L-dopa | n2=en:antibody-drug conjugate sc16ld6.5 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:antienzyme n1=L-dopa | n2=en:antienzyme | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:antigen-targeted personalized breast cancer vaccine n1=L-dopa | n2=en:antigen-targeted personalized breast cancer vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:antihypertensive agent n1=L-dopa | n2=en:antihypertensive agent | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:antilipemic agent n1=L-dopa | n2=en:antilipemic agent | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:antimetabolite n1=L-dopa | n2=en:antimetabolite | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:antimetabolite ff-10502 n1=L-dopa | n2=en:antimetabolite ff-10502 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:antineoplastic agent n1=L-dopa | n2=en:antineoplastic agent | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:antineoplastic agent combination sm-88 n1=L-dopa | n2=en:antineoplastic agent combination sm-88 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:antineoplastic agent trx-818 n1=L-dopa | n2=en:antineoplastic agent trx-818 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:antineoplaston a10 n1=L-dopa | n2=en:antineoplaston a10 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:antineoplaston as2-1 n1=L-dopa | n2=en:antineoplaston as2-1 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:antiperspirant cream f511 n1=L-dopa | n2=en:antiperspirant cream f511 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:antirheumatic agents n1=L-dopa | n2=en:antirheumatic agents | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:antispasmodic agent n1=L-dopa | n2=en:antispasmodic agent | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:antrodia cinnamomea supplement n1=L-dopa | n2=en:antrodia cinnamomea supplement | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:apatinib n1=L-dopa | n2=en:apatinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:apatorsen n1=L-dopa | n2=en:apatorsen | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:apaziquone n1=L-dopa | n2=en:apaziquone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:apc8015f n1=L-dopa | n2=en:apc8015f | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:apf530 n1=L-dopa | n2=en:apf530 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:apilimod dimesylate capsule n1=L-dopa | n2=en:apilimod dimesylate capsule | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:apixaban n1=L-dopa | n2=en:apixaban | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:apomab n1=L-dopa | n2=en:apomab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:apomine n1=L-dopa | n2=en:apomine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:apoptosis inducer bzl101 n1=L-dopa | n2=en:apoptosis inducer bzl101 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:apoptosis inducer mpc-2130 n1=L-dopa | n2=en:apoptosis inducer mpc-2130 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:apoptotic autologous tumor cells-pulsed alpha-type-1 polarized dendritic cells n1=L-dopa | n2=en:apoptotic autologous tumor cells-pulsed alpha-type-1 polarized dendritic cells | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:aprepitant n1=L-dopa | n2=en:aprepitant | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:apricoxib n1=L-dopa | n2=en:apricoxib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ar antagonist bms-641988 n1=L-dopa | n2=en:ar antagonist bms-641988 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ar antagonist odm-201 n1=L-dopa | n2=en:ar antagonist odm-201 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:arginine butyrate n1=L-dopa | n2=en:arginine butyrate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:arginine/omega-3 fatty acids/nucleotides oral supplement n1=L-dopa | n2=en:arginine/omega-3 fatty acids/nucleotides oral supplement | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:armodafinil n1=L-dopa | n2=en:armodafinil | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:arnebia indigo jade pearl topical cream n1=L-dopa | n2=en:arnebia indigo jade pearl topical cream | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:arsanilic acid n1=L-dopa | n2=en:arsanilic acid | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:arsenic trioxide n1=L-dopa | n2=en:arsenic trioxide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:artemether sublingual spray n1=L-dopa | n2=en:artemether sublingual spray | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:artesunate n1=L-dopa | n2=en:artesunate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:artichoke whole phytocomplex concentrate n1=L-dopa | n2=en:artichoke whole phytocomplex concentrate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:arzoxifene hydrochloride n1=L-dopa | n2=en:arzoxifene hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:as03-adjuvanted h1n1 pandemic influenza vaccine n1=L-dopa | n2=en:as03-adjuvanted h1n1 pandemic influenza vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:asaley n1=L-dopa | n2=en:asaley | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:asfotase alfa n1=L-dopa | n2=en:asfotase alfa | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ashwagandha root powder extract n1=L-dopa | n2=en:ashwagandha root powder extract | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:asian ginseng n1=L-dopa | n2=en:asian ginseng | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ask1 inhibitor gs-4997 n1=L-dopa | n2=en:ask1 inhibitor gs-4997 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:asp4132 n1=L-dopa | n2=en:asp4132 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:asp9853 n1=L-dopa | n2=en:asp9853 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:asparaginase n1=L-dopa | n2=en:asparaginase | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:asparaginase erwinia chrysanthemi n1=L-dopa | n2=en:asparaginase erwinia chrysanthemi | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:astringent n1=L-dopa | n2=en:astringent | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:astuprotimut-r n1=L-dopa | n2=en:astuprotimut-r | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:asulacrine isethionate n1=L-dopa | n2=en:asulacrine isethionate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:atamestane n1=L-dopa | n2=en:atamestane | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:atenolol n1=L-dopa | n2=en:atenolol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:atezolizumab n1=L-dopa | n2=en:atezolizumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:atiprimod n1=L-dopa | n2=en:atiprimod | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:atn-161 n1=L-dopa | n2=en:atn-161 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:atomoxetine hydrochloride n1=L-dopa | n2=en:atomoxetine hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:atorvastatin calcium n1=L-dopa | n2=en:atorvastatin calcium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:atr kinase inhibitor azd6738 n1=L-dopa | n2=en:atr kinase inhibitor azd6738 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:atr kinase inhibitor vx-970 n1=L-dopa | n2=en:atr kinase inhibitor vx-970 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:atr-101 n1=L-dopa | n2=en:atr-101 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:atrasentan hydrochloride n1=L-dopa | n2=en:atrasentan hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:attenuated chimpanzee adenovirus 5t4 vaccine n1=L-dopa | n2=en:attenuated chimpanzee adenovirus 5t4 vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:attenuated corynebacterium parvum n1=L-dopa | n2=en:attenuated corynebacterium parvum | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:attenuated listeria monocytogenes crs-100 n1=L-dopa | n2=en:attenuated listeria monocytogenes crs-100 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:attenuated live listeria encoding hpv 16 e7 vaccine adxs11-001 n1=L-dopa | n2=en:attenuated live listeria encoding hpv 16 e7 vaccine adxs11-001 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:auranofin n1=L-dopa | n2=en:auranofin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:aurora a kinase inhibitor tas-119 n1=L-dopa | n2=en:aurora a kinase inhibitor tas-119 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:aurora b serine/threonine kinase inhibitor tak-901 n1=L-dopa | n2=en:aurora b serine/threonine kinase inhibitor tak-901 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:aurora b/c kinase inhibitor gsk1070916a n1=L-dopa | n2=en:aurora b/c kinase inhibitor gsk1070916a | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:aurora kinase inhibitor amg 900 n1=L-dopa | n2=en:aurora kinase inhibitor amg 900 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:aurora kinase inhibitor bi 811283 n1=L-dopa | n2=en:aurora kinase inhibitor bi 811283 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:aurora kinase inhibitor mln8054 n1=L-dopa | n2=en:aurora kinase inhibitor mln8054 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:aurora kinase inhibitor ttp607 n1=L-dopa | n2=en:aurora kinase inhibitor ttp607 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:aurora kinase/vegfr2 inhibitor cyc116 n1=L-dopa | n2=en:aurora kinase/vegfr2 inhibitor cyc116 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous ad-cd154-transduced cll b cells n1=L-dopa | n2=en:autologous ad-cd154-transduced cll b cells | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing cd4+/cd8+ central memory t-lymphocytes jcar014 n1=L-dopa | n2=en:autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing cd4+/cd8+ central memory t-lymphocytes jcar014 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing cd4+/cd8+ t-lymphocytes jcar017 n1=L-dopa | n2=en:autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing cd4+/cd8+ t-lymphocytes jcar017 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing t lymphocytes n1=L-dopa | n2=en:autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing t lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous anti-gp100:154-162 t-cell receptor gene-engineered peripheral blood lymphocytes n1=L-dopa | n2=en:autologous anti-gp100:154-162 t-cell receptor gene-engineered peripheral blood lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous anti-mart-1 f5 t-cell receptor gene-engineered peripheral blood lymphocytes n1=L-dopa | n2=en:autologous anti-mart-1 f5 t-cell receptor gene-engineered peripheral blood lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous anti-psma gene-modified t-lymphocytes n1=L-dopa | n2=en:autologous anti-psma gene-modified t-lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous cd123car-cd28-cd3zeta-egfrt-expressing t lymphocytes n1=L-dopa | n2=en:autologous cd123car-cd28-cd3zeta-egfrt-expressing t lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous cd133-positive btsc mrna-pulsed autologous dendritic cell vaccine n1=L-dopa | n2=en:autologous cd133-positive btsc mrna-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous cd171-specific car-cd28 zeta-4-1-bb-egfrt-expressing t lymphocytes n1=L-dopa | n2=en:autologous cd171-specific car-cd28 zeta-4-1-bb-egfrt-expressing t lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous cd19-28z chimeric antigen receptor-expressing t-lymphocytes n1=L-dopa | n2=en:autologous cd19-28z chimeric antigen receptor-expressing t-lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t cells n1=L-dopa | n2=en:autologous cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t cells | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous cd8 positive pbl sensitized to drosophila cell-presented melanoma peptides n1=L-dopa | n2=en:autologous cd8 positive pbl sensitized to drosophila cell-presented melanoma peptides | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous cd8+ melanoma specific t cells n1=L-dopa | n2=en:autologous cd8+ melanoma specific t cells | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous colon cancer cell vaccine n1=L-dopa | n2=en:autologous colon cancer cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous colorectal tumor antigen-pulsed dendritic cell vaccine n1=L-dopa | n2=en:autologous colorectal tumor antigen-pulsed dendritic cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous ct7/mage-a3/wt1 mrna-electroporated langerhans-type dendritic cells n1=L-dopa | n2=en:autologous ct7/mage-a3/wt1 mrna-electroporated langerhans-type dendritic cells | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous cytotoxic t-lymphocytes induced with muc1 gene-transfected dendritic cells n1=L-dopa | n2=en:autologous cytotoxic t-lymphocytes induced with muc1 gene-transfected dendritic cells | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous cytotoxic t-lymphocytes induced with muc1 peptide-pulsed dendritic cells n1=L-dopa | n2=en:autologous cytotoxic t-lymphocytes induced with muc1 peptide-pulsed dendritic cells | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous dendritic cell vaccine act2001 n1=L-dopa | n2=en:autologous dendritic cell vaccine act2001 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous dendritic cell-adenovirus ccl21 vaccine n1=L-dopa | n2=en:autologous dendritic cell-adenovirus ccl21 vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine n1=L-dopa | n2=en:autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous dendritic cell-autologous tumor mrna-human cd40l vaccine n1=L-dopa | n2=en:autologous dendritic cell-autologous tumor mrna-human cd40l vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous dendritic cell-based immunotherapeutic av0113 n1=L-dopa | n2=en:autologous dendritic cell-based immunotherapeutic av0113 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous dendritic cell-tumor fusion vaccine n1=L-dopa | n2=en:autologous dendritic cell-tumor fusion vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous dinitrophenyl-modified ovarian cancer vaccine n1=L-dopa | n2=en:autologous dinitrophenyl-modified ovarian cancer vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous ebv-ctl cd19car zeta n1=L-dopa | n2=en:autologous ebv-ctl cd19car zeta | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous ebv-transformed b lymphoblastoid-tumor fusion cell vaccine n1=L-dopa | n2=en:autologous ebv-transformed b lymphoblastoid-tumor fusion cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous glioma cell lysate n1=L-dopa | n2=en:autologous glioma cell lysate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous gm-csf-secreting lethally irradiated colorectal cancer cell vaccine n1=L-dopa | n2=en:autologous gm-csf-secreting lethally irradiated colorectal cancer cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous gm-csf-secreting lethally irradiated leukemia cell vaccine n1=L-dopa | n2=en:autologous gm-csf-secreting lethally irradiated leukemia cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous gm-csf-secreting melanoma vaccine n1=L-dopa | n2=en:autologous gm-csf-secreting melanoma vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous heat-shock protein 70 peptide vaccine ag-858 n1=L-dopa | n2=en:autologous heat-shock protein 70 peptide vaccine ag-858 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous hnscc dna-transfected semi-allogeneic fibroblasts mrc-5 vaccine n1=L-dopa | n2=en:autologous hnscc dna-transfected semi-allogeneic fibroblasts mrc-5 vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous hpv-16/18 e6/e7-specific tgf-beta-resistant t lymphocytes n1=L-dopa | n2=en:autologous hpv-16/18 e6/e7-specific tgf-beta-resistant t lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous ic9-gd2-car-expressing vzv-specific t lymphocytes n1=L-dopa | n2=en:autologous ic9-gd2-car-expressing vzv-specific t lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous il-21-modulated cd8+ mart1-specific t cells n1=L-dopa | n2=en:autologous il-21-modulated cd8+ mart1-specific t cells | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous immunoglobulin idiotype-klh conjugate vaccine n1=L-dopa | n2=en:autologous immunoglobulin idiotype-klh conjugate vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous interferon-producing killer dendritic cells n1=L-dopa | n2=en:autologous interferon-producing killer dendritic cells | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous lmp1-/lmp2- specific cytotoxic t-lymphocytes n1=L-dopa | n2=en:autologous lmp1-/lmp2- specific cytotoxic t-lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine n1=L-dopa | n2=en:autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine n1=L-dopa | n2=en:autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine n1=L-dopa | n2=en:autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous lymphoma immunoglobulin-derived scfv-chemokine dna vaccine n1=L-dopa | n2=en:autologous lymphoma immunoglobulin-derived scfv-chemokine dna vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous mage-a3-specific hla-a*01-restricted t cell receptor gene engineered lymphocytes n1=L-dopa | n2=en:autologous mage-a3-specific hla-a*01-restricted t cell receptor gene engineered lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous melanoma lysate-pulsed autologous dendritic cell vaccine n1=L-dopa | n2=en:autologous melanoma lysate-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous melanoma lysate/klh-pulsed autologous dendritic cell vaccine n1=L-dopa | n2=en:autologous melanoma lysate/klh-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous melanoma lysate/ny-eso-1-pulsed autologous dendritic cell vaccine n1=L-dopa | n2=en:autologous melanoma lysate/ny-eso-1-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous mesenchymal stem cells apceth_101 n1=L-dopa | n2=en:autologous mesenchymal stem cells apceth_101 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous neuroblastoma lysate/klh-pulsed dendritic cell vaccine n1=L-dopa | n2=en:autologous neuroblastoma lysate/klh-pulsed dendritic cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous nsclc dna-transfected semi-allogeneic fibroblasts mrc-5 vaccine n1=L-dopa | n2=en:autologous nsclc dna-transfected semi-allogeneic fibroblasts mrc-5 vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous nsclc peptide-specific dendritic cell vaccine n1=L-dopa | n2=en:autologous nsclc peptide-specific dendritic cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous ny-eso-1-melanoma-specific cd8+ t-lymphocytes n1=L-dopa | n2=en:autologous ny-eso-1-melanoma-specific cd8+ t-lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous ofa-ilrp rna-transfected dendritic cell vaccine n1=L-dopa | n2=en:autologous ofa-ilrp rna-transfected dendritic cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous ovarian tumor cell lysate-pulsed dendritic cell vaccine n1=L-dopa | n2=en:autologous ovarian tumor cell lysate-pulsed dendritic cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous peripheral blood lymphocytes cotransduced with retroviral vectors encoding inducible il-12 and anti-ny-eso-1 tcr n1=L-dopa | n2=en:autologous peripheral blood lymphocytes cotransduced with retroviral vectors encoding inducible il-12 and anti-ny-eso-1 tcr | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous pluripotent aldhbr stem cells ald-451 n1=L-dopa | n2=en:autologous pluripotent aldhbr stem cells ald-451 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous renal cell carcinoma tumor lysate-pulsed dendritic cell vaccine n1=L-dopa | n2=en:autologous renal cell carcinoma tumor lysate-pulsed dendritic cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous sarcoma lysate-pulsed dendritic cell vaccine n1=L-dopa | n2=en:autologous sarcoma lysate-pulsed dendritic cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous t-lymphocytes-expressing ny-eso-1-c259-specific enhanced t-cell receptors n1=L-dopa | n2=en:autologous t-lymphocytes-expressing ny-eso-1-c259-specific enhanced t-cell receptors | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous tns9.3.55-transduced cd34-positive cells n1=L-dopa | n2=en:autologous tns9.3.55-transduced cd34-positive cells | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous tumor cell proteoliposome chronic lymphocytic leukemia vaccine n1=L-dopa | n2=en:autologous tumor cell proteoliposome chronic lymphocytic leukemia vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous tumor cell vaccine n1=L-dopa | n2=en:autologous tumor cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous tumor infiltrating lymphocytes ln-144 n1=L-dopa | n2=en:autologous tumor infiltrating lymphocytes ln-144 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous tumor-associated peptide antigen-pulsed dendritic cell vaccine n1=L-dopa | n2=en:autologous tumor-associated peptide antigen-pulsed dendritic cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:autologous wt1-tcrc4 gene-transduced cd8-positive tcm/tn lymphocytes n1=L-dopa | n2=en:autologous wt1-tcrc4 gene-transduced cd8-positive tcm/tn lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:avitinib maleate n1=L-dopa | n2=en:avitinib maleate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:avn944 n1=L-dopa | n2=en:avn944 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:axitinib n1=L-dopa | n2=en:axitinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:axl inhibitor bgb324 n1=L-dopa | n2=en:axl inhibitor bgb324 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:axl inhibitor tp-0903 n1=L-dopa | n2=en:axl inhibitor tp-0903 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:azadirachta indica n1=L-dopa | n2=en:azadirachta indica | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:Azadirachta indica n1=L-dopa | n2=en:Azadirachta indica | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:azapicyl n1=L-dopa | n2=en:azapicyl | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:azathioprine sodium n1=L-dopa | n2=en:azathioprine sodium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:azd5438 n1=L-dopa | n2=en:azd5438 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:azimexon n1=L-dopa | n2=en:azimexon | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:aziridinylbenzoquinone rh1 n1=L-dopa | n2=en:aziridinylbenzoquinone rh1 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:azurin:50-77 cell penetrating peptide p28 n1=L-dopa | n2=en:azurin:50-77 cell penetrating peptide p28 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:b-raf/vegfr-2 inhibitor raf265 n1=L-dopa | n2=en:b-raf/vegfr-2 inhibitor raf265 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:b16alphagal melanoma vaccine n1=L-dopa | n2=en:b16alphagal melanoma vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:b43-pap immunotoxin n1=L-dopa | n2=en:b43-pap immunotoxin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:baclofen n1=L-dopa | n2=en:baclofen | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bafetinib n1=L-dopa | n2=en:bafetinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:banoxantrone n1=L-dopa | n2=en:banoxantrone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:barasertib n1=L-dopa | n2=en:barasertib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bardoxolone n1=L-dopa | n2=en:bardoxolone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:baricitinib n1=L-dopa | n2=en:baricitinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:batanopride n1=L-dopa | n2=en:batanopride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bavituximab n1=L-dopa | n2=en:bavituximab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bay 56-3722 n1=L-dopa | n2=en:bay 56-3722 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bazedoxifene n1=L-dopa | n2=en:bazedoxifene | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bbr 3464 n1=L-dopa | n2=en:bbr 3464 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bc-819 plasmid/polyethylenimine complex n1=L-dopa | n2=en:bc-819 plasmid/polyethylenimine complex | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bcg solution n1=L-dopa | n2=en:bcg solution | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bcl-2 inhibitor bcl201 n1=L-dopa | n2=en:bcl-2 inhibitor bcl201 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bcma-specific car-expressing t lymphocytes n1=L-dopa | n2=en:bcma-specific car-expressing t lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bcr-abl (b2a2)-derived peptide vaccine n1=L-dopa | n2=en:bcr-abl (b2a2)-derived peptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bcr-abl (b3a2)-derived peptide vaccine n1=L-dopa | n2=en:bcr-abl (b3a2)-derived peptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bcr-abl peptide vaccine n1=L-dopa | n2=en:bcr-abl peptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:be a counterpart to something n1=L-dopa | n2=en:be a counterpart to something | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:be the counterpart of n1=L-dopa | n2=en:be the counterpart of | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:becatecarin n1=L-dopa | n2=en:becatecarin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:beclomethasone dipropionate n1=L-dopa | n2=en:beclomethasone dipropionate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:beetroot juice n1=L-dopa | n2=en:beetroot juice | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:belagenpumatucel-l n1=L-dopa | n2=en:belagenpumatucel-l | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:belimumab n1=L-dopa | n2=en:belimumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:belinostat n1=L-dopa | n2=en:belinostat | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:belotecan hydrochloride n1=L-dopa | n2=en:belotecan hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:benazepril hydrochloride n1=L-dopa | n2=en:benazepril hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bendamustine hydrochloride n1=L-dopa | n2=en:bendamustine hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bendamustine-containing nanoparticle-based formulation rxdx-107 n1=L-dopa | n2=en:bendamustine-containing nanoparticle-based formulation rxdx-107 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bendamustine-vorinostat fusion molecule edo-s101 n1=L-dopa | n2=en:bendamustine-vorinostat fusion molecule edo-s101 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:benserazide 50 mg / levodopa 200 mg oral tablet n1=L-dopa | n2=en:benserazide 50 mg / levodopa 200 mg oral tablet | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:benserazide, levodopa drug combination n1=L-dopa | n2=en:benserazide, levodopa drug combination | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:benzoylphenylurea n1=L-dopa | n2=en:benzoylphenylurea | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bep regimen n1=L-dopa | n2=en:bep regimen | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:berberine chloride n1=L-dopa | n2=en:berberine chloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:berubicin hydrochloride n1=L-dopa | n2=en:berubicin hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bet bromodomain inhibitor zen-3694 n1=L-dopa | n2=en:bet bromodomain inhibitor zen-3694 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bet bromodomains 2/3/4 inhibitor mk-8628 n1=L-dopa | n2=en:bet bromodomains 2/3/4 inhibitor mk-8628 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bet inhibitor bay1238097 n1=L-dopa | n2=en:bet inhibitor bay1238097 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bet inhibitor bms-986158 n1=L-dopa | n2=en:bet inhibitor bms-986158 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bet inhibitor cpi-0610 n1=L-dopa | n2=en:bet inhibitor cpi-0610 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bet inhibitor ft-1101 n1=L-dopa | n2=en:bet inhibitor ft-1101 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bet inhibitor gsk525762 n1=L-dopa | n2=en:bet inhibitor gsk525762 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bet inhibitor incb057643 n1=L-dopa | n2=en:bet inhibitor incb057643 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bet inhibitor ten-010 n1=L-dopa | n2=en:bet inhibitor ten-010 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:beta-elemene n1=L-dopa | n2=en:beta-elemene | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:beta-glucan mm-10-001 n1=L-dopa | n2=en:beta-glucan mm-10-001 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:beta-glucan/alginate/hyaluronic acid/squalene/avocado oil-containing emulsion n1=L-dopa | n2=en:beta-glucan/alginate/hyaluronic acid/squalene/avocado oil-containing emulsion | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:beta-lapachone prodrug arq 761 n1=L-dopa | n2=en:beta-lapachone prodrug arq 761 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:beta-thioguanine deoxyriboside n1=L-dopa | n2=en:beta-thioguanine deoxyriboside | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:betulinic acid n1=L-dopa | n2=en:betulinic acid | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bevacizumab n1=L-dopa | n2=en:bevacizumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bevacizumab-irdye 800cw n1=L-dopa | n2=en:bevacizumab-irdye 800cw | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bexarotene n1=L-dopa | n2=en:bexarotene | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bh3 mimetic abt-737 n1=L-dopa | n2=en:bh3 mimetic abt-737 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bi 2536 n1=L-dopa | n2=en:bi 2536 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bi 831266 n1=L-dopa | n2=en:bi 831266 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bi 894999 n1=L-dopa | n2=en:bi 894999 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bi-functional alkylating agent val-083 n1=L-dopa | n2=en:bi-functional alkylating agent val-083 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bi-layered skin substitute from keratinocytes and fibroblasts n1=L-dopa | n2=en:bi-layered skin substitute from keratinocytes and fibroblasts | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bi-shrna-furin/gm-csf-expressing autologous tumor cell vaccine n1=L-dopa | n2=en:bi-shrna-furin/gm-csf-expressing autologous tumor cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:biafine cream n1=L-dopa | n2=en:biafine cream | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bibx 1382 n1=L-dopa | n2=en:bibx 1382 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bicalutamide n1=L-dopa | n2=en:bicalutamide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bifidobacterium lactis/lactobacillus acidophilus/l. plantarum/l. salivarius probiotic supplement n1=L-dopa | n2=en:bifidobacterium lactis/lactobacillus acidophilus/l. plantarum/l. salivarius probiotic supplement | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bifunctional expression vector plasmid dna-bi-shrna ews/fli1 type 1 lipoplex n1=L-dopa | n2=en:bifunctional expression vector plasmid dna-bi-shrna ews/fli1 type 1 lipoplex | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:binetrakin n1=L-dopa | n2=en:binetrakin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:binimetinib n1=L-dopa | n2=en:binimetinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:biological agent n1=L-dopa | n2=en:biological agent | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:biological factors n1=L-dopa | n2=en:biological factors | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:biomed 101 n1=L-dopa | n2=en:biomed 101 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:birinapant n1=L-dopa | n2=en:birinapant | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bis(choline)tetrathiomolybdate n1=L-dopa | n2=en:bis(choline)tetrathiomolybdate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bisantrene hydrochloride n1=L-dopa | n2=en:bisantrene hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bismuth subsalicylate n1=L-dopa | n2=en:bismuth subsalicylate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bispecific antibody 2b1 n1=L-dopa | n2=en:bispecific antibody 2b1 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bispecific antibody mdx-h210 n1=L-dopa | n2=en:bispecific antibody mdx-h210 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bispecific antibody mdx447 n1=L-dopa | n2=en:bispecific antibody mdx447 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bivalent hpv16/18 therapeutic cervical cancer vaccine n1=L-dopa | n2=en:bivalent hpv16/18 therapeutic cervical cancer vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bizelesin n1=L-dopa | n2=en:bizelesin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bl22 immunotoxin n1=L-dopa | n2=en:bl22 immunotoxin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:black cohosh n1=L-dopa | n2=en:black cohosh | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:black tea n1=L-dopa | n2=en:black tea | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:blackberry allergenic extract n1=L-dopa | n2=en:blackberry allergenic extract | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bleomycin sulfate n1=L-dopa | n2=en:bleomycin sulfate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:blex 404 n1=L-dopa | n2=en:blex 404 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:blue citrus-based herbal capsule n1=L-dopa | n2=en:blue citrus-based herbal capsule | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:blueberry powder supplement n1=L-dopa | n2=en:blueberry powder supplement | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bms-188797 n1=L-dopa | n2=en:bms-188797 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bms-275183 n1=L-dopa | n2=en:bms-275183 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bms-817378 n1=L-dopa | n2=en:bms-817378 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:boanmycin hydrochloride n1=L-dopa | n2=en:boanmycin hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:boronophenylalanine-fructose complex n1=L-dopa | n2=en:boronophenylalanine-fructose complex | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bortezomib n1=L-dopa | n2=en:bortezomib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bosutinib n1=L-dopa | n2=en:bosutinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:boswellia serrata extract n1=L-dopa | n2=en:boswellia serrata extract | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:botulinum toxin type a n1=L-dopa | n2=en:botulinum toxin type a | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bp-cx1-platinum complex bp-c1 n1=L-dopa | n2=en:bp-cx1-platinum complex bp-c1 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:br96-doxorubicin immunoconjugate n1=L-dopa | n2=en:br96-doxorubicin immunoconjugate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:braf inhibitor arq 736 n1=L-dopa | n2=en:braf inhibitor arq 736 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:braf inhibitor plx8394 n1=L-dopa | n2=en:braf inhibitor plx8394 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:braf(v600e) inhibitor cep-32496 n1=L-dopa | n2=en:braf(v600e) inhibitor cep-32496 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:braf(v600e) kinase inhibitor ro5212054 n1=L-dopa | n2=en:braf(v600e) kinase inhibitor ro5212054 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:braf/egfr inhibitor bgb-283 n1=L-dopa | n2=en:braf/egfr inhibitor bgb-283 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:brain tumor initiating cell vaccine n1=L-dopa | n2=en:brain tumor initiating cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:branched-chain amino acid supplement n1=L-dopa | n2=en:branched-chain amino acid supplement | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:brassica vegetable n1=L-dopa | n2=en:brassica vegetable | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:brd4 inhibitor plx51107 n1=L-dopa | n2=en:brd4 inhibitor plx51107 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:brequinar n1=L-dopa | n2=en:brequinar | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:briciclib sodium n1=L-dopa | n2=en:briciclib sodium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:brigatinib n1=L-dopa | n2=en:brigatinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:brilacidin oral rinse n1=L-dopa | n2=en:brilacidin oral rinse | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:brivanib n1=L-dopa | n2=en:brivanib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:brivanib alaninate n1=L-dopa | n2=en:brivanib alaninate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:brivudine n1=L-dopa | n2=en:brivudine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:brivudine phosphoramidate n1=L-dopa | n2=en:brivudine phosphoramidate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:broad-spectrum human papillomavirus vaccine v505 n1=L-dopa | n2=en:broad-spectrum human papillomavirus vaccine v505 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bromelains n1=L-dopa | n2=en:bromelains | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bromocriptine mesylate n1=L-dopa | n2=en:bromocriptine mesylate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:brostallicin n1=L-dopa | n2=en:brostallicin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bryostatin 1 n1=L-dopa | n2=en:bryostatin 1 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:btk inhibitor gdc-0853 n1=L-dopa | n2=en:btk inhibitor gdc-0853 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:budesonide/formoterol fumarate dihydrate inhalation aerosol n1=L-dopa | n2=en:budesonide/formoterol fumarate dihydrate inhalation aerosol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:buparlisib n1=L-dopa | n2=en:buparlisib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bupivacaine hydrochloride n1=L-dopa | n2=en:bupivacaine hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:bupropion + naltrexone n1=L-dopa | n2=en:bupropion + naltrexone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:buspirone hydrochloride n1=L-dopa | n2=en:buspirone hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:busulfan n1=L-dopa | n2=en:busulfan | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:busulfan/melphalan regimen n1=L-dopa | n2=en:busulfan/melphalan regimen | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:busulphan n1=L-dopa | n2=en:busulphan | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:c-kit inhibitor plx9486 n1=L-dopa | n2=en:c-kit inhibitor plx9486 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:c-met inhibitor jnj-38877605 n1=L-dopa | n2=en:c-met inhibitor jnj-38877605 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:c-met inhibitor mk2461 n1=L-dopa | n2=en:c-met inhibitor mk2461 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:c-met inhibitor mk8033 n1=L-dopa | n2=en:c-met inhibitor mk8033 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:c-met inhibitor msc2156119j n1=L-dopa | n2=en:c-met inhibitor msc2156119j | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:c-myb antisense oligonucleotide g4460 n1=L-dopa | n2=en:c-myb antisense oligonucleotide g4460 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cabazitaxel n1=L-dopa | n2=en:cabazitaxel | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:caix inhibitor dtp348 n1=L-dopa | n2=en:caix inhibitor dtp348 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:calamine n1=L-dopa | n2=en:calamine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:calaspargase pegol n1=L-dopa | n2=en:calaspargase pegol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:calcipotriene n1=L-dopa | n2=en:calcipotriene | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:calcitonin salmon n1=L-dopa | n2=en:calcitonin salmon | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:calcium aluminosilicate anti-diarrheal n1=L-dopa | n2=en:calcium aluminosilicate anti-diarrheal | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:calcium channel blocker n1=L-dopa | n2=en:calcium channel blocker | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:calcium channel inhibitor n1=L-dopa | n2=en:calcium channel inhibitor | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:calcium citrate n1=L-dopa | n2=en:calcium citrate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:calcium saccharate n1=L-dopa | n2=en:calcium saccharate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:calcium-46 chloride aqueous solution n1=L-dopa | n2=en:calcium-46 chloride aqueous solution | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:camptothecin-20(s)-o-propionate hydrate n1=L-dopa | n2=en:camptothecin-20(s)-o-propionate hydrate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:canarypox-hil-12 melanoma vaccine n1=L-dopa | n2=en:canarypox-hil-12 melanoma vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cancell n1=L-dopa | n2=en:cancell | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cancer stemness kinase inhibitor bbi503 n1=L-dopa | n2=en:cancer stemness kinase inhibitor bbi503 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:candesartan cilexetil n1=L-dopa | n2=en:candesartan cilexetil | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:canfosfamide hydrochloride n1=L-dopa | n2=en:canfosfamide hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cannabidiol n1=L-dopa | n2=en:cannabidiol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cannabinol n1=L-dopa | n2=en:cannabinol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cannabis extract oil sr capsule n1=L-dopa | n2=en:cannabis extract oil sr capsule | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cantuzumab ravtansine n1=L-dopa | n2=en:cantuzumab ravtansine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:capecitabine n1=L-dopa | n2=en:capecitabine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:capecitabine rapidly disintegrating tablet n1=L-dopa | n2=en:capecitabine rapidly disintegrating tablet | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:capox regimen n1=L-dopa | n2=en:capox regimen | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:capsaicin n1=L-dopa | n2=en:capsaicin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:caracemide n1=L-dopa | n2=en:caracemide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbendazim n1=L-dopa | n2=en:carbendazim | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbetimer n1=L-dopa | n2=en:carbetimer | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbidopa / levodopa disintegrating oral product n1=L-dopa | n2=en:carbidopa / levodopa disintegrating oral product | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbidopa / levodopa disintegrating oral tablet n1=L-dopa | n2=en:carbidopa / levodopa disintegrating oral tablet | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbidopa / levodopa extended release oral capsule n1=L-dopa | n2=en:carbidopa / levodopa extended release oral capsule | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbidopa / levodopa extended release oral tablet n1=L-dopa | n2=en:carbidopa / levodopa extended release oral tablet | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbidopa / levodopa pill n1=L-dopa | n2=en:carbidopa / levodopa pill | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbidopa + entacapone + levodopa n1=L-dopa | n2=en:carbidopa + entacapone + levodopa | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbidopa 12.5 mg / entacapone 200 mg / levodopa 50 mg oral tablet [stalevo] n1=L-dopa | n2=en:carbidopa 12.5 mg / entacapone 200 mg / levodopa 50 mg oral tablet [stalevo] | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbidopa 18.75mg + levodopa 75mg + entacapone 200mg tablet n1=L-dopa | n2=en:carbidopa 18.75mg + levodopa 75mg + entacapone 200mg tablet | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbidopa 25 mg / levodopa 100 mg extended release oral tablet n1=L-dopa | n2=en:carbidopa 25 mg / levodopa 100 mg extended release oral tablet | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbidopa 31.25 mg / entacapone 200 mg / levodopa 125 mg oral tablet [stalevo] n1=L-dopa | n2=en:carbidopa 31.25 mg / entacapone 200 mg / levodopa 125 mg oral tablet [stalevo] | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbidopa 31.25mg + levodopa 125mg + entacapone 200mg tablet n1=L-dopa | n2=en:carbidopa 31.25mg + levodopa 125mg + entacapone 200mg tablet | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbidopa 37.5 mg / entacapone 200 mg / levodopa 150 mg oral tablet [stalevo] n1=L-dopa | n2=en:carbidopa 37.5 mg / entacapone 200 mg / levodopa 150 mg oral tablet [stalevo] | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbidopa 37.5mg/levodopa 150mg/entacapone 200mg tablet n1=L-dopa | n2=en:carbidopa 37.5mg/levodopa 150mg/entacapone 200mg tablet | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbidopa 4.63 mg/ml / levodopa 20 mg/ml oral suspension n1=L-dopa | n2=en:carbidopa 4.63 mg/ml / levodopa 20 mg/ml oral suspension | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbidopa 4.63 mg/ml / levodopa 20 mg/ml oral suspension [duopa] n1=L-dopa | n2=en:carbidopa 4.63 mg/ml / levodopa 20 mg/ml oral suspension [duopa] | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbidopa 50 mg / entacapone 200 mg / levodopa 200 mg oral tablet n1=L-dopa | n2=en:carbidopa 50 mg / entacapone 200 mg / levodopa 200 mg oral tablet | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbidopa 50 mg / levodopa 200 mg extended release oral tablet [sinemet] n1=L-dopa | n2=en:carbidopa 50 mg / levodopa 200 mg extended release oral tablet [sinemet] | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbidopa monohydrate n1=L-dopa | n2=en:carbidopa monohydrate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbidopa, levodopa drug combination n1=L-dopa | n2=en:carbidopa, levodopa drug combination | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbidopa+levodopa 12.5mg/50mg tablet n1=L-dopa | n2=en:carbidopa+levodopa 12.5mg/50mg tablet | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbodopa n1=L-dopa | n2=en:carbodopa | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbogen n1=L-dopa | n2=en:carbogen | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbon c 11 choline n1=L-dopa | n2=en:carbon c 11 choline | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbon c 11 n-desmethyl-loperamide n1=L-dopa | n2=en:carbon c 11 n-desmethyl-loperamide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbon c 11 pbr-28 n1=L-dopa | n2=en:carbon c 11 pbr-28 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbon c 13 acetate n1=L-dopa | n2=en:carbon c 13 acetate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbon c 13 lycopene n1=L-dopa | n2=en:carbon c 13 lycopene | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbon c 13 phytofluene n1=L-dopa | n2=en:carbon c 13 phytofluene | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbon c 13/nitrogen n 15-labeled valine n1=L-dopa | n2=en:carbon c 13/nitrogen n 15-labeled valine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbon c 14 anlotinib hydrochloride n1=L-dopa | n2=en:carbon c 14 anlotinib hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbon c 14 ibrutinib n1=L-dopa | n2=en:carbon c 14 ibrutinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbon c 14 lenvatinib mesylate n1=L-dopa | n2=en:carbon c 14 lenvatinib mesylate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbon c 14 oxaliplatin n1=L-dopa | n2=en:carbon c 14 oxaliplatin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbon c 14 telotristat etiprate n1=L-dopa | n2=en:carbon c 14 telotristat etiprate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbon c 14 vemurafenib n1=L-dopa | n2=en:carbon c 14 vemurafenib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbon c-13 dextromethorphan n1=L-dopa | n2=en:carbon c-13 dextromethorphan | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbon c11 temozolomide n1=L-dopa | n2=en:carbon c11 temozolomide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carbon-11 acetate n1=L-dopa | n2=en:carbon-11 acetate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carboplatin/etoposide/melphalan regimen n1=L-dopa | n2=en:carboplatin/etoposide/melphalan regimen | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carboxyamidotriazole orotate n1=L-dopa | n2=en:carboxyamidotriazole orotate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carboxylesterase-expressing allogeneic neural stem cells n1=L-dopa | n2=en:carboxylesterase-expressing allogeneic neural stem cells | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carboxymethylcellulose sodium n1=L-dopa | n2=en:carboxymethylcellulose sodium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carboxyphenyl retinamide n1=L-dopa | n2=en:carboxyphenyl retinamide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carcinoembryonic antigen peptide 1-6d virus-like replicon particles vaccine n1=L-dopa | n2=en:carcinoembryonic antigen peptide 1-6d virus-like replicon particles vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carcinoembryonic antigen rna-pulsed dc cancer vaccine n1=L-dopa | n2=en:carcinoembryonic antigen rna-pulsed dc cancer vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carcinoembryonic antigen-expressing measles virus n1=L-dopa | n2=en:carcinoembryonic antigen-expressing measles virus | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carcinogen n1=L-dopa | n2=en:carcinogen | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carfilzomib n1=L-dopa | n2=en:carfilzomib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:caricotamide/tretazicar n1=L-dopa | n2=en:caricotamide/tretazicar | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carmustine n1=L-dopa | n2=en:carmustine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carmustine in ethanol n1=L-dopa | n2=en:carmustine in ethanol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carrageenan-containing gel n1=L-dopa | n2=en:carrageenan-containing gel | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:carvedilol n1=L-dopa | n2=en:carvedilol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:caseinate protein isolate n1=L-dopa | n2=en:caseinate protein isolate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:casopitant mesylate n1=L-dopa | n2=en:casopitant mesylate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cathelicidin ll-37 n1=L-dopa | n2=en:cathelicidin ll-37 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cationic liposome-encapsulated paclitaxel n1=L-dopa | n2=en:cationic liposome-encapsulated paclitaxel | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:catumaxomab n1=L-dopa | n2=en:catumaxomab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cb10-277 n1=L-dopa | n2=en:cb10-277 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cbp/beta-catenin antagonist pri-724 n1=L-dopa | n2=en:cbp/beta-catenin antagonist pri-724 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cc-1088 n1=L-dopa | n2=en:cc-1088 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cc-401 n1=L-dopa | n2=en:cc-401 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ccl21-expressing h1944 cell vaccine n1=L-dopa | n2=en:ccl21-expressing h1944 cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ccr2 antagonist pf-04136309 n1=L-dopa | n2=en:ccr2 antagonist pf-04136309 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cd105/yb-1/sox2/cdh3/mdm2-polyepitope plasmid dna vaccine n1=L-dopa | n2=en:cd105/yb-1/sox2/cdh3/mdm2-polyepitope plasmid dna vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cd133 antigen peptide-pulsed autologous dendritic cell vaccine n1=L-dopa | n2=en:cd133 antigen peptide-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cd19/cd3 dual-affinity retargeting protein jnj-64052781 n1=L-dopa | n2=en:cd19/cd3 dual-affinity retargeting protein jnj-64052781 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cd19car-cd3zeta-4-1bb-cd28-expressing autologous t-lymphocytes n1=L-dopa | n2=en:cd19car-cd3zeta-4-1bb-cd28-expressing autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cd19car-cd3zeta-4-1bb-expressing autologous t-lymphocytes n1=L-dopa | n2=en:cd19car-cd3zeta-4-1bb-expressing autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cd19car-cd3zeta-expressing autologous t lymphocytes n1=L-dopa | n2=en:cd19car-cd3zeta-expressing autologous t lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cd24 extracellular domain-igg1 fc domain recombinant fusion protein cd24fc n1=L-dopa | n2=en:cd24 extracellular domain-igg1 fc domain recombinant fusion protein cd24fc | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cd33car-cd3zeta-4-1bb-expressing autologous t-lymphocytes n1=L-dopa | n2=en:cd33car-cd3zeta-4-1bb-expressing autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cd4+ cd25+ regulatory t cells n1=L-dopa | n2=en:cd4+ cd25+ regulatory t cells | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cd40 agonist monoclonal antibody cp-870,893 n1=L-dopa | n2=en:cd40 agonist monoclonal antibody cp-870,893 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cd40 agonist monoclonal antibody ro7009789 n1=L-dopa | n2=en:cd40 agonist monoclonal antibody ro7009789 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cd40 agonistic monoclonal antibody apx005m n1=L-dopa | n2=en:cd40 agonistic monoclonal antibody apx005m | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cd95 ecd/igg-fc fusion protein apg101 n1=L-dopa | n2=en:cd95 ecd/igg-fc fusion protein apg101 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cdc7 inhibitor tak-931 n1=L-dopa | n2=en:cdc7 inhibitor tak-931 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cdc7 kinase inhibitor bms-863233 n1=L-dopa | n2=en:cdc7 kinase inhibitor bms-863233 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cdk inhibitor p276-00 n1=L-dopa | n2=en:cdk inhibitor p276-00 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cdk inhibitor sns-032 n1=L-dopa | n2=en:cdk inhibitor sns-032 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cdk2/5/9 inhibitor cyc065 n1=L-dopa | n2=en:cdk2/5/9 inhibitor cyc065 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cdk4 inhibitor p1446a-05 n1=L-dopa | n2=en:cdk4 inhibitor p1446a-05 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cdk4/6 inhibitor g1t28 n1=L-dopa | n2=en:cdk4/6 inhibitor g1t28 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cdki at7519 n1=L-dopa | n2=en:cdki at7519 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cdki r547 n1=L-dopa | n2=en:cdki r547 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cea/tetanus toxoid t helper epitope fusion protein-expressing dna plasmid vaccine n1=L-dopa | n2=en:cea/tetanus toxoid t helper epitope fusion protein-expressing dna plasmid vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cebpa-targeting sarna mtl-cebpa liposome n1=L-dopa | n2=en:cebpa-targeting sarna mtl-cebpa liposome | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cef regimen n1=L-dopa | n2=en:cef regimen | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cefepime hydrochloride n1=L-dopa | n2=en:cefepime hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cefpodoxime proxetil n1=L-dopa | n2=en:cefpodoxime proxetil | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ceftobiprole medocaril n1=L-dopa | n2=en:ceftobiprole medocaril | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ceftriaxone sodium n1=L-dopa | n2=en:ceftriaxone sodium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cell cycle checkpoint/dna repair antagonist ic83 n1=L-dopa | n2=en:cell cycle checkpoint/dna repair antagonist ic83 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cemadotin hydrochloride n1=L-dopa | n2=en:cemadotin hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cenersen n1=L-dopa | n2=en:cenersen | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cenisertib n1=L-dopa | n2=en:cenisertib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:central nervous system agents n1=L-dopa | n2=en:central nervous system agents | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ceritinib n1=L-dopa | n2=en:ceritinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:certolizumab n1=L-dopa | n2=en:certolizumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cesium cs-131 n1=L-dopa | n2=en:cesium cs-131 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cetirizine n1=L-dopa | n2=en:cetirizine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cetuximab n1=L-dopa | n2=en:cetuximab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cfms tyrosine kinase inhibitor arry-382 n1=L-dopa | n2=en:cfms tyrosine kinase inhibitor arry-382 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cgp-6809 n1=L-dopa | n2=en:cgp-6809 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:checkpoint kinase inhibitor azd7762 n1=L-dopa | n2=en:checkpoint kinase inhibitor azd7762 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:checkpoint kinase inhibitor xl844 n1=L-dopa | n2=en:checkpoint kinase inhibitor xl844 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:chelating agent n1=L-dopa | n2=en:chelating agent | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:chewing gum dosage form n1=L-dopa | n2=en:chewing gum dosage form | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:chidamide n1=L-dopa | n2=en:chidamide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:chimeric fibril-reactive monoclonal antibody 111f4 n1=L-dopa | n2=en:chimeric fibril-reactive monoclonal antibody 111f4 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:chimeric humanized anti-cd47 antibody n1=L-dopa | n2=en:chimeric humanized anti-cd47 antibody | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:chinese herbal formulation changtai keli n1=L-dopa | n2=en:chinese herbal formulation changtai keli | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:chinese herbal formulation phy906 n1=L-dopa | n2=en:chinese herbal formulation phy906 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:chk1 inhibitor gdc-0425 n1=L-dopa | n2=en:chk1 inhibitor gdc-0425 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:chk1 inhibitor gdc-0575 n1=L-dopa | n2=en:chk1 inhibitor gdc-0575 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:chk1 inhibitor mk-8776 n1=L-dopa | n2=en:chk1 inhibitor mk-8776 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:chk1 inhibitor pf-477736 n1=L-dopa | n2=en:chk1 inhibitor pf-477736 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:chlorambucil-prednisone regimen n1=L-dopa | n2=en:chlorambucil-prednisone regimen | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:chloroquinoxaline sulfonamide n1=L-dopa | n2=en:chloroquinoxaline sulfonamide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:choleretic agent n1=L-dopa | n2=en:choleretic agent | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:choline kinase alpha inhibitor tcd-717 n1=L-dopa | n2=en:choline kinase alpha inhibitor tcd-717 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cholinergic antagonists n1=L-dopa | n2=en:cholinergic antagonists | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:chp-her-2 peptide vaccine n1=L-dopa | n2=en:chp-her-2 peptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:chp-ny-eso-1 peptide vaccine imf-001 n1=L-dopa | n2=en:chp-ny-eso-1 peptide vaccine imf-001 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ciclopirox olamine lotion n1=L-dopa | n2=en:ciclopirox olamine lotion | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cilengitide n1=L-dopa | n2=en:cilengitide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cimetidine n1=L-dopa | n2=en:cimetidine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cinacalcet hydrochloride n1=L-dopa | n2=en:cinacalcet hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cinobufagin n1=L-dopa | n2=en:cinobufagin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cirmtuzumab n1=L-dopa | n2=en:cirmtuzumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cis-urocanic acid n1=L-dopa | n2=en:cis-urocanic acid | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cisplatin n1=L-dopa | n2=en:cisplatin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cisplatin liposomal n1=L-dopa | n2=en:cisplatin liposomal | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cisplatin-e therapeutic implant n1=L-dopa | n2=en:cisplatin-e therapeutic implant | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:citatuzumab bogatox n1=L-dopa | n2=en:citatuzumab bogatox | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:citric acid + magnesium oxide + sodium picosulfate n1=L-dopa | n2=en:citric acid + magnesium oxide + sodium picosulfate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:citrulline n1=L-dopa | n2=en:citrulline | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cixutumumab n1=L-dopa | n2=en:cixutumumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ck2-targeting synthetic peptide cigb-300 n1=L-dopa | n2=en:ck2-targeting synthetic peptide cigb-300 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:clarithromycin n1=L-dopa | n2=en:clarithromycin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:claudiximab n1=L-dopa | n2=en:claudiximab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:clevudine n1=L-dopa | n2=en:clevudine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:clino-san vaginal lubricant n1=L-dopa | n2=en:clino-san vaginal lubricant | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:clofarabine n1=L-dopa | n2=en:clofarabine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:clomiphen citrate n1=L-dopa | n2=en:clomiphen citrate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:clomiphene citrate n1=L-dopa | n2=en:clomiphene citrate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:clonidine-containing mucoadhesive buccal tablet n1=L-dopa | n2=en:clonidine-containing mucoadhesive buccal tablet | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:clostridium butyricum-containing probiotic n1=L-dopa | n2=en:clostridium butyricum-containing probiotic | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:clostridium novyi-nt spores n1=L-dopa | n2=en:clostridium novyi-nt spores | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cmet car-mrna electroporated autologous t lymphocytes n1=L-dopa | n2=en:cmet car-mrna electroporated autologous t lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cmv n495 peptide n1=L-dopa | n2=en:cmv n495 peptide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cmv pp65 peptide-pulsed autologous dendritic cell vaccine n1=L-dopa | n2=en:cmv pp65 peptide-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cmvpp65-a*0201 peptide vaccine n1=L-dopa | n2=en:cmvpp65-a*0201 peptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cngrc peptide-tnf alpha conjugate n1=L-dopa | n2=en:cngrc peptide-tnf alpha conjugate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:co-beneldopa 25mg/100mg capsule n1=L-dopa | n2=en:co-beneldopa 25mg/100mg capsule | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:co-beneldopa 25mg/100mg dispersible tablet n1=L-dopa | n2=en:co-beneldopa 25mg/100mg dispersible tablet | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:co-beneldopa 25mg/100mg m/r capsule n1=L-dopa | n2=en:co-beneldopa 25mg/100mg m/r capsule | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:co-beneldopa 50mg/200mg capsule n1=L-dopa | n2=en:co-beneldopa 50mg/200mg capsule | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cobalamin n1=L-dopa | n2=en:cobalamin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cobalamine n1=L-dopa | n2=en:cobalamine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cobimetinib n1=L-dopa | n2=en:cobimetinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cobiprostone n1=L-dopa | n2=en:cobiprostone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cocculus/nux vomica/tabacum/petroleum extract n1=L-dopa | n2=en:cocculus/nux vomica/tabacum/petroleum extract | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:code n1=L-dopa | n2=en:code | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:codeine phosphate n1=L-dopa | n2=en:codeine phosphate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:coffee dietary supplement n1=L-dopa | n2=en:coffee dietary supplement | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cold contaminant-free iobenguane i-131 n1=L-dopa | n2=en:cold contaminant-free iobenguane i-131 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:colloidal gold-bound tumor necrosis factor n1=L-dopa | n2=en:colloidal gold-bound tumor necrosis factor | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:colorectal tumor-associated peptides vaccine ima910 n1=L-dopa | n2=en:colorectal tumor-associated peptides vaccine ima910 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:combretastatin a1 diphosphate n1=L-dopa | n2=en:combretastatin a1 diphosphate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:complement c5 inhibitor alxn1210 n1=L-dopa | n2=en:complement c5 inhibitor alxn1210 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:compound kushen injection n1=L-dopa | n2=en:compound kushen injection | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:compound sodium lactate solution n1=L-dopa | n2=en:compound sodium lactate solution | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:computer language n1=L-dopa | n2=en:computer language | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:conatumumab n1=L-dopa | n2=en:conatumumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:concentrated beet crystals n1=L-dopa | n2=en:concentrated beet crystals | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:conditionally replicative adenovirus 5/3-delta24 n1=L-dopa | n2=en:conditionally replicative adenovirus 5/3-delta24 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:conjugated estrogens/bazedoxifene n1=L-dopa | n2=en:conjugated estrogens/bazedoxifene | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:controlled substance n1=L-dopa | n2=en:controlled substance | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:copanlisib n1=L-dopa | n2=en:copanlisib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:copovithane n1=L-dopa | n2=en:copovithane | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:copp regimen n1=L-dopa | n2=en:copp regimen | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:copper cu 62-atsm n1=L-dopa | n2=en:copper cu 62-atsm | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:copper gluconate n1=L-dopa | n2=en:copper gluconate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cord blood-derived expanded natural killer cell infusion pnk-007 n1=L-dopa | n2=en:cord blood-derived expanded natural killer cell infusion pnk-007 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cordycepin n1=L-dopa | n2=en:cordycepin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:coriolus versicolor extract n1=L-dopa | n2=en:coriolus versicolor extract | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:correspond to n1=L-dopa | n2=en:correspond to | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:corticorelin acetate n1=L-dopa | n2=en:corticorelin acetate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:corticotropin 30 [hp_x] in 1 ml / .gamma.-aminobutyric acid 3 [hp_c] in 1 ml / glutamic acid 3 [hp_c] in 1 ml / norepinephrine 30 [hp_c] in 1 ml / acetylcholine chloride 1 [hp_m] in 1 ml / epinephrine 1 [hp_m] in 1 ml / serotonin 1 [hp_m] in 1 ml / thy n1=L-dopa | n2=en:corticotropin 30 [hp_x] in 1 ml / .gamma.-aminobutyric acid 3 [hp_c] in 1 ml / glutamic acid 3 [hp_c] in 1 ml / norepinephrine 30 [hp_c] in 1 ml / acetylcholine chloride 1 [hp_m] in 1 ml / epinephrine 1 [hp_m] in 1 ml / serotonin 1 [hp_m] in 1 ml / thy | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:corticotropin 6 [hp_x] in 1 ml / .gamma.-aminobutyric acid 6 [hp_x] in 1 ml / glutamic acid 6 [hp_x] in 1 ml / norepinephrine 6 [hp_x] in 1 ml / acetylcholine chloride 6 [hp_x] in 1 ml / epinephrine 6 [hp_x] in 1 ml / levodopa 6 [hp_x] in 1 ml / seroto n1=L-dopa | n2=en:corticotropin 6 [hp_x] in 1 ml / .gamma.-aminobutyric acid 6 [hp_x] in 1 ml / glutamic acid 6 [hp_x] in 1 ml / norepinephrine 6 [hp_x] in 1 ml / acetylcholine chloride 6 [hp_x] in 1 ml / epinephrine 6 [hp_x] in 1 ml / levodopa 6 [hp_x] in 1 ml / seroto | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cortifair n1=L-dopa | n2=en:cortifair | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cortisol n1=L-dopa | n2=en:cortisol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:corynebacterium granulosum p40 n1=L-dopa | n2=en:corynebacterium granulosum p40 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:coxsackievirus a21 n1=L-dopa | n2=en:coxsackievirus a21 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cp 461 n1=L-dopa | n2=en:cp 461 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cp-609,754 n1=L-dopa | n2=en:cp-609,754 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cp-724,714 n1=L-dopa | n2=en:cp-724,714 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cpg-28 oligodeoxynucleotide n1=L-dopa | n2=en:cpg-28 oligodeoxynucleotide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cr2-fh fusion protein tt30 n1=L-dopa | n2=en:cr2-fh fusion protein tt30 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:creatine monohydrate n1=L-dopa | n2=en:creatine monohydrate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:crenolanib n1=L-dopa | n2=en:crenolanib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:crenolanib besylate n1=L-dopa | n2=en:crenolanib besylate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cridanimod sodium n1=L-dopa | n2=en:cridanimod sodium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:crisnatol mesylate n1=L-dopa | n2=en:crisnatol mesylate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:crl 1005 n1=L-dopa | n2=en:crl 1005 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:crolibulin n1=L-dopa | n2=en:crolibulin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cryoprotective agent n1=L-dopa | n2=en:cryoprotective agent | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:crystalline genistein formulation axp107-11 n1=L-dopa | n2=en:crystalline genistein formulation axp107-11 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ctp-37-dt vaccine n1=L-dopa | n2=en:ctp-37-dt vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:curcumin n1=L-dopa | n2=en:curcumin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:curcumin/green tea extract/polygonum cuspidatum extract/soybean extract capsule n1=L-dopa | n2=en:curcumin/green tea extract/polygonum cuspidatum extract/soybean extract capsule | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:custirsen sodium n1=L-dopa | n2=en:custirsen sodium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cxc chemokine receptor 2 antagonist azd5069 n1=L-dopa | n2=en:cxc chemokine receptor 2 antagonist azd5069 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cxcr4 antagonist bl-8040 n1=L-dopa | n2=en:cxcr4 antagonist bl-8040 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cxcr4 inhibitor x4p-001 n1=L-dopa | n2=en:cxcr4 inhibitor x4p-001 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cyclin b1 peptide-pulsed autologous dendritic cell vaccine n1=L-dopa | n2=en:cyclin b1 peptide-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cyclodextrin-based polymer-camptothecin crlx101 n1=L-dopa | n2=en:cyclodextrin-based polymer-camptothecin crlx101 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cycloleucine n1=L-dopa | n2=en:cycloleucine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cyclopentenyl cytosine n1=L-dopa | n2=en:cyclopentenyl cytosine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cyclophosphamide n1=L-dopa | n2=en:cyclophosphamide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cyclophosphamide/dactinomycin/vincristine n1=L-dopa | n2=en:cyclophosphamide/dactinomycin/vincristine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cyclosporine ophthalmic emulsion n1=L-dopa | n2=en:cyclosporine ophthalmic emulsion | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cyl-02 plasmid dna n1=L-dopa | n2=en:cyl-02 plasmid dna | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cyp17 inhibitor cfg920 n1=L-dopa | n2=en:cyp17 inhibitor cfg920 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cyp17 inhibitor vt-464 n1=L-dopa | n2=en:cyp17 inhibitor vt-464 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cyp17 lyase inhibitor asn001 n1=L-dopa | n2=en:cyp17 lyase inhibitor asn001 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cyproheptadine hydrochloride n1=L-dopa | n2=en:cyproheptadine hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cystemustine n1=L-dopa | n2=en:cystemustine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cytembena n1=L-dopa | n2=en:cytembena | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cytidine analog rx-3117 n1=L-dopa | n2=en:cytidine analog rx-3117 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cytochlor n1=L-dopa | n2=en:cytochlor | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cytokine-induced killer cells n1=L-dopa | n2=en:cytokine-induced killer cells | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:cytomegalovirus pp65-specific cytotoxic t lymphocytes n1=L-dopa | n2=en:cytomegalovirus pp65-specific cytotoxic t lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:d1/3-mage-3-his fusion protein n1=L-dopa | n2=en:d1/3-mage-3-his fusion protein | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dab389 epidermal growth factor n1=L-dopa | n2=en:dab389 epidermal growth factor | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dabrafenib n1=L-dopa | n2=en:dabrafenib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dacetuzumab n1=L-dopa | n2=en:dacetuzumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dach polymer platinate ap5346 n1=L-dopa | n2=en:dach polymer platinate ap5346 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dach-platin micelle nc-4016 n1=L-dopa | n2=en:dach-platin micelle nc-4016 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:daclatasvir n1=L-dopa | n2=en:daclatasvir | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:daclizumab n1=L-dopa | n2=en:daclizumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dactinomycin n1=L-dopa | n2=en:dactinomycin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:daflon 500 n1=L-dopa | n2=en:daflon 500 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dakins solution n1=L-dopa | n2=en:dakins solution | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dalantercept n1=L-dopa | n2=en:dalantercept | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dalbavancin n1=L-dopa | n2=en:dalbavancin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dalteparin n1=L-dopa | n2=en:dalteparin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:daniquidone n1=L-dopa | n2=en:daniquidone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:danusertib n1=L-dopa | n2=en:danusertib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:daporinad n1=L-dopa | n2=en:daporinad | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dapsone n1=L-dopa | n2=en:dapsone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:darbepoetin alfa n1=L-dopa | n2=en:darbepoetin alfa | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:darinaparsin n1=L-dopa | n2=en:darinaparsin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dasatinib n1=L-dopa | n2=en:dasatinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:daunorubicin hydrochloride n1=L-dopa | n2=en:daunorubicin hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dbve-pc regimen n1=L-dopa | n2=en:dbve-pc regimen | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dc-cholesterol liposome n1=L-dopa | n2=en:dc-cholesterol liposome | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dc-ova vaccine n1=L-dopa | n2=en:dc-ova vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dcds0780a n1=L-dopa | n2=en:dcds0780a | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dec-205/ny-eso-1 fusion protein cdx-1401 n1=L-dopa | n2=en:dec-205/ny-eso-1 fusion protein cdx-1401 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:decitabine n1=L-dopa | n2=en:decitabine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:defined green tea catechin extract n1=L-dopa | n2=en:defined green tea catechin extract | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:degarelix n1=L-dopa | n2=en:degarelix | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:deglycosylated ricin a chain-conjugated anti-cd19/anti-cd22 immunotoxins n1=L-dopa | n2=en:deglycosylated ricin a chain-conjugated anti-cd19/anti-cd22 immunotoxins | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dehydrated human amnion/chorion membrane n1=L-dopa | n2=en:dehydrated human amnion/chorion membrane | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:delanzomib n1=L-dopa | n2=en:delanzomib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:delta-8-tetrahydrocannabinol n1=L-dopa | n2=en:delta-8-tetrahydrocannabinol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:delta-tocotrienol n1=L-dopa | n2=en:delta-tocotrienol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dendritic cell-autologous lung tumor vaccine n1=L-dopa | n2=en:dendritic cell-autologous lung tumor vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dendritic cell-cea peptide vaccine n1=L-dopa | n2=en:dendritic cell-cea peptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dendritic cell-gp100-mart-1 antigen vaccine n1=L-dopa | n2=en:dendritic cell-gp100-mart-1 antigen vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dendritic cell-idiotype-keyhole limpet hemocyanin vaccine n1=L-dopa | n2=en:dendritic cell-idiotype-keyhole limpet hemocyanin vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dendritic cell-precision multiple antigen t-lymphocytes n1=L-dopa | n2=en:dendritic cell-precision multiple antigen t-lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dendritic cell-targeting lentiviral vector id-lv305 n1=L-dopa | n2=en:dendritic cell-targeting lentiviral vector id-lv305 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:denenicokin n1=L-dopa | n2=en:denenicokin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:denibulin hydrochloride n1=L-dopa | n2=en:denibulin hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:denileukin diftitox n1=L-dopa | n2=en:denileukin diftitox | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:denosumab n1=L-dopa | n2=en:denosumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:depatuxizumab n1=L-dopa | n2=en:depatuxizumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:depdc1/mphosh1 peptide vaccine n1=L-dopa | n2=en:depdc1/mphosh1 peptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:desmopressin acetate n1=L-dopa | n2=en:desmopressin acetate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:detorubicin n1=L-dopa | n2=en:detorubicin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dextran n1=L-dopa | n2=en:dextran | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dextroamphetamine-amphetamine n1=L-dopa | n2=en:dextroamphetamine-amphetamine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dextromethorphan hydrobromide n1=L-dopa | n2=en:dextromethorphan hydrobromide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dezaguanine n1=L-dopa | n2=en:dezaguanine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dha-paclitaxel n1=L-dopa | n2=en:dha-paclitaxel | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dhap regimen n1=L-dopa | n2=en:dhap regimen | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dher2 vaccine+as15 adjuvant n1=L-dopa | n2=en:dher2 vaccine+as15 adjuvant | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:di-leu16-il2 immunocytokine n1=L-dopa | n2=en:di-leu16-il2 immunocytokine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dianhydrogalactitol n1=L-dopa | n2=en:dianhydrogalactitol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:diaziquone n1=L-dopa | n2=en:diaziquone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dichloromethotrexate n1=L-dopa | n2=en:dichloromethotrexate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dicumarol n1=L-dopa | n2=en:dicumarol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:didox n1=L-dopa | n2=en:didox | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dienogest n1=L-dopa | n2=en:dienogest | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:diethylstilbestrol n1=L-dopa | n2=en:diethylstilbestrol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:diflomotecan n1=L-dopa | n2=en:diflomotecan | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:digitoxin n1=L-dopa | n2=en:digitoxin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dihydro-5-azacytidine n1=L-dopa | n2=en:dihydro-5-azacytidine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:diindolylmethane n1=L-dopa | n2=en:diindolylmethane | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dimethyl sulfoxide n1=L-dopa | n2=en:dimethyl sulfoxide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dimethylmyleran n1=L-dopa | n2=en:dimethylmyleran | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dinaciclib n1=L-dopa | n2=en:dinaciclib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dinitrophenyl-modified autologous renal cell carcinoma tumor cell vaccine n1=L-dopa | n2=en:dinitrophenyl-modified autologous renal cell carcinoma tumor cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:diphenhydramine hydrochloride n1=L-dopa | n2=en:diphenhydramine hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:diphtheria toxin fragment-interleukin-2 fusion protein e7777 n1=L-dopa | n2=en:diphtheria toxin fragment-interleukin-2 fusion protein e7777 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:diphtheria toxoid/tetanus toxoid/acellular pertussis vaccine adsorbed n1=L-dopa | n2=en:diphtheria toxoid/tetanus toxoid/acellular pertussis vaccine adsorbed | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:distilled water n1=L-dopa | n2=en:distilled water | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dkk1-neutralizing monoclonal antibody dkn-01 n1=L-dopa | n2=en:dkk1-neutralizing monoclonal antibody dkn-01 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dlk1/epha2/hbb/nrp1/rgs5/tem1 peptide-pulsed alpha-type-1 polarized dendritic cell vaccine n1=L-dopa | n2=en:dlk1/epha2/hbb/nrp1/rgs5/tem1 peptide-pulsed alpha-type-1 polarized dendritic cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dm4-conjugated anti-cripto monoclonal antibody biib015 n1=L-dopa | n2=en:dm4-conjugated anti-cripto monoclonal antibody biib015 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dmuc4064a n1=L-dopa | n2=en:dmuc4064a | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dn-101 n1=L-dopa | n2=en:dn-101 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dna interference oligonucleotide pnt2258 n1=L-dopa | n2=en:dna interference oligonucleotide pnt2258 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dna minor groove binding agent pm060184 n1=L-dopa | n2=en:dna minor groove binding agent pm060184 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dna minor groove binding agent sg2000 n1=L-dopa | n2=en:dna minor groove binding agent sg2000 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dna plasmid-encoding interleukin-12/hpv dna plasmids therapeutic vaccine ino-3112 n1=L-dopa | n2=en:dna plasmid-encoding interleukin-12/hpv dna plasmids therapeutic vaccine ino-3112 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dna-pk inhibitor msc2490484a n1=L-dopa | n2=en:dna-pk inhibitor msc2490484a | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dna-pk/tor kinase inhibitor cc-115 n1=L-dopa | n2=en:dna-pk/tor kinase inhibitor cc-115 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:docetaxel emulsion anx-514 n1=L-dopa | n2=en:docetaxel emulsion anx-514 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:docetaxel formulation ckd-810 n1=L-dopa | n2=en:docetaxel formulation ckd-810 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:docetaxel lipid microspheres n1=L-dopa | n2=en:docetaxel lipid microspheres | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:docetaxel-loaded nanopharmaceutical crlx301 n1=L-dopa | n2=en:docetaxel-loaded nanopharmaceutical crlx301 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:doconexent n1=L-dopa | n2=en:doconexent | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:docosahexaenoic acid n1=L-dopa | n2=en:docosahexaenoic acid | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:docusate n1=L-dopa | n2=en:docusate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dolastatin 10 n1=L-dopa | n2=en:dolastatin 10 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:donafenib n1=L-dopa | n2=en:donafenib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:donepezil + memantine n1=L-dopa | n2=en:donepezil + memantine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:donor lymphocytes n1=L-dopa | n2=en:donor lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:donor-derived wt1/prame/ny-eso-1/survivin-specific t-lymphocytes n1=L-dopa | n2=en:donor-derived wt1/prame/ny-eso-1/survivin-specific t-lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dopamine receptor agonist (disposition) n1=L-dopa | n2=en:dopamine receptor agonist (disposition) | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dopamine receptor interactions n1=L-dopa | n2=en:dopamine receptor interactions | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dopamine-somatostatin chimeric molecule bim-23a760 n1=L-dopa | n2=en:dopamine-somatostatin chimeric molecule bim-23a760 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dornase alfa n1=L-dopa | n2=en:dornase alfa | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dotap:cholesterol-fus1 liposome complex n1=L-dopa | n2=en:dotap:cholesterol-fus1 liposome complex | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dovitinib lactate n1=L-dopa | n2=en:dovitinib lactate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:doxercalciferol n1=L-dopa | n2=en:doxercalciferol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:doxorubicin hydrochloride n1=L-dopa | n2=en:doxorubicin hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:doxorubicin-hpma conjugate n1=L-dopa | n2=en:doxorubicin-hpma conjugate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dpt/typhoid/staphylococcus aureus/paratyphoid a/paratyphoid b vaccine n1=L-dopa | n2=en:dpt/typhoid/staphylococcus aureus/paratyphoid a/paratyphoid b vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dr5-targeting tetrameric nanobody agonist tas266 n1=L-dopa | n2=en:dr5-targeting tetrameric nanobody agonist tas266 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:drotrecogin alfa (activated) n1=L-dopa | n2=en:drotrecogin alfa (activated) | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:drug allergy n1=L-dopa | n2=en:drug allergy | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:drug products by fda established pharmacologic class n1=L-dopa | n2=en:drug products by fda established pharmacologic class | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:drug products by va class n1=L-dopa | n2=en:drug products by va class | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:drugs, chinese herbal n1=L-dopa | n2=en:drugs, chinese herbal | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dt(388)il3 fusion protein sl-401 n1=L-dopa | n2=en:dt(388)il3 fusion protein sl-401 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dta-h19 plasmid n1=L-dopa | n2=en:dta-h19 plasmid | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dual igf-1r/insr inhibitor bms-754807 n1=L-dopa | n2=en:dual igf-1r/insr inhibitor bms-754807 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dual pi3 kinase/mtor inhibitor gdc-0980 n1=L-dopa | n2=en:dual pi3 kinase/mtor inhibitor gdc-0980 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dual variable domain immunoglobulin abt-165 n1=L-dopa | n2=en:dual variable domain immunoglobulin abt-165 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:duborimycin n1=L-dopa | n2=en:duborimycin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dulanermin n1=L-dopa | n2=en:dulanermin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:duligotuzumab n1=L-dopa | n2=en:duligotuzumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:duopa n1=L-dopa | n2=en:duopa | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:durvalumab n1=L-dopa | n2=en:durvalumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:dutasteride n1=L-dopa | n2=en:dutasteride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:e-selectin antagonist gmi-1271 n1=L-dopa | n2=en:e-selectin antagonist gmi-1271 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:e-z scrub n1=L-dopa | n2=en:e-z scrub | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:e1a lipid complex n1=L-dopa | n2=en:e1a lipid complex | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:e1m184v peptide vaccine n1=L-dopa | n2=en:e1m184v peptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:e7820 n1=L-dopa | n2=en:e7820 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:east indian sandalwood oil mouth rinse n1=L-dopa | n2=en:east indian sandalwood oil mouth rinse | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ebselen-containing oral capsule spi-1005 n1=L-dopa | n2=en:ebselen-containing oral capsule spi-1005 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:echinomycin n1=L-dopa | n2=en:echinomycin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ecromeximab n1=L-dopa | n2=en:ecromeximab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:eculizumab n1=L-dopa | n2=en:eculizumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:edelfosine n1=L-dopa | n2=en:edelfosine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:edetate calcium disodium n1=L-dopa | n2=en:edetate calcium disodium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:edotecarin n1=L-dopa | n2=en:edotecarin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:edrecolomab n1=L-dopa | n2=en:edrecolomab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:efatutazone dihydrochloride n1=L-dopa | n2=en:efatutazone dihydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:eg5 kinesin-related motor protein inhibitor 4sc-205 n1=L-dopa | n2=en:eg5 kinesin-related motor protein inhibitor 4sc-205 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:eg5 kinesin-related motor protein inhibitor arq 621 n1=L-dopa | n2=en:eg5 kinesin-related motor protein inhibitor arq 621 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:egfr antagonist hemay022 n1=L-dopa | n2=en:egfr antagonist hemay022 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:egfr antisense dna n1=L-dopa | n2=en:egfr antisense dna | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:egfr car-cd3zeta-4-1bb-expressing autologous t-lymphocytes n1=L-dopa | n2=en:egfr car-cd3zeta-4-1bb-expressing autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:egfr inhibitor abt-414 n1=L-dopa | n2=en:egfr inhibitor abt-414 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:egfr inhibitor asp8273 n1=L-dopa | n2=en:egfr inhibitor asp8273 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:egfr inhibitor azd3759 n1=L-dopa | n2=en:egfr inhibitor azd3759 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:egfr inhibitor hm61713 n1=L-dopa | n2=en:egfr inhibitor hm61713 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:egfr t790m inhibitor pf-06747775 n1=L-dopa | n2=en:egfr t790m inhibitor pf-06747775 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:egfr/her2 inhibitor ap32788 n1=L-dopa | n2=en:egfr/her2 inhibitor ap32788 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:egfr/her2 inhibitor av-412 n1=L-dopa | n2=en:egfr/her2 inhibitor av-412 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:egfr/her2 kinase inhibitor tak-285 n1=L-dopa | n2=en:egfr/her2 kinase inhibitor tak-285 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:egfrviii-specific car-transduced autologous t lymphocytes n1=L-dopa | n2=en:egfrviii-specific car-transduced autologous t lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:eicosapentaenoic acid n1=L-dopa | n2=en:eicosapentaenoic acid | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:eicosapentaenoic acid-enriched nutritional supplement n1=L-dopa | n2=en:eicosapentaenoic acid-enriched nutritional supplement | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:eif4e antisense oligonucleotide isis 183750 n1=L-dopa | n2=en:eif4e antisense oligonucleotide isis 183750 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:elacytarabine n1=L-dopa | n2=en:elacytarabine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:electrolyte-free parenteral nutrition emulsion n1=L-dopa | n2=en:electrolyte-free parenteral nutrition emulsion | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:elesclomol n1=L-dopa | n2=en:elesclomol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:elesclomol sodium n1=L-dopa | n2=en:elesclomol sodium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:elinafide n1=L-dopa | n2=en:elinafide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ellagic acid/annona muricata supplement n1=L-dopa | n2=en:ellagic acid/annona muricata supplement | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:elliptinium acetate n1=L-dopa | n2=en:elliptinium acetate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:elotuzumab n1=L-dopa | n2=en:elotuzumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:elsamitrucin n1=L-dopa | n2=en:elsamitrucin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:eltrombopag olamine n1=L-dopa | n2=en:eltrombopag olamine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:emepepimut-s n1=L-dopa | n2=en:emepepimut-s | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:emitefur n1=L-dopa | n2=en:emitefur | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:emricasan n1=L-dopa | n2=en:emricasan | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:emtricitabine n1=L-dopa | n2=en:emtricitabine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:enadenotucirev n1=L-dopa | n2=en:enadenotucirev | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:enavatuzumab n1=L-dopa | n2=en:enavatuzumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ensituximab n1=L-dopa | n2=en:ensituximab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:entecavir n1=L-dopa | n2=en:entecavir | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:enteric-coated trpm8 agonist d-3263 hydrochloride n1=L-dopa | n2=en:enteric-coated trpm8 agonist d-3263 hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:entinostat n1=L-dopa | n2=en:entinostat | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:entolimod n1=L-dopa | n2=en:entolimod | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:enzalutamide n1=L-dopa | n2=en:enzalutamide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:enzastaurin hydrochloride n1=L-dopa | n2=en:enzastaurin hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:enzymatically-hydrolyzed whey protein-based nutritional supplement n1=L-dopa | n2=en:enzymatically-hydrolyzed whey protein-based nutritional supplement | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:enzyme inhibitor n1=L-dopa | n2=en:enzyme inhibitor | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ep4 receptor antagonist aat-007 n1=L-dopa | n2=en:ep4 receptor antagonist aat-007 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:epidermal growth factor ointment n1=L-dopa | n2=en:epidermal growth factor ointment | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:eplerenone n1=L-dopa | n2=en:eplerenone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:epoetin alfa n1=L-dopa | n2=en:epoetin alfa | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:epothilone analog utd1 n1=L-dopa | n2=en:epothilone analog utd1 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:epratuzumab n1=L-dopa | n2=en:epratuzumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:Epsom salt n1=L-dopa | n2=en:Epsom salt | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:epsom salt n1=L-dopa | n2=en:epsom salt | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:era36 modulator icaritin n1=L-dopa | n2=en:era36 modulator icaritin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:erastin analogue prlx 93936 n1=L-dopa | n2=en:erastin analogue prlx 93936 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:erbb-2 inhibitor arry-380 n1=L-dopa | n2=en:erbb-2 inhibitor arry-380 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:eritoran tetrasodium n1=L-dopa | n2=en:eritoran tetrasodium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:erk inhibitor cc-90003 n1=L-dopa | n2=en:erk inhibitor cc-90003 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:erk inhibitor gdc-0994 n1=L-dopa | n2=en:erk inhibitor gdc-0994 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:erk inhibitor ltt462 n1=L-dopa | n2=en:erk inhibitor ltt462 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:erk inhibitor mk-8353 n1=L-dopa | n2=en:erk inhibitor mk-8353 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:estradiol/norethindrone acetate tablet n1=L-dopa | n2=en:estradiol/norethindrone acetate tablet | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:estriol vaginal gel n1=L-dopa | n2=en:estriol vaginal gel | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:eszopiclone n1=L-dopa | n2=en:eszopiclone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:etaracizumab n1=L-dopa | n2=en:etaracizumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ethaselen n1=L-dopa | n2=en:ethaselen | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ethinyl estradiol n1=L-dopa | n2=en:ethinyl estradiol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ethosuximide n1=L-dopa | n2=en:ethosuximide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ethylchlorformate vaccine n1=L-dopa | n2=en:ethylchlorformate vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:etoricoxib n1=L-dopa | n2=en:etoricoxib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:everolimus n1=L-dopa | n2=en:everolimus | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ex vivo-expanded her2-specific t cells n1=L-dopa | n2=en:ex vivo-expanded her2-specific t cells | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:exemestane n1=L-dopa | n2=en:exemestane | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:exenatide n1=L-dopa | n2=en:exenatide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:extended release flucytosine n1=L-dopa | n2=en:extended release flucytosine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ezatiostat hydrochloride n1=L-dopa | n2=en:ezatiostat hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ezetimibe n1=L-dopa | n2=en:ezetimibe | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ezetimibe/simvastatin n1=L-dopa | n2=en:ezetimibe/simvastatin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:f-18 fluoroethyltyrosine n1=L-dopa | n2=en:f-18 fluoroethyltyrosine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:f16-il2 fusion protein n1=L-dopa | n2=en:f16-il2 fusion protein | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:factor viia inhibitor pci-27483 n1=L-dopa | n2=en:factor viia inhibitor pci-27483 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fak inhibitor gsk2256098 n1=L-dopa | n2=en:fak inhibitor gsk2256098 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fak inhibitor vs-4718 n1=L-dopa | n2=en:fak inhibitor vs-4718 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:famitinib n1=L-dopa | n2=en:famitinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fap-specific cd8-positive t cells n1=L-dopa | n2=en:fap-specific cd8-positive t cells | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:farletuzumab n1=L-dopa | n2=en:farletuzumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fas receptor agonist apo010 n1=L-dopa | n2=en:fas receptor agonist apo010 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fas-chimera transgene-expressing endothelial tumor cell-targeting adenovector vb-111 n1=L-dopa | n2=en:fas-chimera transgene-expressing endothelial tumor cell-targeting adenovector vb-111 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fat emulsion n1=L-dopa | n2=en:fat emulsion | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fda established names and unique ingredient identifier codes terminology n1=L-dopa | n2=en:fda established names and unique ingredient identifier codes terminology | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fenretinide lipid matrix n1=L-dopa | n2=en:fenretinide lipid matrix | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fermented wheat germ extract n1=L-dopa | n2=en:fermented wheat germ extract | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ferric carboxymaltose solution n1=L-dopa | n2=en:ferric carboxymaltose solution | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ferrous sulfate n1=L-dopa | n2=en:ferrous sulfate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fgfr inhibitor asp5878 n1=L-dopa | n2=en:fgfr inhibitor asp5878 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fgfr inhibitor debio 1347 n1=L-dopa | n2=en:fgfr inhibitor debio 1347 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fgfr inhibitor incb054828 n1=L-dopa | n2=en:fgfr inhibitor incb054828 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fgfr inhibitor tas-120 n1=L-dopa | n2=en:fgfr inhibitor tas-120 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fgfr/vegfr/pdgfr/flt3/src inhibitor xl999 n1=L-dopa | n2=en:fgfr/vegfr/pdgfr/flt3/src inhibitor xl999 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fibrin sealant n1=L-dopa | n2=en:fibrin sealant | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fidaxomicin n1=L-dopa | n2=en:fidaxomicin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:filgrastim n1=L-dopa | n2=en:filgrastim | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:filgrastim-primed peripheral blood progenitor cells n1=L-dopa | n2=en:filgrastim-primed peripheral blood progenitor cells | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:finasteride n1=L-dopa | n2=en:finasteride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fingolimod hydrochloride n1=L-dopa | n2=en:fingolimod hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:firtecan pegol n1=L-dopa | n2=en:firtecan pegol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:flaxseed n1=L-dopa | n2=en:flaxseed | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:flt3/kit kinase inhibitor akn-028 n1=L-dopa | n2=en:flt3/kit kinase inhibitor akn-028 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:flu matrix peptide p58-66 n1=L-dopa | n2=en:flu matrix peptide p58-66 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fluciclatide f-18 n1=L-dopa | n2=en:fluciclatide f-18 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:flucytosine n1=L-dopa | n2=en:flucytosine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fludarabine phosphate n1=L-dopa | n2=en:fludarabine phosphate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fluorine f 18 5-fluoro-2-deoxycytidine n1=L-dopa | n2=en:fluorine f 18 5-fluoro-2-deoxycytidine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fluorine f 18 alfatide ii n1=L-dopa | n2=en:fluorine f 18 alfatide ii | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fluorine f 18 choline n1=L-dopa | n2=en:fluorine f 18 choline | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fluorine f 18 dcfpyl n1=L-dopa | n2=en:fluorine f 18 dcfpyl | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fluorine f 18 ef5 n1=L-dopa | n2=en:fluorine f 18 ef5 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fluorine f 18 feqa n1=L-dopa | n2=en:fluorine f 18 feqa | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fluorine f 18 fmdht n1=L-dopa | n2=en:fluorine f 18 fmdht | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fluorine f 18 galacto-rgd peptide n1=L-dopa | n2=en:fluorine f 18 galacto-rgd peptide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fluorine f 18 sodium fluoride n1=L-dopa | n2=en:fluorine f 18 sodium fluoride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fluorine f 18-av-133 n1=L-dopa | n2=en:fluorine f 18-av-133 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fluorine f-18 6-fluorodopamine n1=L-dopa | n2=en:fluorine f-18 6-fluorodopamine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fluorine f-18 fluoropaclitaxel n1=L-dopa | n2=en:fluorine f-18 fluoropaclitaxel | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fluorouracil n1=L-dopa | n2=en:fluorouracil | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fluvastatin sodium n1=L-dopa | n2=en:fluvastatin sodium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fluzoparib n1=L-dopa | n2=en:fluzoparib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:folate binding protein e39 peptide vaccine n1=L-dopa | n2=en:folate binding protein e39 peptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:folate binding protein j65 peptide vaccine n1=L-dopa | n2=en:folate binding protein j65 peptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:folate receptor-targeted tubulysin conjugate ec1456 n1=L-dopa | n2=en:folate receptor-targeted tubulysin conjugate ec1456 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:folate receptor-targeted vinca alkaloid/mitomycin c ec0225 n1=L-dopa | n2=en:folate receptor-targeted vinca alkaloid/mitomycin c ec0225 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:foretinib n1=L-dopa | n2=en:foretinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fork wrench n1=L-dopa | n2=en:fork wrench | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:form a pair with something n1=L-dopa | n2=en:form a pair with something | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fosbretabulin disodium n1=L-dopa | n2=en:fosbretabulin disodium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fosbretabulin tromethamine n1=L-dopa | n2=en:fosbretabulin tromethamine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fostriecin n1=L-dopa | n2=en:fostriecin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fowlpox virus vaccine vector n1=L-dopa | n2=en:fowlpox virus vaccine vector | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fowlpox-ny-eso-1 vaccine n1=L-dopa | n2=en:fowlpox-ny-eso-1 vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fu-lv regimen n1=L-dopa | n2=en:fu-lv regimen | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:fulvestrant n1=L-dopa | n2=en:fulvestrant | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:g-quadruplex stabilizer bmvc n1=L-dopa | n2=en:g-quadruplex stabilizer bmvc | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:g207 n1=L-dopa | n2=en:g207 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gabapentin n1=L-dopa | n2=en:gabapentin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gabapentin enacarbil n1=L-dopa | n2=en:gabapentin enacarbil | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gadolinium-chelate n1=L-dopa | n2=en:gadolinium-chelate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:galactomannan derivative n1=L-dopa | n2=en:galactomannan derivative | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:galectin inhibitor gr-md-02 n1=L-dopa | n2=en:galectin inhibitor gr-md-02 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:galectin-1 inhibitor otx008 n1=L-dopa | n2=en:galectin-1 inhibitor otx008 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:galeterone n1=L-dopa | n2=en:galeterone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gallium ga 68 citrate n1=L-dopa | n2=en:gallium ga 68 citrate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gallium ga 68 ops202 n1=L-dopa | n2=en:gallium ga 68 ops202 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gallium ga 68-dotatate n1=L-dopa | n2=en:gallium ga 68-dotatate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gallium ga 68-labeled affibody aby-025 n1=L-dopa | n2=en:gallium ga 68-labeled affibody aby-025 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gallium ga 68-labeled psma-11 n1=L-dopa | n2=en:gallium ga 68-labeled psma-11 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gallium ga 68-labeled-nodaga-mj9 n1=L-dopa | n2=en:gallium ga 68-labeled-nodaga-mj9 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gallium ga 68-neb n1=L-dopa | n2=en:gallium ga 68-neb | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gallium ga 68-rgd n1=L-dopa | n2=en:gallium ga 68-rgd | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gallium maltolate n1=L-dopa | n2=en:gallium maltolate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:galunisertib n1=L-dopa | n2=en:galunisertib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gamma secretase inhibitor pf-03084014 n1=L-dopa | n2=en:gamma secretase inhibitor pf-03084014 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gamma-secretase inhibitor ly3039478 n1=L-dopa | n2=en:gamma-secretase inhibitor ly3039478 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ganglioside gd2 n1=L-dopa | n2=en:ganglioside gd2 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ganitumab n1=L-dopa | n2=en:ganitumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:garlic extract n1=L-dopa | n2=en:garlic extract | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gastrin immunotoxin n1=L-dopa | n2=en:gastrin immunotoxin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gastroenteral dosage form product n1=L-dopa | n2=en:gastroenteral dosage form product | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gd2 lactone/gd3 lactone-klh conjugate bivalent vaccine n1=L-dopa | n2=en:gd2 lactone/gd3 lactone-klh conjugate bivalent vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gd2-car-expressing autologous t-lymphocytes n1=L-dopa | n2=en:gd2-car-expressing autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gd2-klh vaccine n1=L-dopa | n2=en:gd2-klh vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gel protein, gelonium multiflorum n1=L-dopa | n2=en:gel protein, gelonium multiflorum | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gelatin sponge, absorbable n1=L-dopa | n2=en:gelatin sponge, absorbable | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gemcitabine elaidate n1=L-dopa | n2=en:gemcitabine elaidate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gemcitabine hydrochloride n1=L-dopa | n2=en:gemcitabine hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gemcitabine prodrug ly2334737 n1=L-dopa | n2=en:gemcitabine prodrug ly2334737 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gemcitabine-cisplatin regimen n1=L-dopa | n2=en:gemcitabine-cisplatin regimen | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gemcitabine-phosphoramidate hydrochloride nuc-1031 n1=L-dopa | n2=en:gemcitabine-phosphoramidate hydrochloride nuc-1031 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:genistein n1=L-dopa | n2=en:genistein | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:get acquainted with somebody n1=L-dopa | n2=en:get acquainted with somebody | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:get to know somebody n1=L-dopa | n2=en:get to know somebody | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ghrelin peptide analogue n1=L-dopa | n2=en:ghrelin peptide analogue | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gimatecan n1=L-dopa | n2=en:gimatecan | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ginger extract n1=L-dopa | n2=en:ginger extract | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:girentuximab n1=L-dopa | n2=en:girentuximab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:givinostat n1=L-dopa | n2=en:givinostat | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine n1=L-dopa | n2=en:glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:glioma-associated peptide-loaded dendritic cell vaccine sl-701 n1=L-dopa | n2=en:glioma-associated peptide-loaded dendritic cell vaccine sl-701 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:globo h-dt vaccine obi-833 n1=L-dopa | n2=en:globo h-dt vaccine obi-833 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:globo h-klh immunostimulant opt-822 n1=L-dopa | n2=en:globo h-klh immunostimulant opt-822 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:globo-h-gm2-lewis-y-muc1-32(aa)-stn(c)-tf(c)-tn(c)-klh conjugate vaccine n1=L-dopa | n2=en:globo-h-gm2-lewis-y-muc1-32(aa)-stn(c)-tf(c)-tn(c)-klh conjugate vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:globulin component macrophage-activating factor n1=L-dopa | n2=en:globulin component macrophage-activating factor | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:glucosamine sulfate/chondroitin sulfate tablet n1=L-dopa | n2=en:glucosamine sulfate/chondroitin sulfate tablet | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gludopa n1=L-dopa | n2=en:gludopa | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:glufosfamide n1=L-dopa | n2=en:glufosfamide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:glutathione n1=L-dopa | n2=en:glutathione | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gluten-free compact nutritional supplement drink n1=L-dopa | n2=en:gluten-free compact nutritional supplement drink | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gluten-free/fiber-enriched compact nutritional supplement drink n1=L-dopa | n2=en:gluten-free/fiber-enriched compact nutritional supplement drink | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:glycine n1=L-dopa | n2=en:glycine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:glymidine n1=L-dopa | n2=en:glymidine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gm-csf-encoding oncolytic adenovirus cgtg-102 n1=L-dopa | n2=en:gm-csf-encoding oncolytic adenovirus cgtg-102 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gm.cd40l cell vaccine n1=L-dopa | n2=en:gm.cd40l cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gm2/gd2/gd3 lactone-klh conjugate trivalent vaccine n1=L-dopa | n2=en:gm2/gd2/gd3 lactone-klh conjugate trivalent vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:go well together n1=L-dopa | n2=en:go well together | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:go with something n1=L-dopa | n2=en:go with something | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gold sodium thiomalate n1=L-dopa | n2=en:gold sodium thiomalate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:goldenseal 3 [hp_x] in 1 ml / taraxacum officinale 3 [hp_x] in 1 ml / dopamine 6 [hp_x] in 1 ml / levodopa 6 [hp_x] in 1 ml / melatonin 6 [hp_x] in 1 ml / serotonin 6 [hp_x] in 1 ml oral liquid [neuro i] n1=L-dopa | n2=en:goldenseal 3 [hp_x] in 1 ml / taraxacum officinale 3 [hp_x] in 1 ml / dopamine 6 [hp_x] in 1 ml / levodopa 6 [hp_x] in 1 ml / melatonin 6 [hp_x] in 1 ml / serotonin 6 [hp_x] in 1 ml oral liquid [neuro i] | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:goldenseal 3 [hp_x] in 1 ml / taraxacum officinale 3 [hp_x] in 1 ml / dopamine 6 [hp_x] in 1 ml / levodopa 6 [hp_x] in 1 ml / melatonin 6 [hp_x] in 1 ml / serotonin hydrochloride 6 [hp_x] in 1 ml oral liquid [neuro i] n1=L-dopa | n2=en:goldenseal 3 [hp_x] in 1 ml / taraxacum officinale 3 [hp_x] in 1 ml / dopamine 6 [hp_x] in 1 ml / levodopa 6 [hp_x] in 1 ml / melatonin 6 [hp_x] in 1 ml / serotonin hydrochloride 6 [hp_x] in 1 ml oral liquid [neuro i] | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:goldenseal 3 [hp_x] in 1 ml / taraxacum officinale 3 [hp_x] in 1 ml / dopamine hydrochloride 6 [hp_x] in 1 ml / levodopa 6 [hp_x] in 1 ml / melatonin 6 [hp_x] in 1 ml / serotonin hydrochloride 6 [hp_x] in 1 ml oral liquid [neuro i] n1=L-dopa | n2=en:goldenseal 3 [hp_x] in 1 ml / taraxacum officinale 3 [hp_x] in 1 ml / dopamine hydrochloride 6 [hp_x] in 1 ml / levodopa 6 [hp_x] in 1 ml / melatonin 6 [hp_x] in 1 ml / serotonin hydrochloride 6 [hp_x] in 1 ml oral liquid [neuro i] | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:golnerminogene pradenovec n1=L-dopa | n2=en:golnerminogene pradenovec | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:golotimod n1=L-dopa | n2=en:golotimod | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gonadotropin-releasing hormone analog n1=L-dopa | n2=en:gonadotropin-releasing hormone analog | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gp100-fowlpox vaccine n1=L-dopa | n2=en:gp100-fowlpox vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gp100:154-162 peptide vaccine n1=L-dopa | n2=en:gp100:154-162 peptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gp100:209-217(210m) peptide vaccine n1=L-dopa | n2=en:gp100:209-217(210m) peptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gp96-secreting allogeneic bladder cancer cell vaccine hs-410 n1=L-dopa | n2=en:gp96-secreting allogeneic bladder cancer cell vaccine hs-410 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gpi-0100 n1=L-dopa | n2=en:gpi-0100 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:granisetron hydrochloride n1=L-dopa | n2=en:granisetron hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:green tea n1=L-dopa | n2=en:green tea | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gti-2040 n1=L-dopa | n2=en:gti-2040 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gusperimus trihydrochloride n1=L-dopa | n2=en:gusperimus trihydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gvax pancreatic cancer vaccine n1=L-dopa | n2=en:gvax pancreatic cancer vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:gvax prostate cancer vaccine n1=L-dopa | n2=en:gvax prostate cancer vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:haemato fu n1=L-dopa | n2=en:haemato fu | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:haemophilus influenzae b vaccine n1=L-dopa | n2=en:haemophilus influenzae b vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hcv dna vaccine ino-8000 n1=L-dopa | n2=en:hcv dna vaccine ino-8000 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hdac inhibitor 4sc-202 n1=L-dopa | n2=en:hdac inhibitor 4sc-202 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hdac inhibitor ar-42 n1=L-dopa | n2=en:hdac inhibitor ar-42 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hdac inhibitor chr-3996 n1=L-dopa | n2=en:hdac inhibitor chr-3996 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hdac inhibitor cxd101 n1=L-dopa | n2=en:hdac inhibitor cxd101 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hdac inhibitor shp-141 n1=L-dopa | n2=en:hdac inhibitor shp-141 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hdac/egfr/her2 inhibitor cudc-101 n1=L-dopa | n2=en:hdac/egfr/her2 inhibitor cudc-101 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hedgehog inhibitor pf-04449913 n1=L-dopa | n2=en:hedgehog inhibitor pf-04449913 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:henatinib maleate n1=L-dopa | n2=en:henatinib maleate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:heparin derivative sst0001 n1=L-dopa | n2=en:heparin derivative sst0001 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hepatitis a vaccine n1=L-dopa | n2=en:hepatitis a vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hepatitis A vaccine n1=L-dopa | n2=en:hepatitis A vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hepatitis B vaccine n1=L-dopa | n2=en:hepatitis B vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hepatitis b vaccine n1=L-dopa | n2=en:hepatitis b vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:her-2-neu, cea peptides, gm-csf, montanide isa-51 vaccine n1=L-dopa | n2=en:her-2-neu, cea peptides, gm-csf, montanide isa-51 vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:her-2/neu intracellular domain protein n1=L-dopa | n2=en:her-2/neu intracellular domain protein | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:her2-targeted liposomal doxorubicin hydrochloride mm-302 n1=L-dopa | n2=en:her2-targeted liposomal doxorubicin hydrochloride mm-302 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:herba scutellaria barbata n1=L-dopa | n2=en:herba scutellaria barbata | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hexamethylene bisacetamide n1=L-dopa | n2=en:hexamethylene bisacetamide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hexaminolevulinate n1=L-dopa | n2=en:hexaminolevulinate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hexaminolevulinate hydrochloride n1=L-dopa | n2=en:hexaminolevulinate hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:high-selenium baker's yeast n1=L-dopa | n2=en:high-selenium baker's yeast | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:high-titer rsv immune globulin ri-001 n1=L-dopa | n2=en:high-titer rsv immune globulin ri-001 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:histamine dihydrochloride n1=L-dopa | n2=en:histamine dihydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:histrelin acetate n1=L-dopa | n2=en:histrelin acetate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hla-a*2402-restricted urlc10-cdca1-kif20a multipeptide vaccine n1=L-dopa | n2=en:hla-a*2402-restricted urlc10-cdca1-kif20a multipeptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hla-a*2402-restricted urlc10-ttk-vegfr1-vegfr2 multipeptide vaccine n1=L-dopa | n2=en:hla-a*2402-restricted urlc10-ttk-vegfr1-vegfr2 multipeptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hla-a*2402-restricted vegfr1 peptide vaccine n1=L-dopa | n2=en:hla-a*2402-restricted vegfr1 peptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hla-a*2402-restricted vegfr1/2 multipeptide vaccine n1=L-dopa | n2=en:hla-a*2402-restricted vegfr1/2 multipeptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hla-a1, a2, b35-restricted survivin peptides/montanide isa-51 vaccine n1=L-dopa | n2=en:hla-a1, a2, b35-restricted survivin peptides/montanide isa-51 vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:holmium ho 166 poly(l-lactic acid) microspheres n1=L-dopa | n2=en:holmium ho 166 poly(l-lactic acid) microspheres | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:honey n1=L-dopa | n2=en:honey | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hpv 16 e7 antigen-expressing lactobacillis casei vaccine bls-ilb-e710c n1=L-dopa | n2=en:hpv 16 e7 antigen-expressing lactobacillis casei vaccine bls-ilb-e710c | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hpv dna plasmids therapeutic vaccine vgx-3100 n1=L-dopa | n2=en:hpv dna plasmids therapeutic vaccine vgx-3100 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hpv e6/e7 dna vaccine gx-188e n1=L-dopa | n2=en:hpv e6/e7 dna vaccine gx-188e | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hpv-16 e6 peptides vaccine/candida albicans extract n1=L-dopa | n2=en:hpv-16 e6 peptides vaccine/candida albicans extract | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hpv16 l2/e6/e7 fusion protein vaccine ta-cin n1=L-dopa | n2=en:hpv16 l2/e6/e7 fusion protein vaccine ta-cin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hsp90 antagonist kw-2478 n1=L-dopa | n2=en:hsp90 antagonist kw-2478 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hsp90 inhibitor auy922 n1=L-dopa | n2=en:hsp90 inhibitor auy922 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hsp90 inhibitor debio 0932 n1=L-dopa | n2=en:hsp90 inhibitor debio 0932 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hsp90 inhibitor ds-2248 n1=L-dopa | n2=en:hsp90 inhibitor ds-2248 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hsp90 inhibitor hsp990 n1=L-dopa | n2=en:hsp90 inhibitor hsp990 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hsv-1 hf10 n1=L-dopa | n2=en:hsv-1 hf10 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:htert vaccine v934/v935 n1=L-dopa | n2=en:htert vaccine v934/v935 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:htert/survivin/cmv multipeptide vaccine n1=L-dopa | n2=en:htert/survivin/cmv multipeptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:htert/survivin/melanoma tumor cell-derived mrna-transfected dendritic cell vaccine n1=L-dopa | n2=en:htert/survivin/melanoma tumor cell-derived mrna-transfected dendritic cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hu14.18-il2 fusion protein n1=L-dopa | n2=en:hu14.18-il2 fusion protein | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:huachansu n1=L-dopa | n2=en:huachansu | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:human combinatorial antibody library-based monoclonal antibody vay736 n1=L-dopa | n2=en:human combinatorial antibody library-based monoclonal antibody vay736 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:human gp100 plasmid dna vaccine n1=L-dopa | n2=en:human gp100 plasmid dna vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:human menopausal gonadotrophin n1=L-dopa | n2=en:human menopausal gonadotrophin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:human menopausal gonadotropin n1=L-dopa | n2=en:human menopausal gonadotropin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:human mhc non-restricted cytotoxic t-cell line tall-104 n1=L-dopa | n2=en:human mhc non-restricted cytotoxic t-cell line tall-104 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:human monoclonal antibody 216 n1=L-dopa | n2=en:human monoclonal antibody 216 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:human monoclonal antibody b11-hcg beta fusion protein cdx-1307 n1=L-dopa | n2=en:human monoclonal antibody b11-hcg beta fusion protein cdx-1307 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:human papillomavirus 16/18 l1 virus-like particle/as04 vaccine n1=L-dopa | n2=en:human papillomavirus 16/18 l1 virus-like particle/as04 vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:human prostate-specific membrane antigen plasmid dna vaccine n1=L-dopa | n2=en:human prostate-specific membrane antigen plasmid dna vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hyaluronic acid-containing topical cream n1=L-dopa | n2=en:hyaluronic acid-containing topical cream | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hyb2055 n1=L-dopa | n2=en:hyb2055 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hydralazine hydrochloride n1=L-dopa | n2=en:hydralazine hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hydrazine sulfate n1=L-dopa | n2=en:hydrazine sulfate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hydrocortisone n1=L-dopa | n2=en:hydrocortisone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hydromorphone hydrochloride n1=L-dopa | n2=en:hydromorphone hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hydroxytyrosol n1=L-dopa | n2=en:hydroxytyrosol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hyperglycemic agent n1=L-dopa | n2=en:hyperglycemic agent | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hyperpolarized carbon c 13 pyruvate n1=L-dopa | n2=en:hyperpolarized carbon c 13 pyruvate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hyperpolarized helium 3 n1=L-dopa | n2=en:hyperpolarized helium 3 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hypoglycemic agents n1=L-dopa | n2=en:hypoglycemic agents | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:hypoxia-activated prodrug th-302 n1=L-dopa | n2=en:hypoxia-activated prodrug th-302 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:i 131 antiferritin immunoglobulin n1=L-dopa | n2=en:i 131 antiferritin immunoglobulin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:i 131 monoclonal antibody f19 n1=L-dopa | n2=en:i 131 monoclonal antibody f19 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:i 131 monoclonal antibody lym-1 n1=L-dopa | n2=en:i 131 monoclonal antibody lym-1 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:iap inhibitor hgs1029 n1=L-dopa | n2=en:iap inhibitor hgs1029 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:iapa-based dendritic cells/cytotoxic t lymphocytes n1=L-dopa | n2=en:iapa-based dendritic cells/cytotoxic t lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ibandronate sodium n1=L-dopa | n2=en:ibandronate sodium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ibritumomab tiuxetan n1=L-dopa | n2=en:ibritumomab tiuxetan | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ibrutinib n1=L-dopa | n2=en:ibrutinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ibuprofen injection n1=L-dopa | n2=en:ibuprofen injection | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:idh1 inhibitor ag-120 n1=L-dopa | n2=en:idh1 inhibitor ag-120 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:idh2 inhibitor ag-221 n1=L-dopa | n2=en:idh2 inhibitor ag-221 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ido inhibitor nlg919 n1=L-dopa | n2=en:ido inhibitor nlg919 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:idronoxil n1=L-dopa | n2=en:idronoxil | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ih636 grape seed proanthocyanidin extract n1=L-dopa | n2=en:ih636 grape seed proanthocyanidin extract | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:il-10 immunomodulator mk-1966 n1=L-dopa | n2=en:il-10 immunomodulator mk-1966 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:il-12-expressing hsv-1 n1=L-dopa | n2=en:il-12-expressing hsv-1 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:il-2/lptn gene-modified allogeneic neuroblastoma tumor cell vaccine n1=L-dopa | n2=en:il-2/lptn gene-modified allogeneic neuroblastoma tumor cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:il13ralpha2-specific hinge-optimized 41bb-co-stimulatory car truncated cd19-expressing autologous t-lymphocytes n1=L-dopa | n2=en:il13ralpha2-specific hinge-optimized 41bb-co-stimulatory car truncated cd19-expressing autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ilx-295501 n1=L-dopa | n2=en:ilx-295501 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ilx23-7553 n1=L-dopa | n2=en:ilx23-7553 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:imatinib mesylate n1=L-dopa | n2=en:imatinib mesylate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:imetelstat sodium n1=L-dopa | n2=en:imetelstat sodium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:imexon n1=L-dopa | n2=en:imexon | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:imidazolyl ethanamide pentandioic acid n1=L-dopa | n2=en:imidazolyl ethanamide pentandioic acid | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:imisopasem manganese n1=L-dopa | n2=en:imisopasem manganese | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:immediate-release tablet afuresertib n1=L-dopa | n2=en:immediate-release tablet afuresertib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:immunoconjugate ro5479599 n1=L-dopa | n2=en:immunoconjugate ro5479599 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:immunocytokine nhs-il12 n1=L-dopa | n2=en:immunocytokine nhs-il12 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:immunocytokine nhs-il2-lt n1=L-dopa | n2=en:immunocytokine nhs-il2-lt | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:immunomodulator ohr/avr118 n1=L-dopa | n2=en:immunomodulator ohr/avr118 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:immunomodulators n1=L-dopa | n2=en:immunomodulators | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:immunotherapy regimen mkc-1106-mt n1=L-dopa | n2=en:immunotherapy regimen mkc-1106-mt | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:imp321 n1=L-dopa | n2=en:imp321 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:in 111 folic acid n1=L-dopa | n2=en:in 111 folic acid | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:in 111 monoclonal antibody b3 n1=L-dopa | n2=en:in 111 monoclonal antibody b3 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:in 111 monoclonal antibody ll2 n1=L-dopa | n2=en:in 111 monoclonal antibody ll2 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:in 111 monoclonal antibody lym-1 n1=L-dopa | n2=en:in 111 monoclonal antibody lym-1 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:inalimarev n1=L-dopa | n2=en:inalimarev | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:increased central nervous system dopamine activity n1=L-dopa | n2=en:increased central nervous system dopamine activity | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:indibulin n1=L-dopa | n2=en:indibulin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:indisulam n1=L-dopa | n2=en:indisulam | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:indium in 111 bevacizumab n1=L-dopa | n2=en:indium in 111 bevacizumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:indium in 111 capromab pendetide n1=L-dopa | n2=en:indium in 111 capromab pendetide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:indium in 111 chimeric monoclonal antibody 806 n1=L-dopa | n2=en:indium in 111 chimeric monoclonal antibody 806 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:indium in 111-dota-biotin n1=L-dopa | n2=en:indium in 111-dota-biotin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:indole-3-carbinol n1=L-dopa | n2=en:indole-3-carbinol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:indole-3-carbinol/calcium/schizandra/vitamin d3/milk thistle/stinging nettle/lignan-based nutritional capsule n1=L-dopa | n2=en:indole-3-carbinol/calcium/schizandra/vitamin d3/milk thistle/stinging nettle/lignan-based nutritional capsule | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:indoleamine 2,3-dioxygenase peptide vaccine n1=L-dopa | n2=en:indoleamine 2,3-dioxygenase peptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:indomethacin n1=L-dopa | n2=en:indomethacin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ingenol mebutate n1=L-dopa | n2=en:ingenol mebutate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ingenol mebutate gel n1=L-dopa | n2=en:ingenol mebutate gel | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:iniparib n1=L-dopa | n2=en:iniparib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:innate immunostimulator rbbx-01 n1=L-dopa | n2=en:innate immunostimulator rbbx-01 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ino-1001 n1=L-dopa | n2=en:ino-1001 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:inositol n1=L-dopa | n2=en:inositol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:inotuzumab ozogamicin n1=L-dopa | n2=en:inotuzumab ozogamicin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ins316 n1=L-dopa | n2=en:ins316 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:insulin glargine n1=L-dopa | n2=en:insulin glargine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:insulin, regular n1=L-dopa | n2=en:insulin, regular | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:interferon alfacon-1 n1=L-dopa | n2=en:interferon alfacon-1 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:interleukin-12 gene n1=L-dopa | n2=en:interleukin-12 gene | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:interleukin-2 gene n1=L-dopa | n2=en:interleukin-2 gene | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:interleukin-4 pe38kdel immunotoxin n1=L-dopa | n2=en:interleukin-4 pe38kdel immunotoxin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:inulin n1=L-dopa | n2=en:inulin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:iobenguane i-131 n1=L-dopa | n2=en:iobenguane i-131 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:iodine i 123 anti-cea recombinant diabody t84.66 n1=L-dopa | n2=en:iodine i 123 anti-cea recombinant diabody t84.66 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:iodine i 123 monoclonal antibody 81c6 n1=L-dopa | n2=en:iodine i 123 monoclonal antibody 81c6 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:iodine i 124-crgdy-peg-c dots n1=L-dopa | n2=en:iodine i 124-crgdy-peg-c dots | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:iodine i 131 ethiodized oil n1=L-dopa | n2=en:iodine i 131 ethiodized oil | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:iodine i 131 monoclonal antibody 81c6 n1=L-dopa | n2=en:iodine i 131 monoclonal antibody 81c6 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:iodine i 131 monoclonal antibody bc8 n1=L-dopa | n2=en:iodine i 131 monoclonal antibody bc8 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:iodine i 131 monoclonal antibody f16sip n1=L-dopa | n2=en:iodine i 131 monoclonal antibody f16sip | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:iodine i 131 monoclonal antibody tnt-1/b n1=L-dopa | n2=en:iodine i 131 monoclonal antibody tnt-1/b | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:iodine i 131 rituximab n1=L-dopa | n2=en:iodine i 131 rituximab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:iodine i 131 tenatumomab n1=L-dopa | n2=en:iodine i 131 tenatumomab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:iodine i 131 tm-601 n1=L-dopa | n2=en:iodine i 131 tm-601 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:iodine i 131 tositumomab n1=L-dopa | n2=en:iodine i 131 tositumomab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:iodine i-125 n1=L-dopa | n2=en:iodine i-125 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ioflubenzamide i-131 n1=L-dopa | n2=en:ioflubenzamide i-131 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ionomycin n1=L-dopa | n2=en:ionomycin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ipatasertib n1=L-dopa | n2=en:ipatasertib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ipilimumab n1=L-dopa | n2=en:ipilimumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:iratumumab n1=L-dopa | n2=en:iratumumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:irinotecan hydrochloride n1=L-dopa | n2=en:irinotecan hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:irinotecan-eluting beads n1=L-dopa | n2=en:irinotecan-eluting beads | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:irinotecan/p-glycoprotein inhibitor hm30181ak combination tablet n1=L-dopa | n2=en:irinotecan/p-glycoprotein inhibitor hm30181ak combination tablet | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:irofulven n1=L-dopa | n2=en:irofulven | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:iron dextran complex n1=L-dopa | n2=en:iron dextran complex | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:iron isomaltoside 1000 n1=L-dopa | n2=en:iron isomaltoside 1000 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:iron sucrose injection n1=L-dopa | n2=en:iron sucrose injection | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:isavuconazole n1=L-dopa | n2=en:isavuconazole | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:iseganan hydrochloride n1=L-dopa | n2=en:iseganan hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:isis 2503 n1=L-dopa | n2=en:isis 2503 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:iso-fludelone n1=L-dopa | n2=en:iso-fludelone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:iso-sulfan blue n1=L-dopa | n2=en:iso-sulfan blue | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:isoflurane n1=L-dopa | n2=en:isoflurane | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:isoniazid n1=L-dopa | n2=en:isoniazid | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:isopréniques n1=L-dopa | n2=en:isopréniques | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:isopropyl 2-(2-amino-2-methylpropanamido)-3-(3,4-dihydroxyphenyl)propanoate n1=L-dopa | n2=en:isopropyl 2-(2-amino-2-methylpropanamido)-3-(3,4-dihydroxyphenyl)propanoate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:isoquercetin n1=L-dopa | n2=en:isoquercetin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:isosulfan blue n1=L-dopa | n2=en:isosulfan blue | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:isotretinoin n1=L-dopa | n2=en:isotretinoin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:iss 1018 cpg oligodeoxynucleotide n1=L-dopa | n2=en:iss 1018 cpg oligodeoxynucleotide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ivac mutanome vaccine n1=L-dopa | n2=en:ivac mutanome vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ixazomib citrate n1=L-dopa | n2=en:ixazomib citrate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:jak inhibitor incb047986 n1=L-dopa | n2=en:jak inhibitor incb047986 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:jak1 inhibitor incb039110 n1=L-dopa | n2=en:jak1 inhibitor incb039110 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:jak1 inhibitor incb052793 n1=L-dopa | n2=en:jak1 inhibitor incb052793 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:jak2 inhibitor azd1480 n1=L-dopa | n2=en:jak2 inhibitor azd1480 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:jak2 inhibitor bms-911543 n1=L-dopa | n2=en:jak2 inhibitor bms-911543 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:jak2 inhibitor wp1066 n1=L-dopa | n2=en:jak2 inhibitor wp1066 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:jak2 inhibitor xl019 n1=L-dopa | n2=en:jak2 inhibitor xl019 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:jeb regimen n1=L-dopa | n2=en:jeb regimen | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:jin fu kang n1=L-dopa | n2=en:jin fu kang | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:kanglaite n1=L-dopa | n2=en:kanglaite | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:kava-based supplement n1=L-dopa | n2=en:kava-based supplement | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:key moment n1=L-dopa | n2=en:key moment | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:kit/pdgfr inhibitor dcc-2618 n1=L-dopa | n2=en:kit/pdgfr inhibitor dcc-2618 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ksp inhibitor arry-520 n1=L-dopa | n2=en:ksp inhibitor arry-520 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ksp inhibitor azd4877 n1=L-dopa | n2=en:ksp inhibitor azd4877 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:kunecatechins ointment n1=L-dopa | n2=en:kunecatechins ointment | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:l-377,202 n1=L-dopa | n2=en:l-377,202 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:l-arginine/korean ginseng/ginkgo biloba/damiana-based supplement n1=L-dopa | n2=en:l-arginine/korean ginseng/ginkgo biloba/damiana-based supplement | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:l-carnitine l-tartrate n1=L-dopa | n2=en:l-carnitine l-tartrate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:l-gossypol n1=L-dopa | n2=en:l-gossypol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:l-lysine n1=L-dopa | n2=en:l-lysine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:l-ornithine l-aspartate n1=L-dopa | n2=en:l-ornithine l-aspartate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:l19-il2 monoclonal antibody-cytokine fusion protein n1=L-dopa | n2=en:l19-il2 monoclonal antibody-cytokine fusion protein | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lacidipine n1=L-dopa | n2=en:lacidipine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lactase n1=L-dopa | n2=en:lactase | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lactic acid n1=L-dopa | n2=en:lactic acid | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lactobacillus n1=L-dopa | n2=en:lactobacillus | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lactobacillus acidophilus/streptococcus thermophilus/bifidobacterium lactis/l. rhamnosus/b. longum/b. bifidum-based probiotic supplement n1=L-dopa | n2=en:lactobacillus acidophilus/streptococcus thermophilus/bifidobacterium lactis/l. rhamnosus/b. longum/b. bifidum-based probiotic supplement | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lactobacillus fermented extract n1=L-dopa | n2=en:lactobacillus fermented extract | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lactobacillus plantarum strain 299 n1=L-dopa | n2=en:lactobacillus plantarum strain 299 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lactobacillus plantarum strain 299v n1=L-dopa | n2=en:lactobacillus plantarum strain 299v | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lactobacillus rhamnosus gg n1=L-dopa | n2=en:lactobacillus rhamnosus gg | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lactobacillus rhamnosus/l. jensenii/l. crispatus/l. gasseri oral supplement n1=L-dopa | n2=en:lactobacillus rhamnosus/l. jensenii/l. crispatus/l. gasseri oral supplement | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lactoferrin-derived lytic peptide ltx-315 n1=L-dopa | n2=en:lactoferrin-derived lytic peptide ltx-315 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:laetrile n1=L-dopa | n2=en:laetrile | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:laminaria angustata extract n1=L-dopa | n2=en:laminaria angustata extract | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lamivudine n1=L-dopa | n2=en:lamivudine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lanreotide acetate n1=L-dopa | n2=en:lanreotide acetate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lanreotide long-acting aqueous gel n1=L-dopa | n2=en:lanreotide long-acting aqueous gel | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lapachone n1=L-dopa | n2=en:lapachone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lapatinib ditosylate n1=L-dopa | n2=en:lapatinib ditosylate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lapuleucel-t n1=L-dopa | n2=en:lapuleucel-t | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:largetrifoliolious bugbane rhizome supplement n1=L-dopa | n2=en:largetrifoliolious bugbane rhizome supplement | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:laromustine n1=L-dopa | n2=en:laromustine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:laronidase n1=L-dopa | n2=en:laronidase | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:larotaxel n1=L-dopa | n2=en:larotaxel | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lauric diethanolamide n1=L-dopa | n2=en:lauric diethanolamide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ledipasvir n1=L-dopa | n2=en:ledipasvir | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ledipasvir, sofosbuvir drug combination n1=L-dopa | n2=en:ledipasvir, sofosbuvir drug combination | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lentivirus vector rhiv7-shi-tar-ccr5rz-transduced hematopoietic progenitor cells n1=L-dopa | n2=en:lentivirus vector rhiv7-shi-tar-ccr5rz-transduced hematopoietic progenitor cells | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lenvatinib n1=L-dopa | n2=en:lenvatinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lenvatinib mesylate n1=L-dopa | n2=en:lenvatinib mesylate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:leridistim n1=L-dopa | n2=en:leridistim | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lerisetron n1=L-dopa | n2=en:lerisetron | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:leucine-enhanced essential amino acid dietary supplement n1=L-dopa | n2=en:leucine-enhanced essential amino acid dietary supplement | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:leukemic apoptotic corpse-pulsed autologous dendritic cells n1=L-dopa | n2=en:leukemic apoptotic corpse-pulsed autologous dendritic cells | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:levamisole hydrochloride n1=L-dopa | n2=en:levamisole hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:levocarnitine n1=L-dopa | n2=en:levocarnitine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:levocarnitine tartrate n1=L-dopa | n2=en:levocarnitine tartrate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:levodopa 500mg tablet n1=L-dopa | n2=en:levodopa 500mg tablet | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:levofloxacin n1=L-dopa | n2=en:levofloxacin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:levoleucovorin calcium n1=L-dopa | n2=en:levoleucovorin calcium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:levonordefrin n1=L-dopa | n2=en:levonordefrin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lexatumumab n1=L-dopa | n2=en:lexatumumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lexibulin n1=L-dopa | n2=en:lexibulin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:liarozole fumarate n1=L-dopa | n2=en:liarozole fumarate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:licartin n1=L-dopa | n2=en:licartin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:licorice n1=L-dopa | n2=en:licorice | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:linoleyl carbonate-paclitaxel n1=L-dopa | n2=en:linoleyl carbonate-paclitaxel | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:linsitinib n1=L-dopa | n2=en:linsitinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lintuzumab n1=L-dopa | n2=en:lintuzumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lipase n1=L-dopa | n2=en:lipase | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lipomuls n1=L-dopa | n2=en:lipomuls | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:liposomal c-raf antisense oligonucleotide n1=L-dopa | n2=en:liposomal c-raf antisense oligonucleotide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:liposomal cytarabine-daunorubicin cpx-351 n1=L-dopa | n2=en:liposomal cytarabine-daunorubicin cpx-351 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:liposomal daunorubicin citrate n1=L-dopa | n2=en:liposomal daunorubicin citrate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:liposomal eribulin mesylate n1=L-dopa | n2=en:liposomal eribulin mesylate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:liposomal irinotecan n1=L-dopa | n2=en:liposomal irinotecan | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:liposomal muc1/pet-lipid a vaccine n1=L-dopa | n2=en:liposomal muc1/pet-lipid a vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:liposomal nddp n1=L-dopa | n2=en:liposomal nddp | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:liposomal rhenium re 186 n1=L-dopa | n2=en:liposomal rhenium re 186 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:liposome-encapsulated rb94 plasmid dna gene therapy agent sgt-94 n1=L-dopa | n2=en:liposome-encapsulated rb94 plasmid dna gene therapy agent sgt-94 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:liposome-encapsulated recombinant human cu/zn superoxide-dismutase n1=L-dopa | n2=en:liposome-encapsulated recombinant human cu/zn superoxide-dismutase | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:liraglutide n1=L-dopa | n2=en:liraglutide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lirilumab n1=L-dopa | n2=en:lirilumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lisdexamfetamine dimesylate n1=L-dopa | n2=en:lisdexamfetamine dimesylate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lisinopril n1=L-dopa | n2=en:lisinopril | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:listeria monocytogenes-llo-psa vaccine adxs31-142 n1=L-dopa | n2=en:listeria monocytogenes-llo-psa vaccine adxs31-142 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lithium carbonate n1=L-dopa | n2=en:lithium carbonate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:litronesib n1=L-dopa | n2=en:litronesib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:live attenuated measles virus vaccine n1=L-dopa | n2=en:live attenuated measles virus vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:live freeze-dried lactic acid bacteria probiotic n1=L-dopa | n2=en:live freeze-dried lactic acid bacteria probiotic | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:live-attenuated listeria encoding human mesothelin vaccine crs-207 n1=L-dopa | n2=en:live-attenuated listeria encoding human mesothelin vaccine crs-207 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lmb-1 immunotoxin n1=L-dopa | n2=en:lmb-1 immunotoxin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lmb-7 immunotoxin n1=L-dopa | n2=en:lmb-7 immunotoxin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lmp-2:419-427 peptide vaccine n1=L-dopa | n2=en:lmp-2:419-427 peptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lmp1/barf1/ebna1-specific cytotoxic t-lymphocytes n1=L-dopa | n2=en:lmp1/barf1/ebna1-specific cytotoxic t-lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lmp2a-specific cytotoxic t-lymphocytes n1=L-dopa | n2=en:lmp2a-specific cytotoxic t-lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lometrexol n1=L-dopa | n2=en:lometrexol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lonidamine n1=L-dopa | n2=en:lonidamine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lorlatinib n1=L-dopa | n2=en:lorlatinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lorvotuzumab mertansine n1=L-dopa | n2=en:lorvotuzumab mertansine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:losoxantrone n1=L-dopa | n2=en:losoxantrone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lovastatin n1=L-dopa | n2=en:lovastatin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lubricant n1=L-dopa | n2=en:lubricant | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lung-targeted immunomodulator qbkpn n1=L-dopa | n2=en:lung-targeted immunomodulator qbkpn | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lutetium lu 177 dota-biotin n1=L-dopa | n2=en:lutetium lu 177 dota-biotin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lutetium lu 177 dota-jr11 n1=L-dopa | n2=en:lutetium lu 177 dota-jr11 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lutetium lu 177 monoclonal antibody cc49 n1=L-dopa | n2=en:lutetium lu 177 monoclonal antibody cc49 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lutetium lu 177 monoclonal antibody j591 n1=L-dopa | n2=en:lutetium lu 177 monoclonal antibody j591 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lutetium lu-177 capromab n1=L-dopa | n2=en:lutetium lu-177 capromab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ly2624587 n1=L-dopa | n2=en:ly2624587 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ly6k/vegfr1/vegfr2 multipeptide vaccine n1=L-dopa | n2=en:ly6k/vegfr1/vegfr2 multipeptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lycoperdon utriforme fruiting body extract n1=L-dopa | n2=en:lycoperdon utriforme fruiting body extract | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lymphokine-activated killer cells n1=L-dopa | n2=en:lymphokine-activated killer cells | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lyophilized black raspberry lozenge n1=L-dopa | n2=en:lyophilized black raspberry lozenge | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:lyophilized black raspberry saliva substitute n1=L-dopa | n2=en:lyophilized black raspberry saliva substitute | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:m87o-transduced cd34+ peripheral blood stem cells n1=L-dopa | n2=en:m87o-transduced cd34+ peripheral blood stem cells | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mac321 n1=L-dopa | n2=en:mac321 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:macitentan n1=L-dopa | n2=en:macitentan | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mage-a3 peptide vaccine n1=L-dopa | n2=en:mage-a3 peptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mage-a3 reactive t cell receptor-transduced autologous t cells n1=L-dopa | n2=en:mage-a3 reactive t cell receptor-transduced autologous t cells | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mage-a3-expressing adenovirus type 5 vaccine n1=L-dopa | n2=en:mage-a3-expressing adenovirus type 5 vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mage-a3/12-specific tcr gene-transduced autologous pbls n1=L-dopa | n2=en:mage-a3/12-specific tcr gene-transduced autologous pbls | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mage-a3/hpv 16 peptide vaccine n1=L-dopa | n2=en:mage-a3/hpv 16 peptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mage-a4-specific tcr gene-transduced autologous t lymphocytes tbi-1201 n1=L-dopa | n2=en:mage-a4-specific tcr gene-transduced autologous t lymphocytes tbi-1201 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:magnesium citrate n1=L-dopa | n2=en:magnesium citrate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:magnesium isoglycyrrhizinate n1=L-dopa | n2=en:magnesium isoglycyrrhizinate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:magnesium oxide n1=L-dopa | n2=en:magnesium oxide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:magnesium sulfate n1=L-dopa | n2=en:magnesium sulfate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:magnesium sulphate n1=L-dopa | n2=en:magnesium sulphate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:magnesium valproate n1=L-dopa | n2=en:magnesium valproate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:maitake mushroom extract n1=L-dopa | n2=en:maitake mushroom extract | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:make a counterpart to something n1=L-dopa | n2=en:make a counterpart to something | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:make a pair with something n1=L-dopa | n2=en:make a pair with something | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:make somebody 's acquaintance n1=L-dopa | n2=en:make somebody 's acquaintance | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:make somebody's acquaintance n1=L-dopa | n2=en:make somebody's acquaintance | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mammaglobin-a dna vaccine n1=L-dopa | n2=en:mammaglobin-a dna vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:manuka honey n1=L-dopa | n2=en:manuka honey | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mapatumumab n1=L-dopa | n2=en:mapatumumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:maribavir n1=L-dopa | n2=en:maribavir | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mart-1 reactive cd8+ lymphocytes n1=L-dopa | n2=en:mart-1 reactive cd8+ lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mart-1:26-35(27l) peptide vaccine n1=L-dopa | n2=en:mart-1:26-35(27l) peptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:masitinib mesylate n1=L-dopa | n2=en:masitinib mesylate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:masoprocol n1=L-dopa | n2=en:masoprocol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:match n1=L-dopa | n2=en:match | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:matuzumab n1=L-dopa | n2=en:matuzumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:maxzide n1=L-dopa | n2=en:maxzide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mcl-1 inhibitor amg 176 n1=L-dopa | n2=en:mcl-1 inhibitor amg 176 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mcpyv tag-specific polyclonal autologous cd8-positive t cells n1=L-dopa | n2=en:mcpyv tag-specific polyclonal autologous cd8-positive t cells | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mct/lct/fish oil omega-3 fatty acid lipid emulsion n1=L-dopa | n2=en:mct/lct/fish oil omega-3 fatty acid lipid emulsion | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mdx-1379 melanoma vaccine n1=L-dopa | n2=en:mdx-1379 melanoma vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:me-143 n1=L-dopa | n2=en:me-143 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:measles/mumps/rubella vaccine n1=L-dopa | n2=en:measles/mumps/rubella vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:meclocycline sulfosalicylate n1=L-dopa | n2=en:meclocycline sulfosalicylate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:medical marijuana n1=L-dopa | n2=en:medical marijuana | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:medicament n1=L-dopa | n2=en:medicament | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:medication n1=L-dopa | n2=en:medication | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:meet n1=L-dopa | n2=en:meet | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mek 1/2 inhibitor as703988/msc2015103b n1=L-dopa | n2=en:mek 1/2 inhibitor as703988/msc2015103b | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mek inhibitor ci-1040 n1=L-dopa | n2=en:mek inhibitor ci-1040 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mek inhibitor wx-554 n1=L-dopa | n2=en:mek inhibitor wx-554 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:melan-a vlp vaccine n1=L-dopa | n2=en:melan-a vlp vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:melanoma n1=L-dopa | n2=en:melanoma | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:melanoma antigen recognized by t-cells 1, human n1=L-dopa | n2=en:melanoma antigen recognized by t-cells 1, human | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:melphalan hydrochloride n1=L-dopa | n2=en:melphalan hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:menadione topical lotion n1=L-dopa | n2=en:menadione topical lotion | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mesna n1=L-dopa | n2=en:mesna | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mesothelin-specific chimeric antigen receptor-engineered peripheral blood lymphocytes n1=L-dopa | n2=en:mesothelin-specific chimeric antigen receptor-engineered peripheral blood lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:met tyrosine kinase inhibitor bms-777607 n1=L-dopa | n2=en:met tyrosine kinase inhibitor bms-777607 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:metahexamide n1=L-dopa | n2=en:metahexamide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:methoxsalen n1=L-dopa | n2=en:methoxsalen | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:methoxy polyethylene glycol-epoetin beta n1=L-dopa | n2=en:methoxy polyethylene glycol-epoetin beta | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:methyl-gag n1=L-dopa | n2=en:methyl-gag | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:methylene dimethane sulfonate n1=L-dopa | n2=en:methylene dimethane sulfonate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:metoprine n1=L-dopa | n2=en:metoprine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:metreleptin n1=L-dopa | n2=en:metreleptin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:metronidazole hydrochloride n1=L-dopa | n2=en:metronidazole hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:micafungin n1=L-dopa | n2=en:micafungin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:micronutrient-fortified probiotic yogurt n1=L-dopa | n2=en:micronutrient-fortified probiotic yogurt | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mifamurtide n1=L-dopa | n2=en:mifamurtide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:milatuzumab n1=L-dopa | n2=en:milatuzumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:milk acid n1=L-dopa | n2=en:milk acid | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:milk protein-based energy drink n1=L-dopa | n2=en:milk protein-based energy drink | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:minocycline-edta n1=L-dopa | n2=en:minocycline-edta | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:miracle mouthwash plus hydrocortisone n1=L-dopa | n2=en:miracle mouthwash plus hydrocortisone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mitogen n1=L-dopa | n2=en:mitogen | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mitoguazone n1=L-dopa | n2=en:mitoguazone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mk-4280 n1=L-dopa | n2=en:mk-4280 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mknk1 inhibitor bay 1143269 n1=L-dopa | n2=en:mknk1 inhibitor bay 1143269 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mnk1/2 inhibitor eft508 n1=L-dopa | n2=en:mnk1/2 inhibitor eft508 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mnsod mimetic bmx-001 n1=L-dopa | n2=en:mnsod mimetic bmx-001 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:modafinil n1=L-dopa | n2=en:modafinil | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:modified citrus pectin supplement n1=L-dopa | n2=en:modified citrus pectin supplement | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mogamulizumab n1=L-dopa | n2=en:mogamulizumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:monoacetyldiglyceride ec-18 n1=L-dopa | n2=en:monoacetyldiglyceride ec-18 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:monoclonal antibody 11d10 anti-idiotype vaccine n1=L-dopa | n2=en:monoclonal antibody 11d10 anti-idiotype vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:monoclonal antibody 3622w94 n1=L-dopa | n2=en:monoclonal antibody 3622w94 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:monoclonal antibody a1g4 anti-idiotype vaccine n1=L-dopa | n2=en:monoclonal antibody a1g4 anti-idiotype vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:monoclonal antibody agent n1=L-dopa | n2=en:monoclonal antibody agent | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:monoclonal antibody cal n1=L-dopa | n2=en:monoclonal antibody cal | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:monoclonal antibody cc49 n1=L-dopa | n2=en:monoclonal antibody cc49 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:monoclonal antibody cc49-streptavidin conjugate n1=L-dopa | n2=en:monoclonal antibody cc49-streptavidin conjugate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:monoclonal antibody cd19 n1=L-dopa | n2=en:monoclonal antibody cd19 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:monoclonal antibody cep-37250/khk2804 n1=L-dopa | n2=en:monoclonal antibody cep-37250/khk2804 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:monoclonal antibody f19 n1=L-dopa | n2=en:monoclonal antibody f19 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:monoclonal antibody hu3s193 n1=L-dopa | n2=en:monoclonal antibody hu3s193 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:monoclonal antibody huhmfg1 n1=L-dopa | n2=en:monoclonal antibody huhmfg1 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:monoclonal antibody huj591 n1=L-dopa | n2=en:monoclonal antibody huj591 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:monoclonal antibody hupam4 n1=L-dopa | n2=en:monoclonal antibody hupam4 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:monoclonal antibody ing-1 n1=L-dopa | n2=en:monoclonal antibody ing-1 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:monoclonal antibody me1-14 f(ab')2 n1=L-dopa | n2=en:monoclonal antibody me1-14 f(ab')2 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:monoclonal antibody mono-dga-rfb4 n1=L-dopa | n2=en:monoclonal antibody mono-dga-rfb4 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:monoclonal antibody rav12 n1=L-dopa | n2=en:monoclonal antibody rav12 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:monoclonal antibody sgn-30 n1=L-dopa | n2=en:monoclonal antibody sgn-30 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:motexafin gadolinium n1=L-dopa | n2=en:motexafin gadolinium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mouth off to [sb] n1=L-dopa | n2=en:mouth off to [sb] | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:moxetumomab pasudotox n1=L-dopa | n2=en:moxetumomab pasudotox | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mps1 kinase inhibitor bay1161909 n1=L-dopa | n2=en:mps1 kinase inhibitor bay1161909 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mtf-1 inhibitor apto-253 hcl n1=L-dopa | n2=en:mtf-1 inhibitor apto-253 hcl | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mtor kinase inhibitor azd8055 n1=L-dopa | n2=en:mtor kinase inhibitor azd8055 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mtorc1/2 kinase inhibitor bi 860585 n1=L-dopa | n2=en:mtorc1/2 kinase inhibitor bi 860585 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:muc-2-globo h-klh conjugate vaccine n1=L-dopa | n2=en:muc-2-globo h-klh conjugate vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:muc-2-klh vaccine n1=L-dopa | n2=en:muc-2-klh vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:muc1 peptide-poly-iclc adjuvant vaccine n1=L-dopa | n2=en:muc1 peptide-poly-iclc adjuvant vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mucoadhesive oral wound rinse n1=L-dopa | n2=en:mucoadhesive oral wound rinse | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:multicarotenoid supplement mcs-8 n1=L-dopa | n2=en:multicarotenoid supplement mcs-8 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:multidrug resistance modulator n1=L-dopa | n2=en:multidrug resistance modulator | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:multifunctional/multitargeted anticancer agent omn54 n1=L-dopa | n2=en:multifunctional/multitargeted anticancer agent omn54 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:multikinase inhibitor arry614 n1=L-dopa | n2=en:multikinase inhibitor arry614 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:multikinase inhibitor sar103168 n1=L-dopa | n2=en:multikinase inhibitor sar103168 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:multipeptide vaccine s-588210 n1=L-dopa | n2=en:multipeptide vaccine s-588210 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:multitargeted tyrosine kinase inhibitor jnj-26483327 n1=L-dopa | n2=en:multitargeted tyrosine kinase inhibitor jnj-26483327 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:muscadine grape skin extract n1=L-dopa | n2=en:muscadine grape skin extract | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:muscle relaxant n1=L-dopa | n2=en:muscle relaxant | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mutagen n1=L-dopa | n2=en:mutagen | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mycobacterium tuberculosis arabinomannan z-100 n1=L-dopa | n2=en:mycobacterium tuberculosis arabinomannan z-100 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:mycophenolic acid n1=L-dopa | n2=en:mycophenolic acid | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:n-methylformamide n1=L-dopa | n2=en:n-methylformamide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:nab-paclitaxel n1=L-dopa | n2=en:nab-paclitaxel | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:nadolol n1=L-dopa | n2=en:nadolol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:nadroparin calcium n1=L-dopa | n2=en:nadroparin calcium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:nanoparticle-encapsulated doxorubicin hydrochloride n1=L-dopa | n2=en:nanoparticle-encapsulated doxorubicin hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:naproxen n1=L-dopa | n2=en:naproxen | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:nasal saline irrigation solution n1=L-dopa | n2=en:nasal saline irrigation solution | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:natalizumab n1=L-dopa | n2=en:natalizumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:nd-420 n1=L-dopa | n2=en:nd-420 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:necitumumab n1=L-dopa | n2=en:necitumumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:nelfinavir mesylate n1=L-dopa | n2=en:nelfinavir mesylate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:nelipepimut-s plus gm-csf vaccine n1=L-dopa | n2=en:nelipepimut-s plus gm-csf vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:netazepide n1=L-dopa | n2=en:netazepide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:netupitant n1=L-dopa | n2=en:netupitant | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:neuromuscular blocking agents n1=L-dopa | n2=en:neuromuscular blocking agents | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:neutrophil activation probe imaging agent n1=L-dopa | n2=en:neutrophil activation probe imaging agent | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:niacinamide n1=L-dopa | n2=en:niacinamide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:nicotinamide n1=L-dopa | n2=en:nicotinamide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:nicotine n1=L-dopa | n2=en:nicotine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:nicotine lozenge n1=L-dopa | n2=en:nicotine lozenge | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:nicotine nasal spray n1=L-dopa | n2=en:nicotine nasal spray | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:nicotine patch n1=L-dopa | n2=en:nicotine patch | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:nilandron n1=L-dopa | n2=en:nilandron | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:nilotinib n1=L-dopa | n2=en:nilotinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:nimotuzumab n1=L-dopa | n2=en:nimotuzumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:nintedanib n1=L-dopa | n2=en:nintedanib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:nitric oxide-releasing acetylsalicylic acid derivative n1=L-dopa | n2=en:nitric oxide-releasing acetylsalicylic acid derivative | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:nitroglycerin transdermal patch n1=L-dopa | n2=en:nitroglycerin transdermal patch | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:nitroglycerin/sodium citrate/ethanol solution n1=L-dopa | n2=en:nitroglycerin/sodium citrate/ethanol solution | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:nolatrexed dihydrochloride n1=L-dopa | n2=en:nolatrexed dihydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:notch signaling inhibitor pf-06650808 n1=L-dopa | n2=en:notch signaling inhibitor pf-06650808 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:novobiocin n1=L-dopa | n2=en:novobiocin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ns-9 n1=L-dopa | n2=en:ns-9 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:nsclc antigen-loaded dendritic cell-derived exosomesnon-small cell lung cancer tumor antigen-loaded dendritic cell-derived exosomes n1=L-dopa | n2=en:nsclc antigen-loaded dendritic cell-derived exosomesnon-small cell lung cancer tumor antigen-loaded dendritic cell-derived exosomes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:nutraceutical tbl-12 n1=L-dopa | n2=en:nutraceutical tbl-12 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:nutritional supplement drink n1=L-dopa | n2=en:nutritional supplement drink | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:nx-1207 n1=L-dopa | n2=en:nx-1207 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ny-eso-1 protein vaccine plus montanide isa-51 vg n1=L-dopa | n2=en:ny-eso-1 protein vaccine plus montanide isa-51 vg | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ny-eso-1(157-165) peptide-pulsed autologous dendritic cell vaccine n1=L-dopa | n2=en:ny-eso-1(157-165) peptide-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ny-eso-1/lage-1 peptide vaccine n1=L-dopa | n2=en:ny-eso-1/lage-1 peptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ny-eso-1/prame/mage-a3/wt-1 peptide vaccine n1=L-dopa | n2=en:ny-eso-1/prame/mage-a3/wt-1 peptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ny-eso-1b peptide vaccine n1=L-dopa | n2=en:ny-eso-1b peptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ocaratuzumab n1=L-dopa | n2=en:ocaratuzumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ocrelizumab n1=L-dopa | n2=en:ocrelizumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:octreotide acetate n1=L-dopa | n2=en:octreotide acetate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:odanacatib n1=L-dopa | n2=en:odanacatib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:olanzapine n1=L-dopa | n2=en:olanzapine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:olaparib n1=L-dopa | n2=en:olaparib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:olive oil extract/curcumin-based capsule n1=L-dopa | n2=en:olive oil extract/curcumin-based capsule | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:olive oil/soya oil/egg lecithin-based emulsion n1=L-dopa | n2=en:olive oil/soya oil/egg lecithin-based emulsion | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:olive oil/soybean oil/multi-amino acid/glucose parenteral nutrition emulsion n1=L-dopa | n2=en:olive oil/soybean oil/multi-amino acid/glucose parenteral nutrition emulsion | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:olodaterol n1=L-dopa | n2=en:olodaterol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:omalizumab n1=L-dopa | n2=en:omalizumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:omeprazole n1=L-dopa | n2=en:omeprazole | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:onartuzumab n1=L-dopa | n2=en:onartuzumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:oncolytic adenovirus encoding gm-csf n1=L-dopa | n2=en:oncolytic adenovirus encoding gm-csf | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:onyx-015 n1=L-dopa | n2=en:onyx-015 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:opb-111001 n1=L-dopa | n2=en:opb-111001 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:open end wrench n1=L-dopa | n2=en:open end wrench | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:open-end wrench n1=L-dopa | n2=en:open-end wrench | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:open-ended spanner n1=L-dopa | n2=en:open-ended spanner | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:opioid agonist gic-1001 n1=L-dopa | n2=en:opioid agonist gic-1001 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:oppa regimen n1=L-dopa | n2=en:oppa regimen | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:oprelvekin n1=L-dopa | n2=en:oprelvekin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:oral dosage form product n1=L-dopa | n2=en:oral dosage form product | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:oral form carbidopa + levodopa n1=L-dopa | n2=en:oral form carbidopa + levodopa | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:oral sodium phenylbutyrate n1=L-dopa | n2=en:oral sodium phenylbutyrate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:orantinib n1=L-dopa | n2=en:orantinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:orteronel n1=L-dopa | n2=en:orteronel | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:oseltamivir phosphate n1=L-dopa | n2=en:oseltamivir phosphate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:oteracil potassium n1=L-dopa | n2=en:oteracil potassium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:over the counter product n1=L-dopa | n2=en:over the counter product | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:oxitriptan n1=L-dopa | n2=en:oxitriptan | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:oxycodone hydrochloride/naloxone hydrochloride prolonged-release tablet n1=L-dopa | n2=en:oxycodone hydrochloride/naloxone hydrochloride prolonged-release tablet | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:oxymetholone n1=L-dopa | n2=en:oxymetholone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:p-tefb inhibitor bay1143572 n1=L-dopa | n2=en:p-tefb inhibitor bay1143572 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:p16_37-63 peptide vaccine n1=L-dopa | n2=en:p16_37-63 peptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:p53 peptide vaccine n1=L-dopa | n2=en:p53 peptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:p53-synthetic long peptides vaccine n1=L-dopa | n2=en:p53-synthetic long peptides vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:paclitaxel trevatide n1=L-dopa | n2=en:paclitaxel trevatide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pad regimen n1=L-dopa | n2=en:pad regimen | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:padre-cmv fusion peptide vaccine n1=L-dopa | n2=en:padre-cmv fusion peptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pak4 inhibitor pf-03758309 n1=L-dopa | n2=en:pak4 inhibitor pf-03758309 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:palbociclib n1=L-dopa | n2=en:palbociclib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:palivizumab n1=L-dopa | n2=en:palivizumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:palladium-bacteriopheophorbide n1=L-dopa | n2=en:palladium-bacteriopheophorbide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:palm extract phytonutrient supplement n1=L-dopa | n2=en:palm extract phytonutrient supplement | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:palonosetron hydrochloride n1=L-dopa | n2=en:palonosetron hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pamidronate disodium n1=L-dopa | n2=en:pamidronate disodium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pan-her kinase inhibitor ac480 n1=L-dopa | n2=en:pan-her kinase inhibitor ac480 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pan-pi3k/mtor inhibitor sf1126 n1=L-dopa | n2=en:pan-pi3k/mtor inhibitor sf1126 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pan-selectin antagonist gmi-1070 n1=L-dopa | n2=en:pan-selectin antagonist gmi-1070 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:panitumumab n1=L-dopa | n2=en:panitumumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:panitumumab-irdye800 n1=L-dopa | n2=en:panitumumab-irdye800 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pantoprazole sodium n1=L-dopa | n2=en:pantoprazole sodium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:paracetamol n1=L-dopa | n2=en:paracetamol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:parathyroid hormone-related protein (1-36) n1=L-dopa | n2=en:parathyroid hormone-related protein (1-36) | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:parenteral dosage form product n1=L-dopa | n2=en:parenteral dosage form product | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:paricalcitol n1=L-dopa | n2=en:paricalcitol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:paroxetine hydrochloride n1=L-dopa | n2=en:paroxetine hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:parp inhibitor azd2461 n1=L-dopa | n2=en:parp inhibitor azd2461 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:parp inhibitor cep-9722 n1=L-dopa | n2=en:parp inhibitor cep-9722 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:parp-1/2 inhibitor abt-767 n1=L-dopa | n2=en:parp-1/2 inhibitor abt-767 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:parvovirus h-1 n1=L-dopa | n2=en:parvovirus h-1 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:patritumab n1=L-dopa | n2=en:patritumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:patupilone n1=L-dopa | n2=en:patupilone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pazopanib hydrochloride n1=L-dopa | n2=en:pazopanib hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pbcar3 phosphopeptide-tetanus peptide vaccine n1=L-dopa | n2=en:pbcar3 phosphopeptide-tetanus peptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pd0325901 n1=L-dopa | n2=en:pd0325901 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pdcd-1 knockout autologous t-lymphocytes n1=L-dopa | n2=en:pdcd-1 knockout autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pdgfr alpha/kit mutant-specific inhibitor blu-285 n1=L-dopa | n2=en:pdgfr alpha/kit mutant-specific inhibitor blu-285 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pdm08 n1=L-dopa | n2=en:pdm08 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pediatric nutritional supplement drink n1=L-dopa | n2=en:pediatric nutritional supplement drink | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:peg recombinant human megakaryocyte growth and development factor n1=L-dopa | n2=en:peg recombinant human megakaryocyte growth and development factor | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:peg-3350/sodium sulfate/sodium chloride/potassium chloride/sodium ascorbate/ascorbic acid-based laxative n1=L-dopa | n2=en:peg-3350/sodium sulfate/sodium chloride/potassium chloride/sodium ascorbate/ascorbic acid-based laxative | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pegamotecan n1=L-dopa | n2=en:pegamotecan | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pegylated anti-gfr antibody fragment n1=L-dopa | n2=en:pegylated anti-gfr antibody fragment | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pegylated arginine deiminase n1=L-dopa | n2=en:pegylated arginine deiminase | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pegylated granulocyte colony stimulating factor maxy-g34 n1=L-dopa | n2=en:pegylated granulocyte colony stimulating factor maxy-g34 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pegylated human recombinant arginase 1 aeb1102 n1=L-dopa | n2=en:pegylated human recombinant arginase 1 aeb1102 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pegylated recombinant l-asparaginase erwinia chrysanthemi n1=L-dopa | n2=en:pegylated recombinant l-asparaginase erwinia chrysanthemi | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:penicillamine n1=L-dopa | n2=en:penicillamine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:penicillin v potassium n1=L-dopa | n2=en:penicillin v potassium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pentamidine n1=L-dopa | n2=en:pentamidine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pentavalent klh conjugate vaccine n1=L-dopa | n2=en:pentavalent klh conjugate vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pentetic acid n1=L-dopa | n2=en:pentetic acid | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pentetic acid calcium n1=L-dopa | n2=en:pentetic acid calcium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pentoxifylline n1=L-dopa | n2=en:pentoxifylline | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pep-cmv vaccine n1=L-dopa | n2=en:pep-cmv vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:peptide hydrolases n1=L-dopa | n2=en:peptide hydrolases | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:peptides hydrolases n1=L-dopa | n2=en:peptides hydrolases | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:perflubron n1=L-dopa | n2=en:perflubron | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:perflutren n1=L-dopa | n2=en:perflutren | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:perflutren protein-a microsphere n1=L-dopa | n2=en:perflutren protein-a microsphere | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:perindopril erbumine n1=L-dopa | n2=en:perindopril erbumine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pesticide n1=L-dopa | n2=en:pesticide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:petrolatum-mineral oil-lanolin-ceresin ointment n1=L-dopa | n2=en:petrolatum-mineral oil-lanolin-ceresin ointment | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pg13-cd19-h3 (anti-cd19 car) retroviral vector-transduced peripheral blood lymphocytes n1=L-dopa | n2=en:pg13-cd19-h3 (anti-cd19 car) retroviral vector-transduced peripheral blood lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pharmaceutic aids n1=L-dopa | n2=en:pharmaceutic aids | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pharmaceutical dosage form n1=L-dopa | n2=en:pharmaceutical dosage form | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:phenethyl isothiocyanate n1=L-dopa | n2=en:phenethyl isothiocyanate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:phenethyl isothiocyanate-containing watercress juice n1=L-dopa | n2=en:phenethyl isothiocyanate-containing watercress juice | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:phenformin hydrochloride n1=L-dopa | n2=en:phenformin hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:phenobarbital n1=L-dopa | n2=en:phenobarbital | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:phentolamine mesylate n1=L-dopa | n2=en:phentolamine mesylate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:phosphaplatin pt-112 n1=L-dopa | n2=en:phosphaplatin pt-112 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:phosphomannopentaose sulfate n1=L-dopa | n2=en:phosphomannopentaose sulfate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:phytomenadione n1=L-dopa | n2=en:phytomenadione | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:phytonadione n1=L-dopa | n2=en:phytonadione | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pi3k alpha inhibitor mln1117 n1=L-dopa | n2=en:pi3k alpha inhibitor mln1117 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pi3k delta/gamma inhibitor ipi-145 n1=L-dopa | n2=en:pi3k delta/gamma inhibitor ipi-145 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pi3k delta/gamma inhibitor rp6530 n1=L-dopa | n2=en:pi3k delta/gamma inhibitor rp6530 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pi3k family kinase inhibitor xl147 n1=L-dopa | n2=en:pi3k family kinase inhibitor xl147 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pi3k inhibitor acp-319 n1=L-dopa | n2=en:pi3k inhibitor acp-319 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pi3k inhibitor ch5132799 n1=L-dopa | n2=en:pi3k inhibitor ch5132799 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pi3k inhibitor gdc-0084 n1=L-dopa | n2=en:pi3k inhibitor gdc-0084 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pi3k inhibitor gdc-0941 bismesylate n1=L-dopa | n2=en:pi3k inhibitor gdc-0941 bismesylate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pi3k inhibitor gsk1059615 n1=L-dopa | n2=en:pi3k inhibitor gsk1059615 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pi3k inhibitor gsk2126458 n1=L-dopa | n2=en:pi3k inhibitor gsk2126458 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pi3k inhibitor px-866 n1=L-dopa | n2=en:pi3k inhibitor px-866 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pi3k inhibitor wx-037 n1=L-dopa | n2=en:pi3k inhibitor wx-037 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pi3k inhibitor zstk474 n1=L-dopa | n2=en:pi3k inhibitor zstk474 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pi3k p110beta/delta inhibitor ka2237 n1=L-dopa | n2=en:pi3k p110beta/delta inhibitor ka2237 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pi3k-beta inhibitor gsk2636771 n1=L-dopa | n2=en:pi3k-beta inhibitor gsk2636771 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pi3k-delta inhibitor incb050465 n1=L-dopa | n2=en:pi3k-delta inhibitor incb050465 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pi3k-delta inhibitor tgr-1202 n1=L-dopa | n2=en:pi3k-delta inhibitor tgr-1202 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pi3k/mtor inhibitor bez235 n1=L-dopa | n2=en:pi3k/mtor inhibitor bez235 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pi3k/mtor kinase inhibitor ds-7423 n1=L-dopa | n2=en:pi3k/mtor kinase inhibitor ds-7423 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pi3k/mtor kinase inhibitor pf-04691502 n1=L-dopa | n2=en:pi3k/mtor kinase inhibitor pf-04691502 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pi3k/mtor/alk-1/dna-pk inhibitor p7170 n1=L-dopa | n2=en:pi3k/mtor/alk-1/dna-pk inhibitor p7170 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pi3k/mtorc1/mtorc2 inhibitor dcbci0901 n1=L-dopa | n2=en:pi3k/mtorc1/mtorc2 inhibitor dcbci0901 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pi3kbeta inhibitor azd8186 n1=L-dopa | n2=en:pi3kbeta inhibitor azd8186 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pi3kdelta inhibitor incb040093 n1=L-dopa | n2=en:pi3kdelta inhibitor incb040093 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:picropodophyllin n1=L-dopa | n2=en:picropodophyllin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pidilizumab n1=L-dopa | n2=en:pidilizumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pim kinase inhibitor sgi-1776 n1=L-dopa | n2=en:pim kinase inhibitor sgi-1776 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pimasertib n1=L-dopa | n2=en:pimasertib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pimecrolimus n1=L-dopa | n2=en:pimecrolimus | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pimonidazole n1=L-dopa | n2=en:pimonidazole | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pinaverium bromide n1=L-dopa | n2=en:pinaverium bromide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:piperacillin sodium n1=L-dopa | n2=en:piperacillin sodium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:piperazinedione n1=L-dopa | n2=en:piperazinedione | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:piritrexim n1=L-dopa | n2=en:piritrexim | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pirotinib n1=L-dopa | n2=en:pirotinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:piroxicam n1=L-dopa | n2=en:piroxicam | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pirs2 phosphopeptide-tetanus peptide vaccine n1=L-dopa | n2=en:pirs2 phosphopeptide-tetanus peptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pivotal moment n1=L-dopa | n2=en:pivotal moment | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:plectin-1 targeting agent ptp-01 n1=L-dopa | n2=en:plectin-1 targeting agent ptp-01 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pled-based mnsod mimetic n1=L-dopa | n2=en:pled-based mnsod mimetic | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pleiotropic pathway modifier cc-122 hydrochloride n1=L-dopa | n2=en:pleiotropic pathway modifier cc-122 hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:plevitrexed n1=L-dopa | n2=en:plevitrexed | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:plozalizumab n1=L-dopa | n2=en:plozalizumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:plx73086 n1=L-dopa | n2=en:plx73086 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pneumococcal 13-valent conjugate vaccine n1=L-dopa | n2=en:pneumococcal 13-valent conjugate vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pneumococcal polyvalent vaccine n1=L-dopa | n2=en:pneumococcal polyvalent vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pnp-expressing ovine atadenovirus fp253 n1=L-dopa | n2=en:pnp-expressing ovine atadenovirus fp253 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pol i inhibitor cx5461 n1=L-dopa | n2=en:pol i inhibitor cx5461 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:polaprezinc n1=L-dopa | n2=en:polaprezinc | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:polihexanide solution n1=L-dopa | n2=en:polihexanide solution | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:polo-like kinase 1 inhibitor nms-1286937 n1=L-dopa | n2=en:polo-like kinase 1 inhibitor nms-1286937 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:poly iclc n1=L-dopa | n2=en:poly iclc | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:poly-alendronate dextran-guanidine conjugate n1=L-dopa | n2=en:poly-alendronate dextran-guanidine conjugate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:poly-gamma glutamic acid n1=L-dopa | n2=en:poly-gamma glutamic acid | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:polycarbophil/carbomer/glycerin/palm oil glyceride/mineral oil-containing vaginal moisturizer n1=L-dopa | n2=en:polycarbophil/carbomer/glycerin/palm oil glyceride/mineral oil-containing vaginal moisturizer | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:polydextrose n1=L-dopa | n2=en:polydextrose | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:polyethylene glycol n1=L-dopa | n2=en:polyethylene glycol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:polyéthylène glycol n1=L-dopa | n2=en:polyéthylène glycol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:polyethylene glycol polymer surgical sealant n1=L-dopa | n2=en:polyethylene glycol polymer surgical sealant | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:polyglutamate camptothecin n1=L-dopa | n2=en:polyglutamate camptothecin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:polysaccharide-k n1=L-dopa | n2=en:polysaccharide-k | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:polyvinylpyrrolidone-sodium hyaluronate gel n1=L-dopa | n2=en:polyvinylpyrrolidone-sodium hyaluronate gel | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pomegranate-extract pill n1=L-dopa | n2=en:pomegranate-extract pill | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ponatinib hydrochloride n1=L-dopa | n2=en:ponatinib hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ponesimod n1=L-dopa | n2=en:ponesimod | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:porcupine inhibitor wnt974 n1=L-dopa | n2=en:porcupine inhibitor wnt974 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:posaconazole n1=L-dopa | n2=en:posaconazole | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:powder [sth] n1=L-dopa | n2=en:powder [sth] | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:poziotinib n1=L-dopa | n2=en:poziotinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:prame-targeting t-cell receptor/inducible caspase 9 bpx-701 n1=L-dopa | n2=en:prame-targeting t-cell receptor/inducible caspase 9 bpx-701 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:prasterone n1=L-dopa | n2=en:prasterone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pregabalin n1=L-dopa | n2=en:pregabalin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:preimplantation factor pif-1 n1=L-dopa | n2=en:preimplantation factor pif-1 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:prescription drugs n1=L-dopa | n2=en:prescription drugs | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:prima-1 analog apr-246 n1=L-dopa | n2=en:prima-1 analog apr-246 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:prochlorperazine n1=L-dopa | n2=en:prochlorperazine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:proflavine n1=L-dopa | n2=en:proflavine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:proflavine hemisulfate n1=L-dopa | n2=en:proflavine hemisulfate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:progestin n1=L-dopa | n2=en:progestin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:prohibitin-targeting peptide 1 n1=L-dopa | n2=en:prohibitin-targeting peptide 1 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:prostate health cocktail dietary supplement n1=L-dopa | n2=en:prostate health cocktail dietary supplement | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:protein phosphatase 2a inhibitor lb-100 n1=L-dopa | n2=en:protein phosphatase 2a inhibitor lb-100 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pseudomonas aeruginosa preparation n1=L-dopa | n2=en:pseudomonas aeruginosa preparation | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:psychopharmacologic agent n1=L-dopa | n2=en:psychopharmacologic agent | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:puffball n1=L-dopa | n2=en:puffball | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:put powder on something n1=L-dopa | n2=en:put powder on something | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:put talc on something n1=L-dopa | n2=en:put talc on something | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pva microporous hydrospheres/doxorubicin hydrochloride n1=L-dopa | n2=en:pva microporous hydrospheres/doxorubicin hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pyroglutamyl-l-dopa-proline n1=L-dopa | n2=en:pyroglutamyl-l-dopa-proline | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:pyroxamide n1=L-dopa | n2=en:pyroxamide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:quizartinib n1=L-dopa | n2=en:quizartinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:rabusertib n1=L-dopa | n2=en:rabusertib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:radioprotective agent n1=L-dopa | n2=en:radioprotective agent | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:radiosensitizing agent n1=L-dopa | n2=en:radiosensitizing agent | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:raf kinase inhibitor lgx818 n1=L-dopa | n2=en:raf kinase inhibitor lgx818 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:raloxifene n1=L-dopa | n2=en:raloxifene | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:raltitrexed n1=L-dopa | n2=en:raltitrexed | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ramipril n1=L-dopa | n2=en:ramipril | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ramucirumab n1=L-dopa | n2=en:ramucirumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:rar-alpha agonist vtp195183 n1=L-dopa | n2=en:rar-alpha agonist vtp195183 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:raralpha agonist irx5183 n1=L-dopa | n2=en:raralpha agonist irx5183 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ras peptide cancer vaccine n1=L-dopa | n2=en:ras peptide cancer vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:rebastinib tosylate n1=L-dopa | n2=en:rebastinib tosylate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:receptor tyrosine kinase inhibitor r1530 n1=L-dopa | n2=en:receptor tyrosine kinase inhibitor r1530 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:recombinant adenovirus 5 encoding tumor necrosis factor-related apoptosis-inducing ligand n1=L-dopa | n2=en:recombinant adenovirus 5 encoding tumor necrosis factor-related apoptosis-inducing ligand | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:recombinant adenovirus-hifn-beta n1=L-dopa | n2=en:recombinant adenovirus-hifn-beta | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:recombinant adenovirus-interferon/syn3 n1=L-dopa | n2=en:recombinant adenovirus-interferon/syn3 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:recombinant adenovirus-l523s vaccine n1=L-dopa | n2=en:recombinant adenovirus-l523s vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:recombinant adenovirus-p53 sch-58500 n1=L-dopa | n2=en:recombinant adenovirus-p53 sch-58500 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:recombinant bispecific single-chain antibody rm28 n1=L-dopa | n2=en:recombinant bispecific single-chain antibody rm28 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:recombinant dher2 vaccine n1=L-dopa | n2=en:recombinant dher2 vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:recombinant human chorionic gonadotropin n1=L-dopa | n2=en:recombinant human chorionic gonadotropin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:recombinant human serum amyloid p/pentraxin 2 n1=L-dopa | n2=en:recombinant human serum amyloid p/pentraxin 2 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:recombinant interleukin-6 n1=L-dopa | n2=en:recombinant interleukin-6 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:recombinant mip1-alpha variant eci301 n1=L-dopa | n2=en:recombinant mip1-alpha variant eci301 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:recombinant oxytocin n1=L-dopa | n2=en:recombinant oxytocin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:recombinant thymosin n1=L-dopa | n2=en:recombinant thymosin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:recombinant transforming growth factor-beta 2 n1=L-dopa | n2=en:recombinant transforming growth factor-beta 2 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:refametinib n1=L-dopa | n2=en:refametinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:refills prescribed:num:pt:medication:qn n1=L-dopa | n2=en:refills prescribed:num:pt:medication:qn | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:regular insulin n1=L-dopa | n2=en:regular insulin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:remestemcel-l n1=L-dopa | n2=en:remestemcel-l | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:reply to n1=L-dopa | n2=en:reply to | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:reply to somebody n1=L-dopa | n2=en:reply to somebody | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:resistant starch n1=L-dopa | n2=en:resistant starch | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:resminostat n1=L-dopa | n2=en:resminostat | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:respiratory form tiotropium n1=L-dopa | n2=en:respiratory form tiotropium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:respond n1=L-dopa | n2=en:respond | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:respond to somebody n1=L-dopa | n2=en:respond to somebody | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:retinoic acid agent n1=L-dopa | n2=en:retinoic acid agent | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:rhenium re 188 p2045 n1=L-dopa | n2=en:rhenium re 188 p2045 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:rhenium re-186 hydroxyethylidene diphosphonate n1=L-dopa | n2=en:rhenium re-186 hydroxyethylidene diphosphonate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:rhenium re-188 ethiodized oil n1=L-dopa | n2=en:rhenium re-188 ethiodized oil | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:rhubarb/licorice herbal supplement n1=L-dopa | n2=en:rhubarb/licorice herbal supplement | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ribociclib n1=L-dopa | n2=en:ribociclib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ribozyme rpi.4610 n1=L-dopa | n2=en:ribozyme rpi.4610 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ricin immunoconjugate n1=L-dopa | n2=en:ricin immunoconjugate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:rifaximin n1=L-dopa | n2=en:rifaximin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:rimiducid n1=L-dopa | n2=en:rimiducid | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:rintatolimod n1=L-dopa | n2=en:rintatolimod | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:rituximab n1=L-dopa | n2=en:rituximab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:rivaroxaban n1=L-dopa | n2=en:rivaroxaban | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:rk-0202 n1=L-dopa | n2=en:rk-0202 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:rna electroporated cd19car-cd3zeta-4-1bb-expressing autologous t-lymphocytes n1=L-dopa | n2=en:rna electroporated cd19car-cd3zeta-4-1bb-expressing autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:romidepsin n1=L-dopa | n2=en:romidepsin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:rotavirus vaccine, live, oral n1=L-dopa | n2=en:rotavirus vaccine, live, oral | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:roxindole hydrochloride n1=L-dopa | n2=en:roxindole hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:rucaparib n1=L-dopa | n2=en:rucaparib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:rucaparib phosphate n1=L-dopa | n2=en:rucaparib phosphate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:rytary n1=L-dopa | n2=en:rytary | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:s1p receptor agonist krp203 n1=L-dopa | n2=en:s1p receptor agonist krp203 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:sacituzumab govitecan n1=L-dopa | n2=en:sacituzumab govitecan | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:salmonella vnp20009 n1=L-dopa | n2=en:salmonella vnp20009 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:sardomozide n1=L-dopa | n2=en:sardomozide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:sargramostim plasmid dna hepatocellular carcinoma vaccine adjuvant n1=L-dopa | n2=en:sargramostim plasmid dna hepatocellular carcinoma vaccine adjuvant | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:sargramostim plasmid dna melanoma vaccine adjuvant n1=L-dopa | n2=en:sargramostim plasmid dna melanoma vaccine adjuvant | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:sargramostim plasmid dna sarcoma vaccine n1=L-dopa | n2=en:sargramostim plasmid dna sarcoma vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:saxagliptin hydrochloride n1=L-dopa | n2=en:saxagliptin hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:sdf-1-targeted agent nox-a12 n1=L-dopa | n2=en:sdf-1-targeted agent nox-a12 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:semaxanib n1=L-dopa | n2=en:semaxanib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:seribantumab n1=L-dopa | n2=en:seribantumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:shark cartilage extract ae-941 n1=L-dopa | n2=en:shark cartilage extract ae-941 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:sheddase inhibitor incb007839 n1=L-dopa | n2=en:sheddase inhibitor incb007839 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:sheng-mai san n1=L-dopa | n2=en:sheng-mai san | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:sheng-yu-tang n1=L-dopa | n2=en:sheng-yu-tang | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:shu yu wan formula n1=L-dopa | n2=en:shu yu wan formula | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:sialyl lewis-keyhole limpet hemocyanin conjugate vaccine n1=L-dopa | n2=en:sialyl lewis-keyhole limpet hemocyanin conjugate vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:sildenafil citrate n1=L-dopa | n2=en:sildenafil citrate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:sipuleucel-t n1=L-dopa | n2=en:sipuleucel-t | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:sirpa-fc fusion protein tti-621 n1=L-dopa | n2=en:sirpa-fc fusion protein tti-621 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:sivifene n1=L-dopa | n2=en:sivifene | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:smac mimetic lcl161 n1=L-dopa | n2=en:smac mimetic lcl161 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:smokeless tobacco n1=L-dopa | n2=en:smokeless tobacco | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:soapstone n1=L-dopa | n2=en:soapstone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:sodium butyrate n1=L-dopa | n2=en:sodium butyrate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:sodium dibunate n1=L-dopa | n2=en:sodium dibunate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:sodium ferric gluconate complex in sucrose n1=L-dopa | n2=en:sodium ferric gluconate complex in sucrose | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:sodium phenylbutyrate n1=L-dopa | n2=en:sodium phenylbutyrate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:sodium selenite n1=L-dopa | n2=en:sodium selenite | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:solitomab n1=L-dopa | n2=en:solitomab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:solution n1=L-dopa | n2=en:solution | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:sonepcizumab n1=L-dopa | n2=en:sonepcizumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:sorafenib tosylate n1=L-dopa | n2=en:sorafenib tosylate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:sorghum bicolor supplement n1=L-dopa | n2=en:sorghum bicolor supplement | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:sotagliflozin n1=L-dopa | n2=en:sotagliflozin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:source code n1=L-dopa | n2=en:source code | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:source text n1=L-dopa | n2=en:source text | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:soy isoflavones n1=L-dopa | n2=en:soy isoflavones | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:soy protein isolate n1=L-dopa | n2=en:soy protein isolate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:spanner n1=L-dopa | n2=en:spanner | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:sphingosine kinase-2 inhibitor abc294640 n1=L-dopa | n2=en:sphingosine kinase-2 inhibitor abc294640 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:squalamine lactate n1=L-dopa | n2=en:squalamine lactate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:sr31747a n1=L-dopa | n2=en:sr31747a | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:src/tubulin inhibitor kx02 n1=L-dopa | n2=en:src/tubulin inhibitor kx02 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:steatite n1=L-dopa | n2=en:steatite | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:strawberry-blackberry-black raspberry-blueberry mixture n1=L-dopa | n2=en:strawberry-blackberry-black raspberry-blueberry mixture | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:sun's soup n1=L-dopa | n2=en:sun's soup | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:sunitinib malate n1=L-dopa | n2=en:sunitinib malate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:surface-active agent n1=L-dopa | n2=en:surface-active agent | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:surfactant agent n1=L-dopa | n2=en:surfactant agent | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:syk inhibitor hmpl-523 n1=L-dopa | n2=en:syk inhibitor hmpl-523 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:t1e28z car-expressing autologous cd4-positive t lymphocytes n1=L-dopa | n2=en:t1e28z car-expressing autologous cd4-positive t lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:t4n5 liposomal lotion n1=L-dopa | n2=en:t4n5 liposomal lotion | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tabalumab n1=L-dopa | n2=en:tabalumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tablet n1=L-dopa | n2=en:tablet | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:talazoparib n1=L-dopa | n2=en:talazoparib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:talc n1=L-dopa | n2=en:talc | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:talcum n1=L-dopa | n2=en:talcum | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:talcum powder n1=L-dopa | n2=en:talcum powder | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:taliglucerase alfa n1=L-dopa | n2=en:taliglucerase alfa | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:talimogene laherparepvec n1=L-dopa | n2=en:talimogene laherparepvec | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:talmapimod n1=L-dopa | n2=en:talmapimod | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tandutinib n1=L-dopa | n2=en:tandutinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tanezumab n1=L-dopa | n2=en:tanezumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tasisulam sodium n1=L-dopa | n2=en:tasisulam sodium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tasquinimod n1=L-dopa | n2=en:tasquinimod | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tc 99m monoclonal antibody 170 n1=L-dopa | n2=en:tc 99m monoclonal antibody 170 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:technetium tc 99m galactosyl human serum albumin n1=L-dopa | n2=en:technetium tc 99m galactosyl human serum albumin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:technetium tc 99m-3prgd2 n1=L-dopa | n2=en:technetium tc 99m-3prgd2 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:technetium tc-99m n1=L-dopa | n2=en:technetium tc-99m | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:technetium tc-99m ethylenedicysteine-deoxyglucose n1=L-dopa | n2=en:technetium tc-99m ethylenedicysteine-deoxyglucose | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:technetium tc-99m mebrofenin n1=L-dopa | n2=en:technetium tc-99m mebrofenin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:technetium tc-99m sodium pertechnetate n1=L-dopa | n2=en:technetium tc-99m sodium pertechnetate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:technetium tc-99m-nc100692 n1=L-dopa | n2=en:technetium tc-99m-nc100692 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tegafur-gimeracil-oteracil potassium n1=L-dopa | n2=en:tegafur-gimeracil-oteracil potassium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:telomerase-specific type 5 adenovirus obp-301 n1=L-dopa | n2=en:telomerase-specific type 5 adenovirus obp-301 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:temsirolimus n1=L-dopa | n2=en:temsirolimus | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:teniposide n1=L-dopa | n2=en:teniposide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tenofovir disoproxil fumarate n1=L-dopa | n2=en:tenofovir disoproxil fumarate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:teprotumumab n1=L-dopa | n2=en:teprotumumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:teratogen n1=L-dopa | n2=en:teratogen | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tesetaxel n1=L-dopa | n2=en:tesetaxel | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:testosterone gel n1=L-dopa | n2=en:testosterone gel | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tetanus-cmv fusion peptide vaccine n1=L-dopa | n2=en:tetanus-cmv fusion peptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tetracycline hydrochloride n1=L-dopa | n2=en:tetracycline hydrochloride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tgfbdnrii-transduced autologous tumor infiltrating lymphocytes n1=L-dopa | n2=en:tgfbdnrii-transduced autologous tumor infiltrating lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:thalicarpine n1=L-dopa | n2=en:thalicarpine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:therapeutic angiotensin-(1-7) n1=L-dopa | n2=en:therapeutic angiotensin-(1-7) | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:therapeutic autologous lymphocytes n1=L-dopa | n2=en:therapeutic autologous lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:therapeutic cortisone n1=L-dopa | n2=en:therapeutic cortisone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:therapeutic estrone n1=L-dopa | n2=en:therapeutic estrone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:therapeutic hydrocortisone n1=L-dopa | n2=en:therapeutic hydrocortisone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:therapeutic testosterone n1=L-dopa | n2=en:therapeutic testosterone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:thiamine n1=L-dopa | n2=en:thiamine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:thioureidobutyronitrile n1=L-dopa | n2=en:thioureidobutyronitrile | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:thrombopoietin receptor agonist lgd-4665 n1=L-dopa | n2=en:thrombopoietin receptor agonist lgd-4665 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tiazofurin n1=L-dopa | n2=en:tiazofurin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tigapotide n1=L-dopa | n2=en:tigapotide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tigatuzumab n1=L-dopa | n2=en:tigatuzumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tigecycline n1=L-dopa | n2=en:tigecycline | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tin sn 117m dtpa n1=L-dopa | n2=en:tin sn 117m dtpa | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tiomolibdate diammonium n1=L-dopa | n2=en:tiomolibdate diammonium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tivantinib n1=L-dopa | n2=en:tivantinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tlr 7/8 agonist medi9197 n1=L-dopa | n2=en:tlr 7/8 agonist medi9197 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tlr9 agonist duk-cpg-001 n1=L-dopa | n2=en:tlr9 agonist duk-cpg-001 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tlr9 agonist emd 1201081 n1=L-dopa | n2=en:tlr9 agonist emd 1201081 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tlr9 agonist sd-101 n1=L-dopa | n2=en:tlr9 agonist sd-101 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:to answer n1=L-dopa | n2=en:to answer | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:to answer sb back n1=L-dopa | n2=en:to answer sb back | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:to be the counterpart of n1=L-dopa | n2=en:to be the counterpart of | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:to correspond to n1=L-dopa | n2=en:to correspond to | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:to match n1=L-dopa | n2=en:to match | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:to meet n1=L-dopa | n2=en:to meet | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:to reply to n1=L-dopa | n2=en:to reply to | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:to respond to n1=L-dopa | n2=en:to respond to | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:to return n1=L-dopa | n2=en:to return | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tocilizumab n1=L-dopa | n2=en:tocilizumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tocotrienol-rich fraction n1=L-dopa | n2=en:tocotrienol-rich fraction | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:topical betulinic acid n1=L-dopa | n2=en:topical betulinic acid | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:topical pvdf/sirolimus n1=L-dopa | n2=en:topical pvdf/sirolimus | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:topoisomerase i/ii inhibitor nev-801 n1=L-dopa | n2=en:topoisomerase i/ii inhibitor nev-801 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tositumomab n1=L-dopa | n2=en:tositumomab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:total tumor rna-loaded dendritic cell vaccine n1=L-dopa | n2=en:total tumor rna-loaded dendritic cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:toxicologic measurement n1=L-dopa | n2=en:toxicologic measurement | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tranexamic acid n1=L-dopa | n2=en:tranexamic acid | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:transferrin receptor-targeted anti-rrm2 sirna calaa-01 n1=L-dopa | n2=en:transferrin receptor-targeted anti-rrm2 sirna calaa-01 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:transgenic lymphocyte immunization vaccine n1=L-dopa | n2=en:transgenic lymphocyte immunization vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:trastuzumab n1=L-dopa | n2=en:trastuzumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:trastuzumab emtansine n1=L-dopa | n2=en:trastuzumab emtansine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:trastuzumab vc-seco-duba n1=L-dopa | n2=en:trastuzumab vc-seco-duba | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tremelimumab n1=L-dopa | n2=en:tremelimumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tretinoin n1=L-dopa | n2=en:tretinoin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tri-virus/gd2-specific allogeneic cytotoxic t-lymphocytes n1=L-dopa | n2=en:tri-virus/gd2-specific allogeneic cytotoxic t-lymphocytes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:triazinate n1=L-dopa | n2=en:triazinate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:trivalent live-attenuated influenza vaccine n1=L-dopa | n2=en:trivalent live-attenuated influenza vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:trk inhibitor azd6918 n1=L-dopa | n2=en:trk inhibitor azd6918 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tubulin inhibitor alb 109564(a) n1=L-dopa | n2=en:tubulin inhibitor alb 109564(a) | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tyroserleutide n1=L-dopa | n2=en:tyroserleutide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:tyrosine kinase inhibitor xl228 n1=L-dopa | n2=en:tyrosine kinase inhibitor xl228 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ublituximab n1=L-dopa | n2=en:ublituximab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ulvwf multimer-targeting agent arc1779 n1=L-dopa | n2=en:ulvwf multimer-targeting agent arc1779 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:urea/lactic acid-based topical cream n1=L-dopa | n2=en:urea/lactic acid-based topical cream | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ustekinumab n1=L-dopa | n2=en:ustekinumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:uv1 telomerase peptide vaccine n1=L-dopa | n2=en:uv1 telomerase peptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:v930 vaccine n1=L-dopa | n2=en:v930 vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:vadastuximab talirine n1=L-dopa | n2=en:vadastuximab talirine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:valacyclovir n1=L-dopa | n2=en:valacyclovir | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:valerian n1=L-dopa | n2=en:valerian | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:valproic acid n1=L-dopa | n2=en:valproic acid | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:vancomycin n1=L-dopa | n2=en:vancomycin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:vandetanib n1=L-dopa | n2=en:vandetanib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:vardenafil hydrochloride trihydrate n1=L-dopa | n2=en:vardenafil hydrochloride trihydrate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:vcl-cb01 vaccine n1=L-dopa | n2=en:vcl-cb01 vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:vedolizumab n1=L-dopa | n2=en:vedolizumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:vegfr inhibitor krn951 n1=L-dopa | n2=en:vegfr inhibitor krn951 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:vegfr/pdgfr tyrosine kinase inhibitor tak-593 n1=L-dopa | n2=en:vegfr/pdgfr tyrosine kinase inhibitor tak-593 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:vegfr1-1084 peptide vaccine n1=L-dopa | n2=en:vegfr1-1084 peptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:veliparib n1=L-dopa | n2=en:veliparib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:veltuzumab n1=L-dopa | n2=en:veltuzumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:verteporfin n1=L-dopa | n2=en:verteporfin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:veterinary drugs n1=L-dopa | n2=en:veterinary drugs | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:viagenpumatucel-l n1=L-dopa | n2=en:viagenpumatucel-l | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:vinblastine n1=L-dopa | n2=en:vinblastine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:vinblastine sulfate n1=L-dopa | n2=en:vinblastine sulfate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:vincristine sulfate liposome n1=L-dopa | n2=en:vincristine sulfate liposome | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:vinflunine n1=L-dopa | n2=en:vinflunine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:vinfosiltine n1=L-dopa | n2=en:vinfosiltine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:visilizumab n1=L-dopa | n2=en:visilizumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:vistusertib n1=L-dopa | n2=en:vistusertib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:vitamin a compound n1=L-dopa | n2=en:vitamin a compound | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:vitamin e compound n1=L-dopa | n2=en:vitamin e compound | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:vitespen n1=L-dopa | n2=en:vitespen | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:volasertib n1=L-dopa | n2=en:volasertib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:voxtalisib n1=L-dopa | n2=en:voxtalisib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:warfarin n1=L-dopa | n2=en:warfarin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:weight control agent n1=L-dopa | n2=en:weight control agent | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:whey protein isolate n1=L-dopa | n2=en:whey protein isolate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:wrench n1=L-dopa | n2=en:wrench | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:wt1 124-138 peptide vaccine n1=L-dopa | n2=en:wt1 124-138 peptide vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:wt1 mrna-electroporated autologous dendritic cell vaccine n1=L-dopa | n2=en:wt1 mrna-electroporated autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:wt1 protein-derived peptide vaccine dsp-7888 n1=L-dopa | n2=en:wt1 protein-derived peptide vaccine dsp-7888 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:xenogeneic tyrosinase dna vaccine n1=L-dopa | n2=en:xenogeneic tyrosinase dna vaccine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:y 90 monoclonal antibody hmfg1 n1=L-dopa | n2=en:y 90 monoclonal antibody hmfg1 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:y 90 monoclonal antibody m170 n1=L-dopa | n2=en:y 90 monoclonal antibody m170 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:ym598 n1=L-dopa | n2=en:ym598 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:yttrium y 90 daclizumab n1=L-dopa | n2=en:yttrium y 90 daclizumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:yttrium y 90 dota anti-cea monoclonal antibody m5a n1=L-dopa | n2=en:yttrium y 90 dota anti-cea monoclonal antibody m5a | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:yttrium y 90 monoclonal antibody hu3s193 n1=L-dopa | n2=en:yttrium y 90 monoclonal antibody hu3s193 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:yttrium y 90 monoclonal antibody mn-14 n1=L-dopa | n2=en:yttrium y 90 monoclonal antibody mn-14 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:yttrium y 90 resin microspheres n1=L-dopa | n2=en:yttrium y 90 resin microspheres | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:yttrium y 90-dota-di-hsg peptide imp-288 n1=L-dopa | n2=en:yttrium y 90-dota-di-hsg peptide imp-288 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:yttrium y-90 epratuzumab tetraxetan n1=L-dopa | n2=en:yttrium y-90 epratuzumab tetraxetan | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:yttrium y-90 ibritumomab tiuxetan n1=L-dopa | n2=en:yttrium y-90 ibritumomab tiuxetan | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:zalutumumab n1=L-dopa | n2=en:zalutumumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:zanolimumab n1=L-dopa | n2=en:zanolimumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:zidovudine n1=L-dopa | n2=en:zidovudine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:zinc gluconate n1=L-dopa | n2=en:zinc gluconate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:zinc sulfate n1=L-dopa | n2=en:zinc sulfate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:zinc sulphate n1=L-dopa | n2=en:zinc sulphate | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:zirconium zr 89 bevacizumab n1=L-dopa | n2=en:zirconium zr 89 bevacizumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:zirconium zr 89 df-iab2m n1=L-dopa | n2=en:zirconium zr 89 df-iab2m | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:zirconium zr 89 girentuximab n1=L-dopa | n2=en:zirconium zr 89 girentuximab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:zirconium zr 89-labeled anti-ca19-9 monoclonal antibody 5b1 n1=L-dopa | n2=en:zirconium zr 89-labeled anti-ca19-9 monoclonal antibody 5b1 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:zirconium zr 89-labeled ro5479599 n1=L-dopa | n2=en:zirconium zr 89-labeled ro5479599 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:zolmitriptan n1=L-dopa | n2=en:zolmitriptan | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> en:zoptarelin doxorubicin n1=L-dopa | n2=en:zoptarelin doxorubicin | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> enzalutamide n1=L-dopa | n2=enzalutamide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> eplérénone n1=L-dopa | n2=eplérénone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> éponge de gélatine résorbable n1=L-dopa | n2=éponge de gélatine résorbable | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> éthosuximide n1=L-dopa | n2=éthosuximide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> ézétimibe n1=L-dopa | n2=ézétimibe | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> facteurs biologiques n1=L-dopa | n2=facteurs biologiques | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> faire connaissance n1=L-dopa | n2=faire connaissance | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> faire connaissance avec n1=L-dopa | n2=faire connaissance avec | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> faire connaissance avec [qqn] n1=L-dopa | n2=faire connaissance avec [qqn] | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> faire connaissance avec quelqu'un n1=L-dopa | n2=faire connaissance avec quelqu'un | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> faire connaissance de n1=L-dopa | n2=faire connaissance de | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> faire connaissance de [qqn] n1=L-dopa | n2=faire connaissance de [qqn] | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> faire connaissance de quelqu'un n1=L-dopa | n2=faire connaissance de quelqu'un | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> faire pendant n1=L-dopa | n2=faire pendant | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> faire pendant à n1=L-dopa | n2=faire pendant à | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> famitinib n1=L-dopa | n2=famitinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> filgrastim n1=L-dopa | n2=filgrastim | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> finastéride n1=L-dopa | n2=finastéride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> flucytosine n1=L-dopa | n2=flucytosine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> fluoro-uracile n1=L-dopa | n2=fluoro-uracile | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> fluorouracile n1=L-dopa | n2=fluorouracile | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> gabapentine n1=L-dopa | n2=gabapentine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> génistéine n1=L-dopa | n2=génistéine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> girentuximab n1=L-dopa | n2=girentuximab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> gluconate de cuivre n1=L-dopa | n2=gluconate de cuivre | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> glutathion n1=L-dopa | n2=glutathion | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> glycol polyéthylénique n1=L-dopa | n2=glycol polyéthylénique | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> gonadotrophine de femmes ménopausées n1=L-dopa | n2=gonadotrophine de femmes ménopausées | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> gonadotrophine ménopausique humaine n1=L-dopa | n2=gonadotrophine ménopausique humaine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> graisse de machines n1=L-dopa | n2=graisse de machines | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> Helicobacter pylori n1=L-dopa | n2=Helicobacter pylori | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> hormone gonadotrope ménopausique humaine n1=L-dopa | n2=hormone gonadotrope ménopausique humaine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> hydrocortisone n1=L-dopa | n2=hydrocortisone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> hydrocortisones n1=L-dopa | n2=hydrocortisones | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> hydroxytyrosol n1=L-dopa | n2=hydroxytyrosol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> ibrutinib n1=L-dopa | n2=ibrutinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> immuno-modulateurs n1=L-dopa | n2=immuno-modulateurs | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> immunomodulateurs n1=L-dopa | n2=immunomodulateurs | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> indométhacine n1=L-dopa | n2=indométhacine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> inhibiteur d'enzymes n1=L-dopa | n2=inhibiteur d'enzymes | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> inhibiteur des canaux calciques n1=L-dopa | n2=inhibiteur des canaux calciques | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> Inhibiteur enzymatique n1=L-dopa | n2=Inhibiteur enzymatique | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> inhibiteur enzymatique n1=L-dopa | n2=inhibiteur enzymatique | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> inositol n1=L-dopa | n2=inositol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> insuline glargine n1=L-dopa | n2=insuline glargine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> insuline normale n1=L-dopa | n2=insuline normale | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> insuline ordinaire n1=L-dopa | n2=insuline ordinaire | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> inuline n1=L-dopa | n2=inuline | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> ionomycine n1=L-dopa | n2=ionomycine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> ipilimumab n1=L-dopa | n2=ipilimumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> isavuconazole n1=L-dopa | n2=isavuconazole | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> isoflurane n1=L-dopa | n2=isoflurane | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> isoniazide n1=L-dopa | n2=isoniazide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> isotrétinoïne n1=L-dopa | n2=isotrétinoïne | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> lacidipine n1=L-dopa | n2=lacidipine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> lactase n1=L-dopa | n2=lactase | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> lactobacillus n1=L-dopa | n2=lactobacillus | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> lamivudine n1=L-dopa | n2=lamivudine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> langage informatique n1=L-dopa | n2=langage informatique | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> Langage informatique n1=L-dopa | n2=Langage informatique | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> lenvatinib n1=L-dopa | n2=lenvatinib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> lergotrile n1=L-dopa | n2=lergotrile | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> lévofloxacine n1=L-dopa | n2=lévofloxacine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> licorice n1=L-dopa | n2=licorice | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> lier connaissance avec n1=L-dopa | n2=lier connaissance avec | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> lier connaissance avec [qqn] n1=L-dopa | n2=lier connaissance avec [qqn] | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> lier connaissance avec quelqu'un n1=L-dopa | n2=lier connaissance avec quelqu'un | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> lilas d'Espagne n1=L-dopa | n2=lilas d'Espagne | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> lipase n1=L-dopa | n2=lipase | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> liraglutide n1=L-dopa | n2=liraglutide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> lisinopril n1=L-dopa | n2=lisinopril | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> lisuride n1=L-dopa | n2=lisuride | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> lovastatine n1=L-dopa | n2=lovastatine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> macitentan n1=L-dopa | n2=macitentan | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> Médecine n1=L-dopa | n2=Médecine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> medicament n1=L-dopa | n2=medicament | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> médicaments animaux n1=L-dopa | n2=médicaments animaux | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> médicaments vétérinaires n1=L-dopa | n2=médicaments vétérinaires | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> melanoma n1=L-dopa | n2=melanoma | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> mélanome n1=L-dopa | n2=mélanome | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> mesna n1=L-dopa | n2=mesna | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> méthoxsalène n1=L-dopa | n2=méthoxsalène | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> mitogène n1=L-dopa | n2=mitogène | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> mitoguazone n1=L-dopa | n2=mitoguazone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> mitoguazones n1=L-dopa | n2=mitoguazones | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> modafinil n1=L-dopa | n2=modafinil | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> moment décisif n1=L-dopa | n2=moment décisif | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> mutagène n1=L-dopa | n2=mutagène | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> myorelaxante n1=L-dopa | n2=myorelaxante | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> nadolol n1=L-dopa | n2=nadolol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> nadroparine calcique n1=L-dopa | n2=nadroparine calcique | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> naproxène n1=L-dopa | n2=naproxène | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> natalizumab n1=L-dopa | n2=natalizumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> niacinamide n1=L-dopa | n2=niacinamide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> nicotinamide n1=L-dopa | n2=nicotinamide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> nicotine n1=L-dopa | n2=nicotine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> nicotinique n1=L-dopa | n2=nicotinique | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> novobiocine n1=L-dopa | n2=novobiocine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> ocrelizumab n1=L-dopa | n2=ocrelizumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> olanzapine n1=L-dopa | n2=olanzapine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> olaparib n1=L-dopa | n2=olaparib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> omalizumab n1=L-dopa | n2=omalizumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> oméprazole n1=L-dopa | n2=oméprazole | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> omeprazole n1=L-dopa | n2=omeprazole | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> oxitriptan n1=L-dopa | n2=oxitriptan | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> oxyde de magnésium n1=L-dopa | n2=oxyde de magnésium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> oxymétholone n1=L-dopa | n2=oxymétholone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> palbociclib n1=L-dopa | n2=palbociclib | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> pénicillamine n1=L-dopa | n2=pénicillamine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> pentamidine n1=L-dopa | n2=pentamidine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> pentoxifylline n1=L-dopa | n2=pentoxifylline | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> peptides hydrolases n1=L-dopa | n2=peptides hydrolases | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> pesticide n1=L-dopa | n2=pesticide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> phénobarbital n1=L-dopa | n2=phénobarbital | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> phylloquinone n1=L-dopa | n2=phylloquinone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> phytoménadione n1=L-dopa | n2=phytoménadione | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> phytonadione n1=L-dopa | n2=phytonadione | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> pierre à savon n1=L-dopa | n2=pierre à savon | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> Pierre à savon n1=L-dopa | n2=Pierre à savon | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> pimecrolimus n1=L-dopa | n2=pimecrolimus | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> piroxicam n1=L-dopa | n2=piroxicam | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> polydextrose n1=L-dopa | n2=polydextrose | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> polyéthylène glycol n1=L-dopa | n2=polyéthylène glycol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> ponesimod n1=L-dopa | n2=ponesimod | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> posaconazole n1=L-dopa | n2=posaconazole | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> poudrer n1=L-dopa | n2=poudrer | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> prastérone n1=L-dopa | n2=prastérone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> préparation d'hydrocortisone n1=L-dopa | n2=préparation d'hydrocortisone | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> préparation de cortisol n1=L-dopa | n2=préparation de cortisol | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> préparation du composé f n1=L-dopa | n2=préparation du composé f | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> préparation du composé F n1=L-dopa | n2=préparation du composé F | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> préparation pharmaceutique n1=L-dopa | n2=préparation pharmaceutique | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> prochlorpérazine n1=L-dopa | n2=prochlorpérazine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> produit anesthésiant n1=L-dopa | n2=produit anesthésiant | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> proflavine n1=L-dopa | n2=proflavine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> progestine n1=L-dopa | n2=progestine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> ramipril n1=L-dopa | n2=ramipril | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> ramucirumab n1=L-dopa | n2=ramucirumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> répondre à n1=L-dopa | n2=répondre à | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> répondre à [qqn] n1=L-dopa | n2=répondre à [qqn] | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> répondre à qn n1=L-dopa | n2=répondre à qn | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> répondre à quelqu'un n1=L-dopa | n2=répondre à quelqu'un | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> rituximab n1=L-dopa | n2=rituximab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> rivaroxaban n1=L-dopa | n2=rivaroxaban | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> se joindre n1=L-dopa | n2=se joindre | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> sel d'Epsom n1=L-dopa | n2=sel d'Epsom | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> spanner n1=L-dopa | n2=spanner | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> stéatite n1=L-dopa | n2=stéatite | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> sulfate de magnésie n1=L-dopa | n2=sulfate de magnésie | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> sulfate de magnésium n1=L-dopa | n2=sulfate de magnésium | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> sulfate de zinc n1=L-dopa | n2=sulfate de zinc | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> talc n1=L-dopa | n2=talc | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> talquer [qch] n1=L-dopa | n2=talquer [qch] | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> talquer quelque chose n1=L-dopa | n2=talquer quelque chose | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> temsirolimus n1=L-dopa | n2=temsirolimus | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> téniposide n1=L-dopa | n2=téniposide | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> tératogène n1=L-dopa | n2=tératogène | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> texte source n1=L-dopa | n2=texte source | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> Thé noir n1=L-dopa | n2=Thé noir | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> thé noir n1=L-dopa | n2=thé noir | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> thiamine n1=L-dopa | n2=thiamine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> timbre anti-tabac n1=L-dopa | n2=timbre anti-tabac | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> tocilizumab n1=L-dopa | n2=tocilizumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> trastuzumab n1=L-dopa | n2=trastuzumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> trétinoïne n1=L-dopa | n2=trétinoïne | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> trihexyphénidyle n1=L-dopa | n2=trihexyphénidyle | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> trioxyde d'arsenic n1=L-dopa | n2=trioxyde d'arsenic | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> ustekinumab n1=L-dopa | n2=ustekinumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> vaccin anti-hépatite A n1=L-dopa | n2=vaccin anti-hépatite A | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> vaccin anti-hépatite B n1=L-dopa | n2=vaccin anti-hépatite B | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> vaccin anti-hépatite b n1=L-dopa | n2=vaccin anti-hépatite b | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> vaccin contre l'hépatite a n1=L-dopa | n2=vaccin contre l'hépatite a | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> vaccin contre l'hépatite A n1=L-dopa | n2=vaccin contre l'hépatite A | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> Vaccin contre l'hépatite A n1=L-dopa | n2=Vaccin contre l'hépatite A | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> vaccin contre l'hépatite b n1=L-dopa | n2=vaccin contre l'hépatite b | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> Vaccin contre l'hépatite B n1=L-dopa | n2=Vaccin contre l'hépatite B | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> vaccin contre l'hépatite B n1=L-dopa | n2=vaccin contre l'hépatite B | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> Valeriana n1=L-dopa | n2=Valeriana | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> valériane n1=L-dopa | n2=valériane | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> vancomycine n1=L-dopa | n2=vancomycine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> vedolizumab n1=L-dopa | n2=vedolizumab | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> vesse de loup n1=L-dopa | n2=vesse de loup | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> vinblastine n1=L-dopa | n2=vinblastine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> vitamine B1 n1=L-dopa | n2=vitamine B1 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> vitamine K1 n1=L-dopa | n2=vitamine K1 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> vitamine k1 n1=L-dopa | n2=vitamine k1 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> Vitamine K1 n1=L-dopa | n2=Vitamine K1 | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> warfarine n1=L-dopa | n2=warfarine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> zidovudine n1=L-dopa | n2=zidovudine | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 5 / 0.019 -> zolmitriptan n1=L-dopa | n2=zolmitriptan | rel=r_associated | relid=0 | w=5 L-dopa -- r_associated #0: 4 / 0.016 -> agonistes de la dopamine n1=L-dopa | n2=agonistes de la dopamine | rel=r_associated | relid=0 | w=4 L-dopa -- r_associated #0: 4 / 0.016 -> COMT n1=L-dopa | n2=COMT | rel=r_associated | relid=0 | w=4 L-dopa -- r_associated #0: 4 / 0.016 -> dextrogyre n1=L-dopa | n2=dextrogyre | rel=r_associated | relid=0 | w=4 L-dopa -- r_associated #0: 4 / 0.016 -> Dopamine n1=L-dopa | n2=Dopamine | rel=r_associated | relid=0 | w=4 L-dopa -- r_associated #0: 4 / 0.016 -> phosphate de pyridoxal n1=L-dopa | n2=phosphate de pyridoxal | rel=r_associated | relid=0 | w=4 L-dopa -- r_associated #0: 4 / 0.016 -> prix Nobel n1=L-dopa | n2=prix Nobel | rel=r_associated | relid=0 | w=4 L-dopa -- r_associated #0: 4 / 0.016 -> Tyrosine n1=L-dopa | n2=Tyrosine | rel=r_associated | relid=0 | w=4 L-dopa -- r_associated #0: 3 / 0.012 -> analyte n1=L-dopa | n2=analyte | rel=r_associated | relid=0 | w=3 L-dopa -- r_associated #0: 3 / 0.012 -> dopaminergiques n1=L-dopa | n2=dopaminergiques | rel=r_associated | relid=0 | w=3 L-dopa -- r_associated #0: 3 / 0.012 -> microbiote intestinal n1=L-dopa | n2=microbiote intestinal | rel=r_associated | relid=0 | w=3 L-dopa -- r_associated #0: 3 / 0.012 -> Microbiote intestinal n1=L-dopa | n2=Microbiote intestinal | rel=r_associated | relid=0 | w=3 L-dopa -- r_associated #0: 2 / 0.008 -> Antibiotique n1=L-dopa | n2=Antibiotique | rel=r_associated | relid=0 | w=2 L-dopa -- r_associated #0: 2 / 0.008 -> Dextrogyre n1=L-dopa | n2=Dextrogyre | rel=r_associated | relid=0 | w=2 L-dopa -- r_associated #0: 2 / 0.008 -> ergoline n1=L-dopa | n2=ergoline | rel=r_associated | relid=0 | w=2 L-dopa -- r_associated #0: 2 / 0.008 -> Phosphate de pyridoxal n1=L-dopa | n2=Phosphate de pyridoxal | rel=r_associated | relid=0 | w=2 L-dopa -- r_associated #0: 2 / 0.008 -> Prix Nobel n1=L-dopa | n2=Prix Nobel | rel=r_associated | relid=0 | w=2 L-dopa -- r_associated #0: 2 / 0.008 -> substance (matière) n1=L-dopa | n2=substance (matière) | rel=r_associated | relid=0 | w=2 L-dopa -- r_associated #0: 2 / 0.008 -> Syndrome malin des neuroleptiques n1=L-dopa | n2=Syndrome malin des neuroleptiques | rel=r_associated | relid=0 | w=2

≈ 364 relations entrantes médecine --- r_associated #0: 173 --> L-dopa n1=médecine | n2=L-dopa | rel=r_associated | relid=0 | w=173 lévodopa --- r_associated #0: 148 --> L-dopa n1=lévodopa | n2=L-dopa | rel=r_associated | relid=0 | w=148 en:dopa --- r_associated #0: 145 --> L-dopa n1=en:dopa | n2=L-dopa | rel=r_associated | relid=0 | w=145 en:levodopa --- r_associated #0: 145 --> L-dopa n1=en:levodopa | n2=L-dopa | rel=r_associated | relid=0 | w=145 3,4-dihydroxyphénylalanine --- r_associated #0: 135 --> L-dopa n1=3,4-dihydroxyphénylalanine | n2=L-dopa | rel=r_associated | relid=0 | w=135 dopa --- r_associated #0: 84 --> L-dopa n1=dopa | n2=L-dopa | rel=r_associated | relid=0 | w=84 préparation de l-dopa --- r_associated #0: 62 --> L-dopa n1=préparation de l-dopa | n2=L-dopa | rel=r_associated | relid=0 | w=62 préparation de L-dopa --- r_associated #0: 60 --> L-dopa n1=préparation de L-dopa | n2=L-dopa | rel=r_associated | relid=0 | w=60 inhibiteurs de la COMT --- r_associated #0: 40 --> L-dopa n1=inhibiteurs de la COMT | n2=L-dopa | rel=r_associated | relid=0 | w=40 dopamine --- r_associated #0: 35 --> L-dopa n1=dopamine | n2=L-dopa | rel=r_associated | relid=0 | w=35 en:dopamine --- r_associated #0: 35 --> L-dopa n1=en:dopamine | n2=L-dopa | rel=r_associated | relid=0 | w=35 l-3-hydroxytyrosine --- r_associated #0: 34 --> L-dopa n1=l-3-hydroxytyrosine | n2=L-dopa | rel=r_associated | relid=0 | w=34 l-dopa --- r_associated #0: 33 --> L-dopa n1=l-dopa | n2=L-dopa | rel=r_associated | relid=0 | w=33 L-DOPA --- r_associated #0: 32 --> L-dopa n1=L-DOPA | n2=L-dopa | rel=r_associated | relid=0 | w=32 dihydroxyphénylalanine --- r_associated #0: 32 --> L-dopa n1=dihydroxyphénylalanine | n2=L-dopa | rel=r_associated | relid=0 | w=32 en:dihydroxyphenylalanine --- r_associated #0: 31 --> L-dopa n1=en:dihydroxyphenylalanine | n2=L-dopa | rel=r_associated | relid=0 | w=31 dihydroxyphénylalanines --- r_associated #0: 30 --> L-dopa n1=dihydroxyphénylalanines | n2=L-dopa | rel=r_associated | relid=0 | w=30 en:L-dopa --- r_associated #0: 30 --> L-dopa n1=en:L-dopa | n2=L-dopa | rel=r_associated | relid=0 | w=30 DOPA --- r_associated #0: 23 --> L-dopa n1=DOPA | n2=L-dopa | rel=r_associated | relid=0 | w=23 aboulie --- r_associated #0: 23 --> L-dopa n1=aboulie | n2=L-dopa | rel=r_associated | relid=0 | w=23 en:3,4-dihydroxyphenylethylamine --- r_associated #0: 21 --> L-dopa n1=en:3,4-dihydroxyphenylethylamine | n2=L-dopa | rel=r_associated | relid=0 | w=21 3,4 --- r_associated #0: 20 --> L-dopa n1=3,4 | n2=L-dopa | rel=r_associated | relid=0 | w=20 barrière hémato-encéphalique --- r_associated #0: 20 --> L-dopa n1=barrière hémato-encéphalique | n2=L-dopa | rel=r_associated | relid=0 | w=20 barrière hématoencéphalique --- r_associated #0: 20 --> L-dopa n1=barrière hématoencéphalique | n2=L-dopa | rel=r_associated | relid=0 | w=20 biologie --- r_associated #0: 20 --> L-dopa n1=biologie | n2=L-dopa | rel=r_associated | relid=0 | w=20 catécholamine --- r_associated #0: 20 --> L-dopa n1=catécholamine | n2=L-dopa | rel=r_associated | relid=0 | w=20 catécholamines --- r_associated #0: 20 --> L-dopa n1=catécholamines | n2=L-dopa | rel=r_associated | relid=0 | w=20 di-iodotyrosine --- r_associated #0: 20 --> L-dopa n1=di-iodotyrosine | n2=L-dopa | rel=r_associated | relid=0 | w=20 diiodotyrosine --- r_associated #0: 20 --> L-dopa n1=diiodotyrosine | n2=L-dopa | rel=r_associated | relid=0 | w=20 doper --- r_associated #0: 20 --> L-dopa n1=doper | n2=L-dopa | rel=r_associated | relid=0 | w=20 effet d'un médicament --- r_associated #0: 20 --> L-dopa n1=effet d'un médicament | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:2,4,5-trihydroxyphenylalanine quinone --- r_associated #0: 20 --> L-dopa n1=en:2,4,5-trihydroxyphenylalanine quinone | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:2,4-dihydroxyphenylalanine --- r_associated #0: 20 --> L-dopa n1=en:2,4-dihydroxyphenylalanine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:2,6-difluoro-3,4-dihydroxyphenylalanine --- r_associated #0: 20 --> L-dopa n1=en:2,6-difluoro-3,4-dihydroxyphenylalanine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:2-fluorodopa --- r_associated #0: 20 --> L-dopa n1=en:2-fluorodopa | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:24 hr pramipexole dihydrochloride 2.25 mg extended release oral tablet --- r_associated #0: 20 --> L-dopa n1=en:24 hr pramipexole dihydrochloride 2.25 mg extended release oral tablet | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:24 hr pramipexole dihydrochloride 3.75 mg extended release oral tablet --- r_associated #0: 20 --> L-dopa n1=en:24 hr pramipexole dihydrochloride 3.75 mg extended release oral tablet | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:24 hr ropinirole 4 mg extended release oral tablet --- r_associated #0: 20 --> L-dopa n1=en:24 hr ropinirole 4 mg extended release oral tablet | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:3,4,6-trihydroxyphenylalanine quinone --- r_associated #0: 20 --> L-dopa n1=en:3,4,6-trihydroxyphenylalanine quinone | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:3-(2-fluoro-4,5-dihydroxyphenyl)-2-methylalanine --- r_associated #0: 20 --> L-dopa n1=en:3-(2-fluoro-4,5-dihydroxyphenyl)-2-methylalanine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:3-iodotyrosine --- r_associated #0: 20 --> L-dopa n1=en:3-iodotyrosine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:3-methoxytyramine --- r_associated #0: 20 --> L-dopa n1=en:3-methoxytyramine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:3-methoxytyrosine --- r_associated #0: 20 --> L-dopa n1=en:3-methoxytyrosine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:3-o-methyl-6-fluoro-dopa --- r_associated #0: 20 --> L-dopa n1=en:3-o-methyl-6-fluoro-dopa | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:3-o-sulfato-6-fluoro-dopa --- r_associated #0: 20 --> L-dopa n1=en:3-o-sulfato-6-fluoro-dopa | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:3-prenyl-beta-hydroxytyrosine --- r_associated #0: 20 --> L-dopa n1=en:3-prenyl-beta-hydroxytyrosine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:5-fluorodopa --- r_associated #0: 20 --> L-dopa n1=en:5-fluorodopa | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:5-hydroxydopa --- r_associated #0: 20 --> L-dopa n1=en:5-hydroxydopa | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:5-lipoyl-dopa --- r_associated #0: 20 --> L-dopa n1=en:5-lipoyl-dopa | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:5-s-cysteinyl-3,4-dihydroxyphenylalanine --- r_associated #0: 20 --> L-dopa n1=en:5-s-cysteinyl-3,4-dihydroxyphenylalanine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:6-hydroxydopa --- r_associated #0: 20 --> L-dopa n1=en:6-hydroxydopa | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:6-hydroxydopa quinone --- r_associated #0: 20 --> L-dopa n1=en:6-hydroxydopa quinone | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:8 hr carbidopa 23.75 mg / levodopa 95 mg extended release oral capsule --- r_associated #0: 20 --> L-dopa n1=en:8 hr carbidopa 23.75 mg / levodopa 95 mg extended release oral capsule | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:8 hr carbidopa 36.25 mg / levodopa 145 mg extended release oral capsule --- r_associated #0: 20 --> L-dopa n1=en:8 hr carbidopa 36.25 mg / levodopa 145 mg extended release oral capsule | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:8 hr carbidopa 61.25 mg / levodopa 245 mg extended release oral capsule --- r_associated #0: 20 --> L-dopa n1=en:8 hr carbidopa 61.25 mg / levodopa 245 mg extended release oral capsule | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:DOPA --- r_associated #0: 20 --> L-dopa n1=en:DOPA | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:adrogolide --- r_associated #0: 20 --> L-dopa n1=en:adrogolide | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:adrogolide hydrochloride --- r_associated #0: 20 --> L-dopa n1=en:adrogolide hydrochloride | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:agonists --- r_associated #0: 20 --> L-dopa n1=en:agonists | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:alentemol --- r_associated #0: 20 --> L-dopa n1=en:alentemol | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:alentemol hydrobromide --- r_associated #0: 20 --> L-dopa n1=en:alentemol hydrobromide | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:alpha-difluoromethyl-dopa --- r_associated #0: 20 --> L-dopa n1=en:alpha-difluoromethyl-dopa | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:alpha-methyldopamine --- r_associated #0: 20 --> L-dopa n1=en:alpha-methyldopamine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:amantadine --- r_associated #0: 20 --> L-dopa n1=en:amantadine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:amino acid --- r_associated #0: 20 --> L-dopa n1=en:amino acid | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:analysis aspect --- r_associated #0: 20 --> L-dopa n1=en:analysis aspect | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:anticholinergic agent --- r_associated #0: 20 --> L-dopa n1=en:anticholinergic agent | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:antimuscarinic agent used in parkinsonism --- r_associated #0: 20 --> L-dopa n1=en:antimuscarinic agent used in parkinsonism | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:antiparkinson agents, other --- r_associated #0: 20 --> L-dopa n1=en:antiparkinson agents, other | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:antiparkinsonian agent --- r_associated #0: 20 --> L-dopa n1=en:antiparkinsonian agent | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:aplindore --- r_associated #0: 20 --> L-dopa n1=en:aplindore | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:aplindore fumarate --- r_associated #0: 20 --> L-dopa n1=en:aplindore fumarate | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:apomorphine --- r_associated #0: 20 --> L-dopa n1=en:apomorphine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:apomorphine diacetate --- r_associated #0: 20 --> L-dopa n1=en:apomorphine diacetate | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:apomorphine hydrochloride --- r_associated #0: 20 --> L-dopa n1=en:apomorphine hydrochloride | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:apomorphine hydrochloride 10mg/ml injection solution 2ml ampule --- r_associated #0: 20 --> L-dopa n1=en:apomorphine hydrochloride 10mg/ml injection solution 2ml ampule | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:apomorphine hydrochloride 30mg/3ml prefilled pen --- r_associated #0: 20 --> L-dopa n1=en:apomorphine hydrochloride 30mg/3ml prefilled pen | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:apomorphine hydrochloride anhydrous --- r_associated #0: 20 --> L-dopa n1=en:apomorphine hydrochloride anhydrous | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:arbutamine --- r_associated #0: 20 --> L-dopa n1=en:arbutamine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:aromatic amino acid decarboxylase inhibitors --- r_associated #0: 20 --> L-dopa n1=en:aromatic amino acid decarboxylase inhibitors | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:aspects of adverse effects --- r_associated #0: 20 --> L-dopa n1=en:aspects of adverse effects | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:aspects of radiation effects --- r_associated #0: 20 --> L-dopa n1=en:aspects of radiation effects | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:benserazide --- r_associated #0: 20 --> L-dopa n1=en:benserazide | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:benserazide hydrochloride --- r_associated #0: 20 --> L-dopa n1=en:benserazide hydrochloride | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:benztropine --- r_associated #0: 20 --> L-dopa n1=en:benztropine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:besonprodil --- r_associated #0: 20 --> L-dopa n1=en:besonprodil | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:betalains --- r_associated #0: 20 --> L-dopa n1=en:betalains | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:bioformation --- r_associated #0: 20 --> L-dopa n1=en:bioformation | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:biperiden --- r_associated #0: 20 --> L-dopa n1=en:biperiden | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:biperiden hydrochloride --- r_associated #0: 20 --> L-dopa n1=en:biperiden hydrochloride | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:biperiden lactate --- r_associated #0: 20 --> L-dopa n1=en:biperiden lactate | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:botiacrine --- r_associated #0: 20 --> L-dopa n1=en:botiacrine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:brasofensine --- r_associated #0: 20 --> L-dopa n1=en:brasofensine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:brasofensine maleate --- r_associated #0: 20 --> L-dopa n1=en:brasofensine maleate | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:brexpiprazole --- r_associated #0: 20 --> L-dopa n1=en:brexpiprazole | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:bromocriptine --- r_associated #0: 20 --> L-dopa n1=en:bromocriptine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:budipine --- r_associated #0: 20 --> L-dopa n1=en:budipine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:butaperazine --- r_associated #0: 20 --> L-dopa n1=en:butaperazine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:butaperazine maleate --- r_associated #0: 20 --> L-dopa n1=en:butaperazine maleate | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:cabergoline --- r_associated #0: 20 --> L-dopa n1=en:cabergoline | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:carbidopa --- r_associated #0: 20 --> L-dopa n1=en:carbidopa | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:carbidopa + levodopa 25mg/100mg m/r tablet --- r_associated #0: 20 --> L-dopa n1=en:carbidopa + levodopa 25mg/100mg m/r tablet | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:carbidopa 10 mg / levodopa 100 mg disintegrating oral tablet --- r_associated #0: 20 --> L-dopa n1=en:carbidopa 10 mg / levodopa 100 mg disintegrating oral tablet | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:carbidopa 10 mg / levodopa 100 mg oral tablet --- r_associated #0: 20 --> L-dopa n1=en:carbidopa 10 mg / levodopa 100 mg oral tablet | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:carbidopa 12.5mg/levodopa 50mg/entacapone 200mg tablet --- r_associated #0: 20 --> L-dopa n1=en:carbidopa 12.5mg/levodopa 50mg/entacapone 200mg tablet | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:carbidopa 25 mg / levodopa 100 mg disintegrating oral tablet --- r_associated #0: 20 --> L-dopa n1=en:carbidopa 25 mg / levodopa 100 mg disintegrating oral tablet | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:carbidopa 25 mg / levodopa 100 mg oral tablet --- r_associated #0: 20 --> L-dopa n1=en:carbidopa 25 mg / levodopa 100 mg oral tablet | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:carbidopa 25 mg / levodopa 250 mg oral tablet --- r_associated #0: 20 --> L-dopa n1=en:carbidopa 25 mg / levodopa 250 mg oral tablet | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:carbidopa 25mg/levodopa 100mg/entacapone 200mg tablet --- r_associated #0: 20 --> L-dopa n1=en:carbidopa 25mg/levodopa 100mg/entacapone 200mg tablet | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:carbidopa 50 mg / levodopa 200 mg extended release oral tablet --- r_associated #0: 20 --> L-dopa n1=en:carbidopa 50 mg / levodopa 200 mg extended release oral tablet | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:carbidopa anhydrous --- r_associated #0: 20 --> L-dopa n1=en:carbidopa anhydrous | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:carmantadine --- r_associated #0: 20 --> L-dopa n1=en:carmantadine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:carmoxirole --- r_associated #0: 20 --> L-dopa n1=en:carmoxirole | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:catechol-o-methyltransferase inhibitor --- r_associated #0: 20 --> L-dopa n1=en:catechol-o-methyltransferase inhibitor | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:catecholamine --- r_associated #0: 20 --> L-dopa n1=en:catecholamine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:cellular secretion --- r_associated #0: 20 --> L-dopa n1=en:cellular secretion | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:chemical aspects --- r_associated #0: 20 --> L-dopa n1=en:chemical aspects | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:chemical synthesis --- r_associated #0: 20 --> L-dopa n1=en:chemical synthesis | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:cianergoline --- r_associated #0: 20 --> L-dopa n1=en:cianergoline | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:ciladopa --- r_associated #0: 20 --> L-dopa n1=en:ciladopa | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:cliropamine --- r_associated #0: 20 --> L-dopa n1=en:cliropamine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:cocaine --- r_associated #0: 20 --> L-dopa n1=en:cocaine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:contraindications aspect --- r_associated #0: 20 --> L-dopa n1=en:contraindications aspect | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:cyclo-dopa --- r_associated #0: 20 --> L-dopa n1=en:cyclo-dopa | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:cycrimine --- r_associated #0: 20 --> L-dopa n1=en:cycrimine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:cycrimine hydrochloride --- r_associated #0: 20 --> L-dopa n1=en:cycrimine hydrochloride | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:cysteinyldopa --- r_associated #0: 20 --> L-dopa n1=en:cysteinyldopa | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:deficiency aspects --- r_associated #0: 20 --> L-dopa n1=en:deficiency aspects | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:delergotrile --- r_associated #0: 20 --> L-dopa n1=en:delergotrile | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:dihydroergocornine --- r_associated #0: 20 --> L-dopa n1=en:dihydroergocornine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:dihydroergocornine mesylate --- r_associated #0: 20 --> L-dopa n1=en:dihydroergocornine mesylate | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:dihydroergocristine --- r_associated #0: 20 --> L-dopa n1=en:dihydroergocristine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:dihydroergocristine mesylate --- r_associated #0: 20 --> L-dopa n1=en:dihydroergocristine mesylate | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:dihydroergocryptine --- r_associated #0: 20 --> L-dopa n1=en:dihydroergocryptine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:dihydroergotamine --- r_associated #0: 20 --> L-dopa n1=en:dihydroergotamine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:dihydroergotamine mesylate --- r_associated #0: 20 --> L-dopa n1=en:dihydroergotamine mesylate | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:dihydroxyphenylalanine hydrochloride, (2:1) --- r_associated #0: 20 --> L-dopa n1=en:dihydroxyphenylalanine hydrochloride, (2:1) | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:diiodotyrosine --- r_associated #0: 20 --> L-dopa n1=en:diiodotyrosine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:diphenhydramine --- r_associated #0: 20 --> L-dopa n1=en:diphenhydramine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:diprobutine --- r_associated #0: 20 --> L-dopa n1=en:diprobutine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:dobutamine --- r_associated #0: 20 --> L-dopa n1=en:dobutamine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:docarpamine --- r_associated #0: 20 --> L-dopa n1=en:docarpamine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:dopa 3-phosphate --- r_associated #0: 20 --> L-dopa n1=en:dopa 3-phosphate | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:dopa 4-phosphate --- r_associated #0: 20 --> L-dopa n1=en:dopa 4-phosphate | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:dopa decarboxylase --- r_associated #0: 20 --> L-dopa n1=en:dopa decarboxylase | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:dopa decarboxylase inhibitors --- r_associated #0: 20 --> L-dopa n1=en:dopa decarboxylase inhibitors | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:dopa melanin --- r_associated #0: 20 --> L-dopa n1=en:dopa melanin | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:dopa, dl- --- r_associated #0: 20 --> L-dopa n1=en:dopa, dl- | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:dopamantine --- r_associated #0: 20 --> L-dopa n1=en:dopamantine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:dopamine agonist --- r_associated #0: 20 --> L-dopa n1=en:dopamine agonist | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:dopamine precursors/ l-amino acid decarboxylase inhibitors --- r_associated #0: 20 --> L-dopa n1=en:dopamine precursors/ l-amino acid decarboxylase inhibitors | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:dopaminergic agents --- r_associated #0: 20 --> L-dopa n1=en:dopaminergic agents | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:dopaquinone --- r_associated #0: 20 --> L-dopa n1=en:dopaquinone | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:dopexamine --- r_associated #0: 20 --> L-dopa n1=en:dopexamine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:dopexamine hydrochloride --- r_associated #0: 20 --> L-dopa n1=en:dopexamine hydrochloride | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:doreptide --- r_associated #0: 20 --> L-dopa n1=en:doreptide | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:droxidopa --- r_associated #0: 20 --> L-dopa n1=en:droxidopa | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:drug effect --- r_associated #0: 20 --> L-dopa n1=en:drug effect | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:entacapone --- r_associated #0: 20 --> L-dopa n1=en:entacapone | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:entacapone 200mg tablet --- r_associated #0: 20 --> L-dopa n1=en:entacapone 200mg tablet | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:epinephrine --- r_associated #0: 20 --> L-dopa n1=en:epinephrine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:epinephrine + norepinephrine --- r_associated #0: 20 --> L-dopa n1=en:epinephrine + norepinephrine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:ergonovine --- r_associated #0: 20 --> L-dopa n1=en:ergonovine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:ergonovine maleate --- r_associated #0: 20 --> L-dopa n1=en:ergonovine maleate | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:ethopropazine --- r_associated #0: 20 --> L-dopa n1=en:ethopropazine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:etilevodopa --- r_associated #0: 20 --> L-dopa n1=en:etilevodopa | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:etisulergine --- r_associated #0: 20 --> L-dopa n1=en:etisulergine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:exposure as collected domain --- r_associated #0: 20 --> L-dopa n1=en:exposure as collected domain | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:fencamfamin --- r_associated #0: 20 --> L-dopa n1=en:fencamfamin | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:fencamfamin hydrochloride --- r_associated #0: 20 --> L-dopa n1=en:fencamfamin hydrochloride | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:fenclonine --- r_associated #0: 20 --> L-dopa n1=en:fenclonine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:fenoldopam --- r_associated #0: 20 --> L-dopa n1=en:fenoldopam | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:fenoldopam mesylate --- r_associated #0: 20 --> L-dopa n1=en:fenoldopam mesylate | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:flunamine --- r_associated #0: 20 --> L-dopa n1=en:flunamine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:fluorine f 18 fluorodopa --- r_associated #0: 20 --> L-dopa n1=en:fluorine f 18 fluorodopa | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:fosopamine --- r_associated #0: 20 --> L-dopa n1=en:fosopamine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:free catecholamines --- r_associated #0: 20 --> L-dopa n1=en:free catecholamines | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:free fractionated catecholamine --- r_associated #0: 20 --> L-dopa n1=en:free fractionated catecholamine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:gamma-glutamyl dopa --- r_associated #0: 20 --> L-dopa n1=en:gamma-glutamyl dopa | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:genetic aspects --- r_associated #0: 20 --> L-dopa n1=en:genetic aspects | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:glycyltyrosine --- r_associated #0: 20 --> L-dopa n1=en:glycyltyrosine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:halonamine --- r_associated #0: 20 --> L-dopa n1=en:halonamine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:historical aspects qualifier --- r_associated #0: 20 --> L-dopa n1=en:historical aspects qualifier | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:hyoscyamine --- r_associated #0: 20 --> L-dopa n1=en:hyoscyamine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:ibopamine --- r_associated #0: 20 --> L-dopa n1=en:ibopamine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:immunology aspects --- r_associated #0: 20 --> L-dopa n1=en:immunology aspects | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:in blood --- r_associated #0: 20 --> L-dopa n1=en:in blood | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:in cerebrospinal fluid --- r_associated #0: 20 --> L-dopa n1=en:in cerebrospinal fluid | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:in urine --- r_associated #0: 20 --> L-dopa n1=en:in urine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:iron(iii)-dopa complex --- r_associated #0: 20 --> L-dopa n1=en:iron(iii)-dopa complex | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:isoproterenol --- r_associated #0: 20 --> L-dopa n1=en:isoproterenol | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:istradefylline --- r_associated #0: 20 --> L-dopa n1=en:istradefylline | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:l-norepinephrine --- r_associated #0: 20 --> L-dopa n1=en:l-norepinephrine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:l-tyrosine --- r_associated #0: 20 --> L-dopa n1=en:l-tyrosine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:l-tyrosine powder --- r_associated #0: 20 --> L-dopa n1=en:l-tyrosine powder | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:lergotrile --- r_associated #0: 20 --> L-dopa n1=en:lergotrile | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:lergotrile mesylate --- r_associated #0: 20 --> L-dopa n1=en:lergotrile mesylate | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:levodopa 100 mg oral capsule --- r_associated #0: 20 --> L-dopa n1=en:levodopa 100 mg oral capsule | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:levodopa 100 mg oral tablet --- r_associated #0: 20 --> L-dopa n1=en:levodopa 100 mg oral tablet | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:levodopa 500 mg oral capsule --- r_associated #0: 20 --> L-dopa n1=en:levodopa 500 mg oral capsule | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:lisuride --- r_associated #0: 20 --> L-dopa n1=en:lisuride | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:lometraline hydrochloride --- r_associated #0: 20 --> L-dopa n1=en:lometraline hydrochloride | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:manifaxine --- r_associated #0: 20 --> L-dopa n1=en:manifaxine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:mechanism of action qualifier --- r_associated #0: 20 --> L-dopa n1=en:mechanism of action qualifier | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:medifoxamine --- r_associated #0: 20 --> L-dopa n1=en:medifoxamine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:melanin --- r_associated #0: 20 --> L-dopa n1=en:melanin | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:melevodopa --- r_associated #0: 20 --> L-dopa n1=en:melevodopa | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:melphalan --- r_associated #0: 20 --> L-dopa n1=en:melphalan | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:memantine --- r_associated #0: 20 --> L-dopa n1=en:memantine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:memantine hydrochloride --- r_associated #0: 20 --> L-dopa n1=en:memantine hydrochloride | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:mesocarb --- r_associated #0: 20 --> L-dopa n1=en:mesocarb | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:mesulergine --- r_associated #0: 20 --> L-dopa n1=en:mesulergine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:metabolic aspects --- r_associated #0: 20 --> L-dopa n1=en:metabolic aspects | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:metanephrine --- r_associated #0: 20 --> L-dopa n1=en:metanephrine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:metaproterenol --- r_associated #0: 20 --> L-dopa n1=en:metaproterenol | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:metergoline --- r_associated #0: 20 --> L-dopa n1=en:metergoline | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:methixene --- r_associated #0: 20 --> L-dopa n1=en:methixene | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:methyldopa --- r_associated #0: 20 --> L-dopa n1=en:methyldopa | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:methyldopate hydrochloride --- r_associated #0: 20 --> L-dopa n1=en:methyldopate hydrochloride | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:methyltyrosines --- r_associated #0: 20 --> L-dopa n1=en:methyltyrosines | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:monoamine oxidase b (mao-b) inhibitors --- r_associated #0: 20 --> L-dopa n1=en:monoamine oxidase b (mao-b) inhibitors | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:n-acetyl-alpha, beta-dehydro-3,4-dihydroxyphenylalanine ethyl ester --- r_associated #0: 20 --> L-dopa n1=en:n-acetyl-alpha, beta-dehydro-3,4-dihydroxyphenylalanine ethyl ester | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:n-beta-alanyl-5-s-glutathionyl-3,4-dihydroxyphenylalanine --- r_associated #0: 20 --> L-dopa n1=en:n-beta-alanyl-5-s-glutathionyl-3,4-dihydroxyphenylalanine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:n-formylmethionine leucyl-phenylalanine --- r_associated #0: 20 --> L-dopa n1=en:n-formylmethionine leucyl-phenylalanine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:nebicapone --- r_associated #0: 20 --> L-dopa n1=en:nebicapone | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:nolomirole --- r_associated #0: 20 --> L-dopa n1=en:nolomirole | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:norepinephrine, dl- --- r_associated #0: 20 --> L-dopa n1=en:norepinephrine, dl- | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:normetanephrine --- r_associated #0: 20 --> L-dopa n1=en:normetanephrine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:omidoline --- r_associated #0: 20 --> L-dopa n1=en:omidoline | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:orphenadrine --- r_associated #0: 20 --> L-dopa n1=en:orphenadrine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:oxidopamine --- r_associated #0: 20 --> L-dopa n1=en:oxidopamine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:oxiperomide --- r_associated #0: 20 --> L-dopa n1=en:oxiperomide | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:p-fluorophenylalanine --- r_associated #0: 20 --> L-dopa n1=en:p-fluorophenylalanine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:pardoprunox --- r_associated #0: 20 --> L-dopa n1=en:pardoprunox | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:pardoprunox hydrochloride --- r_associated #0: 20 --> L-dopa n1=en:pardoprunox hydrochloride | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:pareptide --- r_associated #0: 20 --> L-dopa n1=en:pareptide | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:pergolide --- r_associated #0: 20 --> L-dopa n1=en:pergolide | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:pergolide mesylate --- r_associated #0: 20 --> L-dopa n1=en:pergolide mesylate | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:pharmacokinetic aspects --- r_associated #0: 20 --> L-dopa n1=en:pharmacokinetic aspects | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:phenylalanine --- r_associated #0: 20 --> L-dopa n1=en:phenylalanine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:phenylalanine supplementation --- r_associated #0: 20 --> L-dopa n1=en:phenylalanine supplementation | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:phenylthiohydantoin-3,4-dihydroxyphenylalanine --- r_associated #0: 20 --> L-dopa n1=en:phenylthiohydantoin-3,4-dihydroxyphenylalanine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:phosphotyrosine --- r_associated #0: 20 --> L-dopa n1=en:phosphotyrosine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:physiological aspects --- r_associated #0: 20 --> L-dopa n1=en:physiological aspects | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:piribedil --- r_associated #0: 20 --> L-dopa n1=en:piribedil | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:piroheptine --- r_associated #0: 20 --> L-dopa n1=en:piroheptine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:poisoning aspects --- r_associated #0: 20 --> L-dopa n1=en:poisoning aspects | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:poly(3,4-dihydroxyphenylalanine) --- r_associated #0: 20 --> L-dopa n1=en:poly(3,4-dihydroxyphenylalanine) | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:poly(o,o'-dicarbobenzoyx-l-beta-3,4-dihydroxyphenyl-alpha- alanine) --- r_associated #0: 20 --> L-dopa n1=en:poly(o,o'-dicarbobenzoyx-l-beta-3,4-dihydroxyphenyl-alpha- alanine) | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:pramipexole --- r_associated #0: 20 --> L-dopa n1=en:pramipexole | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:pramipexole 700micrograms tablet --- r_associated #0: 20 --> L-dopa n1=en:pramipexole 700micrograms tablet | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:pramipexole dihydrochloride --- r_associated #0: 20 --> L-dopa n1=en:pramipexole dihydrochloride | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:pramipexole dihydrochloride 3mg extended release tablet --- r_associated #0: 20 --> L-dopa n1=en:pramipexole dihydrochloride 3mg extended release tablet | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:pramipexole dihydrochloride 4.5mg extended release tablet --- r_associated #0: 20 --> L-dopa n1=en:pramipexole dihydrochloride 4.5mg extended release tablet | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:pramipexole dihydrochloride 500micrograms tablet --- r_associated #0: 20 --> L-dopa n1=en:pramipexole dihydrochloride 500micrograms tablet | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:pramipexole dihydrochloride 750microgram extended release tablet --- r_associated #0: 20 --> L-dopa n1=en:pramipexole dihydrochloride 750microgram extended release tablet | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:pramipexole dihydrochloride 750microgram tablet --- r_associated #0: 20 --> L-dopa n1=en:pramipexole dihydrochloride 750microgram tablet | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:preladenant --- r_associated #0: 20 --> L-dopa n1=en:preladenant | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:procyclidine --- r_associated #0: 20 --> L-dopa n1=en:procyclidine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:procyclidine hydrochloride --- r_associated #0: 20 --> L-dopa n1=en:procyclidine hydrochloride | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:prodipine --- r_associated #0: 20 --> L-dopa n1=en:prodipine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:proterguride --- r_associated #0: 20 --> L-dopa n1=en:proterguride | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:quinagolide --- r_associated #0: 20 --> L-dopa n1=en:quinagolide | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:radafaxine --- r_associated #0: 20 --> L-dopa n1=en:radafaxine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:rasagiline --- r_associated #0: 20 --> L-dopa n1=en:rasagiline | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:rasagiline 0.5mg tablet --- r_associated #0: 20 --> L-dopa n1=en:rasagiline 0.5mg tablet | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:rasagiline mesylate --- r_associated #0: 20 --> L-dopa n1=en:rasagiline mesylate | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:romergoline --- r_associated #0: 20 --> L-dopa n1=en:romergoline | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:ropinirole --- r_associated #0: 20 --> L-dopa n1=en:ropinirole | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:ropinirole 250micrograms tablet --- r_associated #0: 20 --> L-dopa n1=en:ropinirole 250micrograms tablet | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:ropinirole 2mg tablet --- r_associated #0: 20 --> L-dopa n1=en:ropinirole 2mg tablet | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:ropinirole 500micrograms tablet --- r_associated #0: 20 --> L-dopa n1=en:ropinirole 500micrograms tablet | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:ropinirole 5mg tablet --- r_associated #0: 20 --> L-dopa n1=en:ropinirole 5mg tablet | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:ropinirole 8mg extended release tablet --- r_associated #0: 20 --> L-dopa n1=en:ropinirole 8mg extended release tablet | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:ropinirole hydrochloride --- r_associated #0: 20 --> L-dopa n1=en:ropinirole hydrochloride | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:rotigotine --- r_associated #0: 20 --> L-dopa n1=en:rotigotine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:rotigotine 2mg/24hours transdermal patch --- r_associated #0: 20 --> L-dopa n1=en:rotigotine 2mg/24hours transdermal patch | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:rotigotine 4mg/24hours transdermal patch --- r_associated #0: 20 --> L-dopa n1=en:rotigotine 4mg/24hours transdermal patch | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:roxindole --- r_associated #0: 20 --> L-dopa n1=en:roxindole | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:selegiline --- r_associated #0: 20 --> L-dopa n1=en:selegiline | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:selegiline 1.25mg orally disintegrating tablet --- r_associated #0: 20 --> L-dopa n1=en:selegiline 1.25mg orally disintegrating tablet | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:selegiline hydrochloride 5mg tablet --- r_associated #0: 20 --> L-dopa n1=en:selegiline hydrochloride 5mg tablet | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:sibenadet hydrochloride --- r_associated #0: 20 --> L-dopa n1=en:sibenadet hydrochloride | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:sinemet --- r_associated #0: 20 --> L-dopa n1=en:sinemet | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:standards characteristics --- r_associated #0: 20 --> L-dopa n1=en:standards characteristics | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:sumanirole --- r_associated #0: 20 --> L-dopa n1=en:sumanirole | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:taxonomic --- r_associated #0: 20 --> L-dopa n1=en:taxonomic | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:therapeutic epinephrine --- r_associated #0: 20 --> L-dopa n1=en:therapeutic epinephrine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:therapeutic use - qualifier --- r_associated #0: 20 --> L-dopa n1=en:therapeutic use - qualifier | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:tirofiban --- r_associated #0: 20 --> L-dopa n1=en:tirofiban | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:tolcapone --- r_associated #0: 20 --> L-dopa n1=en:tolcapone | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:tolcapone 100mg tablet --- r_associated #0: 20 --> L-dopa n1=en:tolcapone 100mg tablet | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:tolcapone 200mg tablet --- r_associated #0: 20 --> L-dopa n1=en:tolcapone 200mg tablet | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:toxicity aspects --- r_associated #0: 20 --> L-dopa n1=en:toxicity aspects | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:trihexyphenidyl --- r_associated #0: 20 --> L-dopa n1=en:trihexyphenidyl | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:trihexyphenidyl hydrochloride --- r_associated #0: 20 --> L-dopa n1=en:trihexyphenidyl hydrochloride | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:triiodotyrosine --- r_associated #0: 20 --> L-dopa n1=en:triiodotyrosine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:vanoxerine --- r_associated #0: 20 --> L-dopa n1=en:vanoxerine | n2=L-dopa | rel=r_associated | relid=0 | w=20 en:zelandopam --- r_associated #0: 20 --> L-dopa n1=en:zelandopam | n2=L-dopa | rel=r_associated | relid=0 | w=20 maladie de Parkinson --- r_associated #0: 20 --> L-dopa n1=maladie de Parkinson | n2=L-dopa | rel=r_associated | relid=0 | w=20 médicaments --- r_associated #0: 20 --> L-dopa n1=médicaments | n2=L-dopa | rel=r_associated | relid=0 | w=20 mélanine --- r_associated #0: 20 --> L-dopa n1=mélanine | n2=L-dopa | rel=r_associated | relid=0 | w=20 phénylalanine --- r_associated #0: 20 --> L-dopa n1=phénylalanine | n2=L-dopa | rel=r_associated | relid=0 | w=20 précurseur --- r_associated #0: 20 --> L-dopa n1=précurseur | n2=L-dopa | rel=r_associated | relid=0 | w=20 toxicologie --- r_associated #0: 20 --> L-dopa n1=toxicologie | n2=L-dopa | rel=r_associated | relid=0 | w=20 Doose (syndrome de) --- r_associated #0: 15 --> L-dopa n1=Doose (syndrome de) | n2=L-dopa | rel=r_associated | relid=0 | w=15 L-3-hydroxytyrosine --- r_associated #0: 15 --> L-dopa n1=L-3-hydroxytyrosine | n2=L-dopa | rel=r_associated | relid=0 | w=15 dihydroptéridine réductase (déficit en) --- r_associated #0: 15 --> L-dopa n1=dihydroptéridine réductase (déficit en) | n2=L-dopa | rel=r_associated | relid=0 | w=15 Catécholamine --- r_associated #0: 10 --> L-dopa n1=Catécholamine | n2=L-dopa | rel=r_associated | relid=0 | w=10 Catécholamines --- r_associated #0: 10 --> L-dopa n1=Catécholamines | n2=L-dopa | rel=r_associated | relid=0 | w=10 Phénylalanine --- r_associated #0: 10 --> L-dopa n1=Phénylalanine | n2=L-dopa | rel=r_associated | relid=0 | w=10 amantadine --- r_associated #0: 10 --> L-dopa n1=amantadine | n2=L-dopa | rel=r_associated | relid=0 | w=10 apomorphine --- r_associated #0: 10 --> L-dopa n1=apomorphine | n2=L-dopa | rel=r_associated | relid=0 | w=10 benztropine --- r_associated #0: 10 --> L-dopa n1=benztropine | n2=L-dopa | rel=r_associated | relid=0 | w=10 bipéridène --- r_associated #0: 10 --> L-dopa n1=bipéridène | n2=L-dopa | rel=r_associated | relid=0 | w=10 brexpiprazole --- r_associated #0: 10 --> L-dopa n1=brexpiprazole | n2=L-dopa | rel=r_associated | relid=0 | w=10 bromocriptine --- r_associated #0: 10 --> L-dopa n1=bromocriptine | n2=L-dopa | rel=r_associated | relid=0 | w=10 cabergoline --- r_associated #0: 10 --> L-dopa n1=cabergoline | n2=L-dopa | rel=r_associated | relid=0 | w=10 carbidopa --- r_associated #0: 10 --> L-dopa n1=carbidopa | n2=L-dopa | rel=r_associated | relid=0 | w=10 cystéinyldopa --- r_associated #0: 10 --> L-dopa n1=cystéinyldopa | n2=L-dopa | rel=r_associated | relid=0 | w=10 dihydroergocornine --- r_associated #0: 10 --> L-dopa n1=dihydroergocornine | n2=L-dopa | rel=r_associated | relid=0 | w=10 dihydroergocristine --- r_associated #0: 10 --> L-dopa n1=dihydroergocristine | n2=L-dopa | rel=r_associated | relid=0 | w=10 dihydroergotamine --- r_associated #0: 10 --> L-dopa n1=dihydroergotamine | n2=L-dopa | rel=r_associated | relid=0 | w=10 diphenhydramine --- r_associated #0: 10 --> L-dopa n1=diphenhydramine | n2=L-dopa | rel=r_associated | relid=0 | w=10 diphénhydramine --- r_associated #0: 10 --> L-dopa n1=diphénhydramine | n2=L-dopa | rel=r_associated | relid=0 | w=10 dobutamine --- r_associated #0: 10 --> L-dopa n1=dobutamine | n2=L-dopa | rel=r_associated | relid=0 | w=10 dopaquinone --- r_associated #0: 10 --> L-dopa n1=dopaquinone | n2=L-dopa | rel=r_associated | relid=0 | w=10 en:DOPA decarboxylase --- r_associated #0: 10 --> L-dopa n1=en:DOPA decarboxylase | n2=L-dopa | rel=r_associated | relid=0 | w=10 en:catecholamines --- r_associated #0: 10 --> L-dopa n1=en:catecholamines | n2=L-dopa | rel=r_associated | relid=0 | w=10 entacapone --- r_associated #0: 10 --> L-dopa n1=entacapone | n2=L-dopa | rel=r_associated | relid=0 | w=10 ergonovine --- r_associated #0: 10 --> L-dopa n1=ergonovine | n2=L-dopa | rel=r_associated | relid=0 | w=10 hyoscyamine --- r_associated #0: 10 --> L-dopa n1=hyoscyamine | n2=L-dopa | rel=r_associated | relid=0 | w=10 isoprotérénol --- r_associated #0: 10 --> L-dopa n1=isoprotérénol | n2=L-dopa | rel=r_associated | relid=0 | w=10 lergotrile --- r_associated #0: 10 --> L-dopa n1=lergotrile | n2=L-dopa | rel=r_associated | relid=0 | w=10 lisuride --- r_associated #0: 10 --> L-dopa n1=lisuride | n2=L-dopa | rel=r_associated | relid=0 | w=10 melphalan --- r_associated #0: 10 --> L-dopa n1=melphalan | n2=L-dopa | rel=r_associated | relid=0 | w=10 mémantine --- r_associated #0: 10 --> L-dopa n1=mémantine | n2=L-dopa | rel=r_associated | relid=0 | w=10 métanéphrine --- r_associated #0: 10 --> L-dopa n1=métanéphrine | n2=L-dopa | rel=r_associated | relid=0 | w=10 méthyldopa --- r_associated #0: 10 --> L-dopa n1=méthyldopa | n2=L-dopa | rel=r_associated | relid=0 | w=10 piribédil --- r_associated #0: 10 --> L-dopa n1=piribédil | n2=L-dopa | rel=r_associated | relid=0 | w=10 pramipexole --- r_associated #0: 10 --> L-dopa n1=pramipexole | n2=L-dopa | rel=r_associated | relid=0 | w=10 rotigotine --- r_associated #0: 10 --> L-dopa n1=rotigotine | n2=L-dopa | rel=r_associated | relid=0 | w=10 sélégiline --- r_associated #0: 10 --> L-dopa n1=sélégiline | n2=L-dopa | rel=r_associated | relid=0 | w=10 trihexyphénidyle --- r_associated #0: 10 --> L-dopa n1=trihexyphénidyle | n2=L-dopa | rel=r_associated | relid=0 | w=10 épinéphrine --- r_associated #0: 10 --> L-dopa n1=épinéphrine | n2=L-dopa | rel=r_associated | relid=0 | w=10 DOPA réaction --- r_associated #0: 5 --> L-dopa n1=DOPA réaction | n2=L-dopa | rel=r_associated | relid=0 | w=5 DOPA-décarboxylase --- r_associated #0: 5 --> L-dopa n1=DOPA-décarboxylase | n2=L-dopa | rel=r_associated | relid=0 | w=5 Maladie de Parkinson --- r_associated #0: 5 --> L-dopa n1=Maladie de Parkinson | n2=L-dopa | rel=r_associated | relid=0 | w=5 cocaine --- r_associated #0: 5 --> L-dopa n1=cocaine | n2=L-dopa | rel=r_associated | relid=0 | w=5 dihydropyridine --- r_associated #0: 5 --> L-dopa n1=dihydropyridine | n2=L-dopa | rel=r_associated | relid=0 | w=5 dihydropyrimidine déshydrogénase --- r_associated #0: 5 --> L-dopa n1=dihydropyrimidine déshydrogénase | n2=L-dopa | rel=r_associated | relid=0 | w=5 dihydrosphingosine --- r_associated #0: 5 --> L-dopa n1=dihydrosphingosine | n2=L-dopa | rel=r_associated | relid=0 | w=5 dihydrosphingosine-déshydrogénase --- r_associated #0: 5 --> L-dopa n1=dihydrosphingosine-déshydrogénase | n2=L-dopa | rel=r_associated | relid=0 | w=5 dihydrotestotérone --- r_associated #0: 5 --> L-dopa n1=dihydrotestotérone | n2=L-dopa | rel=r_associated | relid=0 | w=5 dihydroxyacétone --- r_associated #0: 5 --> L-dopa n1=dihydroxyacétone | n2=L-dopa | rel=r_associated | relid=0 | w=5 dopa-décarboxylase --- r_associated #0: 5 --> L-dopa n1=dopa-décarboxylase | n2=L-dopa | rel=r_associated | relid=0 | w=5 dopachrome --- r_associated #0: 5 --> L-dopa n1=dopachrome | n2=L-dopa | rel=r_associated | relid=0 | w=5 dopage génétique --- r_associated #0: 5 --> L-dopa n1=dopage génétique | n2=L-dopa | rel=r_associated | relid=0 | w=5 déficit en dihydroptéridine réductase --- r_associated #0: 5 --> L-dopa n1=déficit en dihydroptéridine réductase | n2=L-dopa | rel=r_associated | relid=0 | w=5 en:sarcolysin --- r_associated #0: 5 --> L-dopa n1=en:sarcolysin | n2=L-dopa | rel=r_associated | relid=0 | w=5 en:shaking palsy --- r_associated #0: 5 --> L-dopa n1=en:shaking palsy | n2=L-dopa | rel=r_associated | relid=0 | w=5 en:toxicologic measurement --- r_associated #0: 5 --> L-dopa n1=en:toxicologic measurement | n2=L-dopa | rel=r_associated | relid=0 | w=5 syndrome de Doose --- r_associated #0: 5 --> L-dopa n1=syndrome de Doose | n2=L-dopa | rel=r_associated | relid=0 | w=5 chimie --- r_associated #0: 2 --> L-dopa n1=chimie | n2=L-dopa | rel=r_associated | relid=0 | w=2